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6Abstract
Cancer  is  one  of  the  leading  causes  of  death  in  the  developed  world. 
Nevertheless, many pharmaceutical products available in the clinic lack of tissue 
specificity, and often have severe side effects. Nowadays, advances in molecular 
biology   and  biotechnology  have  allowed  the  development  of  biological 
therapeutic  approaches  aimed  to  give  a  step  forward  on  cancer treatment. 
Biotherapy  involves the use of biomolecules such as antibodies that have the 
potential to increase the specificity of anticancer treatments, thus limiting the 
side effects. Unfortunately, the effectiveness of such biomolecules is hindered by 
their  pharmacokinetics,  and  their  translation  into  patient  care  is  heavily 
restricted by low solubility in water, instability  / degradation in vivo and low 
efficiency.  Besides  that,  such  biomolecules  require  appropriate  delivery 
strategies  to  penetrate  cellular  barriers,  thus  being  able  to  interfere  with 
pathways that can be involved in cancer development.
This  research  project  aims  to  bridge  the  lack  of  technology regarding  the 
development  of  an  effective  and  biocompatible  delivery   system.  The  pH 
sensitive  PMPC-PDPA  ((poly(2-(methacryloyloxy)ethyl  phosphorylcholine)  - 
poly(2-(diisopropylamino)ethyl methacrylate)) polymersome was employed as 
candidate for the intracellular delivery of functional therapeutic antibodies  in 
live cells. The PMPC-PDPA diblock copolymer combines the ability to release 
the  loaded  cargo  upon  acidification  within  the  endosomes  with  an  overall 
biocompatibility.
First, the antifouling proprieties of polymersomes were investigated, and then 
compared to  micelles. Subsequently, electroporation was  exploited as reliable 
technique  to  effectively   encapsulate  antibodies  within  polymersomes.  The   
delivery of antibodies in live cells was assessed using anti γ-tubulin antibody as 
a model system.
Finally,  Ki-67  was  explored  as  a  possible  target  for  anticancer  therapy. 
Interestingly, relevant differences in the biological functions of this marker were 
revealed between cancerous and non-cancerous cells. Furthermore, antibodies 
against Ki-67 were delivered in live cells, and their activity was tested to explore 
the potential of Ki-67 as a target for anticancer therapy.
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20Project Impact
Cancer is one of the leading causes of death in the developed world. According 
to the American Cancer Society, only  in U.S.A, more than 580,000 people died 
from this disease in 2013, while the latest data in UK have reported more than 
159,000 cases (CancerResearchUK, 2014; Siegel et al., 2013) (see Figure 1). In 
the last few decades, academic researchers as well as pharmaceutical industries 
have spent considerable resources in cancer research, and yet we do not have a 
universal  cure.  As  far  as  UK  healthcare,  cancer  care  is  one  of  the  largest 
expenditures for the National Health Service (NHS). Latest economical figures 
show that between 5-7% of the NHS budget is spent on cancer care in the UK. 
This is a total of £9.5 billion in 2011 and it is predicted to rise over £15 billion by 
2021 (NHS-UK, 2014).  Although many pharmaceutical  products  are  already 
available  in  the  clinic,  these  are  mainly  based  on  traditional  1950-60’s 
chemotherapeutic  agents  (i.e.  alkylating-like  agents  and  DNA intercalators) 
with  little  or  none  tissue  specificity  and  consequently  severe  side  effects 
(Ruoslahti  et  al.,  2010).  Much  hope  is  coming  from  recent  advances  in 
molecular  biology  and  biotechnological  sciences,  finding  specific  molecular 
markers and biochemical singularities in cancer cells (Ruoslahti et al., 2010). 
Potentially,  these  new approaches  could  bring  innovative  therapies  for  the 
treatment of solid tumours. A good example of this is the use of monoclonal 
antibodies, such as trastuzumab (Herceptin®) (Pegram et al., 2000a). Today, 
there are 23 therapeutic products in the market based on monoclonal antibodies 
and other 3 based on antibody fragments. 
Their economic impact is calculated to be over 1$ billion per year (Sidhu and 
Fellouse, 2006). Although antibodies have high potential, their use is heavily 
restricted  to  extracellular targets  because  of  their inability  to  enter the  cell 
cytosol.  Antibodies  are  possibly  the  closest  system  to  Ehrlich's  “magic 
bullet” (Strebhardt and Ullrich, 2008), this because they  have high specificity. 
However,  their  clinical  implementation  is  hindered  by chemical  instability, 
aggregation and protease  sensitivity, with consequent poor pharmacokinetics 
(Blanco  et al., 2011). Here is where nanotechnology can greatly  help with the 
21design of fully synthetic nanocarriers to efficiently deliver biomolecules such as 
antibodies, in order to enable a new strategy for cancer treatment. 
With nanotechnology, there is a real possibility to develop the state-of-the-art in 
antitumoural therapy; a step closer to patient-tailored strategies and to restrict 
side effects on existing treatments. 
            
Figure 1. Estimated new cases and deaths by sex in USA, considering the ten 
most common types of cancer (Siegel et al., 2013).
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Introduction
1.1. CANCER CELL BIOLOGY
Cancer is a cellular disease that is due to an uncontrolled cellular proliferation. 
This results from the losses of multiple intracellular controls mechanisms that 
lead to an abnormal cell growth. Naturally, the cell life is characterised by  well 
programmed  consecutive  phases  such as:  proliferation,  maturation,  division 
and death. Cancerous cells lose the ability to regulate these steps properly and 
this  promotes  continuous  cycles  of  growth  and  cellular  division. Moreover, 
cancer  cells  lose  or  alter  their  phenotypical  functions  with  associated 
physiological disorders. In addition, their incessant proliferation causes local 
damage on the surrounding tissues, and finally, cancer cells  can also  escape 
their  primary  site  and  spread  into  other  organs  (i.e.  metastasis).  Cancer 
development  is  not  just  produced  from  a  single  genetic  modification. 
Computational  analyses  indicate  that  the  minimal  number  of  mutations 
developed in a cell to induce tumorigenesis is between five to eight (Balmain et 
al., 1993). These genetic alterations can lead to the development of disease and 
promote the cancer hallmarks that can be summarised as shown in Figure 1.1.
23Figure  1.1. I l l u s t r a t i o n  t h a t  s u m m a r i s e s  t h e  t e n  h a l l m a r k s  o f  c a n c e r  
pathogenesis (Hanahan and Weinberg, 2011).
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The  cellular  division  is  a  process  controlled  from  a  complex  intracellular 
machinery, and it is divided in sequential steps that define a unique cycle. 
The  understanding  of  the  multiple  factors  involved  in  such  important 
mechanisms are critical to design anticancer therapies. At the same time, it is 
very  important to recognise that most of the mutations affecting cancerous cells 
involve the dysregulation of this fundamental biological process, namely the cell 
cycle  (Sherr,  1996).  As  schematised  in  Figure  1.2,  four  different  phases 
characterise  the  cell  cycle,  and  the  passage  from  one  phase  to  another is 
regulated by dedicated proteins machineries.
The different cellular cycle steps are reported below with a brief description of 
their respective function: 
G1
In  this  phase the cell  is  preparing its metabolic  machinery for  the 
subsequent DNA replication (gap1).
S At this point, the DNA is ﬁrst synthesised and then replicated. 
G2
Here, the cell start to prepare all “protein materials” needed for  the 
subsequent mitosis (gap2).
M Cellular division, mitosis.
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sub-phases:
Prophase Chromosomes assemble with chromatids and centromere. 
Simultaneous formation of the mitotic spindle.
Metaphase Mitotic  spindle  interaction  with  centromeres  present  in  the 
relative chromosomes.
Anaphase Centromeres  division  and  consequent  separation  of  equal 
chromatids to the opposite pole. 
Telophase Chromatids decondensation and new chromosomes formation.  
Figure 1.2. Schematic of the eukaryotic cell cycle. The phases G1, S and G2 
constitute the interphase (I) while the M phase includes mitosis and cytokinesis. 
In the table are described the four phases composing the mitosis.
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quiescent state called G0 phase. During this phase, the cell does all the routine 
actions, aimed to maintain its functionality. 
Most of  the  adult  human  body  cells  are  non proliferating,  and  maintain a 
permanent quiescent state. Out of these, some specific cells have the ability to 
withdrawn from the G0  phase and become temporarily proliferating (e.g. glial 
cells  and hepatocytes) as  a function of a given stimulus, which are typically 
nutrients  and  mitogens  (Hall  and  Watt, 1989;  Pardee,  1974;  Williams  and 
Stoeber, 2007) .
Finally, there is a minority of permanently proliferating cells, mostly located in 
confined  niches,  which  feed  self  renewing  tissues  (e.g.  bone  marrow  and 
epithelia) (Potten and Loeffler, 1990) .
The intracellular proteins that have the critical role to control the cell cycle are 
the cyclins  and their corresponding kinases, cyclin dependent kinases (Cdks). 
The interaction between Cdks and cyclins, as well as other correlated factors, 
drive the cell cycle across the different phases (Morgan, 1995). Furthermore, the 
variable expression of  cyclins, between different phases  of the cycle, directly 
mediate  the  Cdk  activity,  thus  working  as  internal  control  mechanism. 
Depending  on  the  cycle  phase,  different  cyclins  are  engaged  for  the  Cdk 
regulation. For this reason, the latter can be divided in four different groups: G1 
cyclins, such as the cyclin D that push the cell to the G1 phase; G1/S cyclins, such 
as the cyclin E that induce the cell to enter to the S phase; S cyclins, such as the 
cyclin A that drive the cell across the S phase; and the M cyclins, such as the 
cyclin B that control the mitosis  (Sherr, 1996; Sherr, 2000).
The importance of cyclins is indeed well known for the above explained role that 
they have in the cell cycle regulations and progression. Moreover, it also  well 
established that their abnormal gene expression can lead to cancer development 
(Sherr, 2000; Sutherland and Musgrove, 2004; Tetsu and McCormick, 1999; Yu 
et al., 2001). The Cdk factors are also subjected to specific regulative pathways. 
For this propose, there are proteins called Cdk inhibitors (CDKIs), that serve as 
fundamental negative controllers for the Cdk biological action. In such a way, 
these proteins act as “brake” of the cell cycle progression by regulating the Cdk 
activity. Two principal classes of proteins constitute the CDKI family: the INK4 
class that acts on the Cdk D and the KIP that inhibits Cdk E and A (Sherr and 
Roberts, 1999). These proteins  represent an important biological element to 
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27prevent abnormal cell cycle progression and thus cellular proliferation. For this 
reason, genes  that encode  for CDKIs  factors  are  named  tumour suppressor 
genes (Reed et al., 1996; Solomon and Kaldis, 1998; Talve et al., 1997). Among 
these, the most studied are the transcription factor p53 and the retinoblastoma 
protein  (Rb).  p53  binds  DNA  to  control  the  expression  of  several  factors 
involved  in the cell cycle. A typical example of p53 function is  during DNA 
damage, where its expression is activated to stop cell proliferation to facilitate 
DNA repair. If the latter is beyond repair, p53 can than force the cell to undergo 
controlled death (i.e., apoptosis) (Hickman et al., 2002; Sandal, 2002). While 
p53  acts  as  a  controller  of  intracellular  abnormalities,  ranging  from  DNA 
damage to inadequate nutrients and insufficient oxygen level, the Rb factor is 
implicated  in  the  transduction  of  extracellular signals  within  the  cell.  This 
protein  is  in  fact  able  to  sense  external  factors  and  modulate  the  cellular 
machinery in response to growth or inhibitory inputs. Rb is able to control the 
cellular proliferation and eventually stop the cell cycle entry in the presence of 
inhibitory conditions (Burkhart and Sage, 2008). 
One of the critical landmark of cancer cells is their inability to control the cell 
cycle together with the presence of non-functioning tumour suppressors genes. 
This could be the effect of specific mutations that lead to the synthesis of non-
functional  proteins,  leading  then  to  tumour  development.  For  instance, 
mutations  that affect p53 activity result in serious  consequences  for the cell 
genetic  stability  and  could  rapidly  promote  a  non-controlled  cellular 
proliferation that can lead to a cancerous phenotype (Sherr, 2004 ).  Similarly, 
mutations that are expressed at the level of  Rb gene (chromosome 13) could 
promote  a constitutive  Rb active state. In this  case, the cell is pushed to  an 
unregulated  progression  on  the  S  phase  with  a  consequent  high  risk  of 
malignant phenotype development (Giacinti and Giordano, 2006).
1.1.2. Promotions of a proliferative status
Cancerous  cells  are  characterised  from  genetic  modifications  on  tumour 
suppressors genes that allow their escape from cell cycle arrest. Furthermore, by 
comparing cancerous with normal cells, the former also  develop mechanisms 
aimed to accelerate cellular division and proliferation. 
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regulated  extracellular release of proliferative  inducing factors. These  signals 
have the specific role to drive the targeted cells into a progressive cell cycle with 
a consequent increase on their proliferative status. 
To  this  respect,  cancerous  cells  acquire  the  ability  to  deregulate  these 
mechanisms, becoming able to proliferate independently.
In normal tissues, the extracellularly  released growing molecules bind the cell 
surface  receptors,  typically characterised  by  an intracellular  tyrosine  kinase 
domain.  The  intracellular  portions  of  the  receptor mediate  several  cascade 
effects, ranging from cellular proliferation to metabolism modifications. 
Cancerous cells are able to maintain active this induced proliferation signalling 
pathway by exploiting several strategies. For example, they can increase the 
production and  release of  growing molecules, or force normal cells  to  do  so 
(Bhowmick et al., 2004;  Cheng et al., 2008). Alternatively, they can directly 
over express these growth factor receptors on their surface (Wang and Hung, 
2001). Moreover, the mutation of growth factor receptors, or the mutation of 
correlated  proteins,  is  associated  with the  promotion of  constitutively active 
functional state.              
To this respect, an example of this category of oncoproteins is represented by 
the Ras proteins. Ras is an inner-membrane anchored class of proteins, part of 
the  small GTPases  family. The  intracellular function of  this  molecule  is  the 
translations  of signals  that could  be triggered  from different origins. Indeed, 
Ras  proteins exploits their actions by interacting either with trans-membrane 
proteins such as growth factor receptors, and with intracellular proteins such as 
the oestrogen receptor-a (Olson and Marais, 2000). The constitutive active state 
of  Ras proteins could be the result of point mutations occurring on its gene. 
These  mutations  may  then  lead  to  a  continuous  Ras  active  state,  thus 
continuously  promoting the correlated  kinase cascade. This  persistent signal 
transmission at the nuclear level will result in cellular abnormal proliferation 
and growth (Lowy and Willumsen, 1993). 
1.1.3. Escaping the apoptosis
In normal cells, the controlled death, i.e. apoptosis, serves to  limit abnormal 
cellular growth  and  to  maintain the  normal  physiology  of  the  tissue.  It is 
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29established  that  the  programmed  cell  death is  triggered  as  consequence  of 
external stress  that induces  the activation of intracellular factors, which then   
culminate with the cell destruction (Adams and Cory, 2007). Several regulation 
proteins are involved in this process, and they can be classified into two distinct 
categories.  The  first  category includes  factors  that  respond  to  intracellular 
signals. The second category senses extracellular stimuli.
In both cases,  the  triggering of one  of  these  two  pathways  results  with the 
activation of the intracellular proteolytic caspases  8 and 9, and consequently 
this culminates with the cell death. 
The  class  of  proteins  called  Bcl-2 are  among  the  most  important apoptosis 
effectors. The Bcl-2 members  bind, and thus inhibit, the apoptotic triggering 
factors Bak and Bax. If not inhibited, these two factors induce the mitochondrial 
membrane  destabilisation  and  consequently the  cytochrome  c  release.  The 
latter, in turn, activates the caspases 8 and 9 (Adams and Cory, 2007). 
Different strategies are adopted from the mutated cancerous cells to escape this 
irreversible  mechanism,  including  mutations  that  preclude  the  p53 protein 
activity (see Section 1.1.1). Furthermore, the same result can be obtained with 
the over-expression of anti-apoptotic factors, such as the discussed Bcl-2, or by 
down-expressing the pro-apoptotic Bak/Bax proteins.            
1.1.4. Cellular immortalisation
Normal  cells  have  a  very  defined  number  of  proliferative  cycles,  finely 
controlled by  an enzyme known as the telomerase. This is a specialised protein 
that has the role to add repeated hexanucleotidic sequences at the terminus part 
of the chromosomes, termed as telomeres. The telomeres sequence has the vital 
function  to  protect the  chromosome  extremity,  thus  preserving  the  genetic 
materials. However, the telomerase loses its activity  as function of cell ageing   
and the telomeres sequences are progressively lost as the cell undergoes several 
division  cycles  (i.e.  senescence).  This  ultimately  leads  to  expose  the 
chromosomes DNA ends that can fuse to each other causing a decreasing in the 
cellular viability (Blasco, 2005).
It is  observed  that cancerous  cells  develop  telomerase  able  to  continuously 
perform  their  enzymatic  action,  thus  maintaining  over  time  the  ending 
chromosomal telomeres  protecting sequences  (Shay and  Wright, 2011). This 
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emergence  allows  the  cancerous  cells  to  escape  from  mechanisms  such  as 
senescence and apoptosis, entering in an unlimited number of replicative cycles. 
1.1.5. Cellular metabolism modifications
The  exponential  growth  that  defines  a  tumour  tissue  leads  to  an  hypoxic 
environment (i.e. oxygen depletion). This, in turn, affects the cell metabolism 
and  cancer  cells  have  developed  several  strategies  to  cope  with  such  an 
inhospitable environment. These modified metabolic strategies have the role to 
promote the fast production of energy, and the synthesis of macromolecules for 
the  continuos  cellular  proliferation.  Normally,  cells  in  aerobic  conditions 
accumulate energy in the form of adenosine triphosphate (ATP) through two 
subsequent steps: initially, the assimilated glucose is metabolised in pyruvate 
during the glycolysis process and, subsequently, the latter is converted in CO2 
via the Krebs cycle. These sub-sequential metabolic steps are very profitable 
from the energetic point of view, but it is necessary to remember the elevate 
request of oxygen necessary to exploit the Krebs cycle. 
Cancerous cells mostly produce ATP through glycolysis process, as it requires 
lower provision of oxygen (Weinhouse, 1956). Furthermore, there are studies 
showing that cancerous cells are able to use the glycolytic intermediates for the 
synthesis of  biomolecules such as amino  acids (Vander Heiden et al., 2009). 
Other recent biological investigations proved the existence of two metabolically 
correlated  sub-populations  of  cells  in  tumour  tissues.  These  two  cellular 
population are linked by a symbiotic relation. Whilst one cell population bases 
its energetic production on glycolysis, releasing extracellularly lactate, the other 
group  bases  their energy production on the  excess  of  lactate  (Feron, 2009; 
Kennedy and Dewhirst, 2010).           
1.1.6. Promoted angiogenesis
All  the  body tissues  need  for their  maintenance  an  adequate  provision  of 
nutrients.  The  vasculature  network  has  thus  the  function  to  distribute  the   
essential components around the human organism. In normal conditions, the 
vascular  system  is  essentially  evolved  during  the  embryonic  development. 
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(vasculogenesis),  and  for  the  spreading  of  new  vasculature  ramifications 
(angiogenesis).  After  the  vessels  establishment  and  maturations,  these  cells 
became thus essentially quiescent (Hanahan and Folkman, 1996). 
Unlike normal tissues, tumours require an increased supply of nutrients and 
oxygen to sustain their fast growth. For this reason, cancerous cells are able to 
promote  a neo-vasculature  formations. The  neo-formed  vessels  are  however 
characterised  by  irregular  branching,  leakiness  and  abnormal  capillary 
morphology (Nagy et al., 2010; Nagy and Dvorak, 2012). Cancer cells control 
angiogenesis via the expression of angiogenic regulators that stimulate and / or 
inhibit endothelia growth. This feedback mechanism is regulated by the inducer   
vascular endothelial growth factor-A (VEGF-A), and by the inhibitor thrombo- 
spondin-1  (TSP-1),  respectively.  The  binding  of  VEGF-A  to  its  associated 
tyrosine  kinases  receptors  (VEGFR-1-3)  is  at the  base  of  the  activations  of 
endothelial cells for the formations of new vessels. Cancerous cells are therefore 
capable  of  considerably  increasing  the  secretion  in  the  extracellular 
environment  of  this  protein,  thus  stimulating  the  surrounding  vasculature 
formations (Ferrara, 2009; Mac Gabhann and Popel, 2008). On the other hand, 
they are also  capable of down-regulating the TSP-1 factor, which acts as anti-
angiogenic signal, thus  reinforcing the VEGF-A function (Kazerounian et al., 
2008).   
1.1.7. Promoted inflammation
The last decades of studies in cancer research have shown that tumour tissues 
are  interested  by the  presence of specialised  immune  cells  that promote  an 
inflammatory  status.  In  the  past,  it  was  believed  that  the  inflammatory 
contributions on the neoplastic region was an attempt by the immune system to 
overcome  the  developing  cancerous  cells.  Nevertheless, more  recent  studies 
proved that the same cancer cell induce immune cells migrations to the tumour 
site. The inflammatory microenvironment, supported by  the  cancerous  cells, 
favours  the accumulations of growth factors, proliferative signals, angiogenic 
molecules, and of other biomolecules that increase  the  tumour development 
(Grivennikov et al., 2010; Qian and Pollard, 2010).         
Furthermore, tumour penetrating immune cells release active molecules such as 
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32reactive  oxygen  species  (ROS)  that  contribute  to  the  mutagenic  process 
(Grivennikov et al., 2010; Qian and Pollard, 2010).   
1.1.8. Escaping the immune system
The  complex role  that the  immune  system has  on  tumour  progression was 
tackled only  in the last decades. It is experimentally established that both the 
adaptive and the innate immune system are involved in tumorigenesis. Indeed, 
reduced activity  of cells such as CD8+ cytotoxic T lymphocytes (CTLs), CD4+ Th1 
helper T cells, and natural killer (NK), are associated with increased tumour 
development (Teng et al., 2008). Different strategies can be used by cancerous 
cells to escape the immune detection. One mechanism involves the production 
of inhibiting factors such as the transforming growth factor beta (TGF-β), that 
decreases  the  NK  cells  functionality (Yang  et  al.,  2010).  Another  strategy 
includes  the  activation  of  inflammatory cells  such  as  the  myeloid-derived 
suppressor cells (MDSCs) and regulatory T cells (Tregs) that, in turn, produces 
an immunosuppressive effect (Mougiakakos et al., 2010).    
1.1.9. Activation of the metastatic process
The metastasis is a multistep process that allows the cancerous cells to spread 
around  the subjected organism. This  diffusive  mechanism can be  divided  in 
several consecutive steps. Initially, the cancerous cells become able to  invade 
the surrounding space. Afterwards, their permeations into the lymphatic and 
blood vessels allows them to extravasate into other distal tissues. At this point, 
the  colonisation  process  is  complete  and  the established  neoplastic  colonies 
continue  their growth,  distributed  around  the  affected  organism. Important 
factors that plays a key role in this tumour development are several classes of 
cell surface proteins. These proteins have, in normal conditions, the function to 
anchor  the  cells  to  the  surrounding  elements,  such  as  others  cells  or  the 
extracellular  matrix  (ECM).  The  cadherins,  namely  immunoglobulin  cell 
adhesion molecules  (Ig-CAMs),  and  the  integrins  are  the  principal  class  of 
proteins that allow this function (Cavallaro and Dejana, 2011). The role of these 
proteins  in tumour development is  strongly  related  with the  loss  of  cellular 
adhesion  capacity,  and  consequent  metastasis.  This  is  considerably  due  by 
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unable  to  correctly function, thus  driving  cancerous  cell to  spread  into  the 
neighbours tissues (Cavallaro and Christofori, 2004; Cox et al., 2006).    
1.1.10. Drug resistance
The  acquired ability of cancerous  cells  to  elude therapeutic anticancer drugs 
activity is  defined as  drug resistance. Cancerous cells  can make ineffective a 
drug treatment either by hindering its adsorption or by activating intracellular 
protective pathways. These include protein factors involved in DNA repair, anti-
apoptotic effectors (e.g. cytochrome P450) and  ATP-dependent efflux pumps 
that secrete the drug out of the cell (Holohan et al., 2013). 
1.2. BIOLOGICAL BARRIERS
Although the steps forward obtained in recent years into the developing of new 
approaches  in  anticancer  therapy,  these  are  often  restricted  from  several 
limitations. Indeed, an important biological aspect that have to be considered 
for the effectiveness of therapeutic agents, ranging from chemical compounds, 
biomolecules and polymeric nano-carriers, is represented by their capacity  to 
overcome  the  biological  barriers  encountered  during  and  after  their 
administration. 
Furthermore,  to  improve  the  efficacy  of  the  treatment,  it  is  necessary  to   
optimise properties such as half-life time blood circulation, targeting selectivity, 
enhanced stability and decreased clearance. The biological barriers define all 
the  mechanisms  of  preservations  that  our  organism  exploits  to  avoid  the 
internalisation  and  diffusions  of  an  external  factor.  The  latter,  could  be 
represented by  a virus, a toxin, a bacteria, but also from an administered drug. 
Thus, the biological barriers can be summarised as follows:
• Physical barriers.
• Molecular interactions.
• Reticuloendothelial system (RES).
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34• Vascular wall.
• Cellular barrier.
1.2.1. Physical barriers
Depending on the nature of the drug treatment, different administration routes 
can be considered. Oral, pulmonary, dermal and intravenous  represent some 
examples  of  the  exploitable  ways  to  administer  a  therapeutic  compound. 
Nevertheless,  they  characterise  the  first  biological  barrier  that  has  to  be 
overcome. Indeed, each of these routes presents physical limitations that can 
hinder the effectiveness of the treatment. Between the previously listed ways, 
the  oral administration denotes  the higher patient compliance. Also  for this 
reason, drugs formulations such as capsules and tablets are the most diffused in 
the  market  (Calleja  et  al.,  2012).  Nevertheless,  the  presence  in  the 
gastrointestinal tract (GIT) of adverse conditions such as low pH, degradative 
enzymes and thick mucus lining the digestive tract, are all aspects that limit the 
resulting bioavailability (Ensign et al., 2012; Roger et al., 2010).   
Looking to  another non-invasive  route, the drug administration through the 
pulmonary way  has to be considered. The neutral pH conditions present at this 
level, combined with the high permeability  of the alveoli epithelium, represent 
characteristics that favourite this approach. However, the pulmonary surfaces 
coated with mucous  and the abundant immune system presence on this site, 
constitute challenging barriers to overcome (Ruge et al., 2013). 
Also  the  transdermal  delivery  can  be  exploited  as  route  for  drugs 
administration.  However, the  skin as  a  physical  barrier constitutes  a  major 
limitation for drugs absorption through this way. In fact, the two multilayers 
tissues,  namely  epidermis  and  dermis,  which  compose  this  organ  are  an 
important challenge to be overtaken. In particular, the epidermic layer, which is 
principally  constituted  by  keratinocyte,  is  specialised  to  prevent  the 
penetrations through this route of external factors including drugs (Alexander et 
al., 2012). 
The last mentioned administration route is the intravenous. This is the most 
direct way to make a drug accessible into the organism, as it is directly injected 
in the  bloodstream.  Nevertheless,  also  in  this  case  the  possible  aggregative 
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present  in  the  circulation)  represent  the  major  limitation  that  affect  this 
administration route (Timerbaev et al., 2006).
1.2.2. Molecular interactions 
As  mentioned before, upon accessing the  circulation, drugs formulations are 
exposed to their interaction with blood protein components. The establishment 
of  these  surface-surface  attractive  forces  generates  a phenomena referred  as 
protein adsorption. Polymeric formulations such as drug loaded nano-carriers
(which are going to be discussed in detail in the following sections) are also 
affected by  this process. In this case, the proteins surface interaction cause the 
formation of the so called protein corona (Lynch and Dawson, 2008; Monopoli 
et al., 2011). The protein adsorption process  can thus  modify the  physical  / 
chemical  properties  such  as  external  charge  and  size  of  the  subjected 
compound. As a consequence of this mechanism, the therapeutic agent can lose 
its  effectiveness  and  thus  became  easily  recognisable  from  the 
reticuloendothelial  system  (RES).  This  can  culminate  with  its  premature 
elimination from the blood circulation (Lynch et al., 2009; Owens and Peppas, 
2006).   
Proteins with different nature can participate at the absorption process. These 
are  generally  referred  as  opsonin,  and  include  proteins  such  as 
immunoglobulins,  albumin,  fibrinogen,  apolipoproteins,  fibronectin, 
complement components and many others. Nevertheless, forces with different 
nature  can  be  implicated  to  explain  the  dynamic  aspect  of  the  proteins 
adsorption equilibrium, established within a therapeutic compound.        
Thus, externally exposed charges could be indicated as contributing factors, as 
well as the hydrophilic / hydrophobic balance between the serum components 
and  the  introduced  therapeutic  formulations  (Lundqvist  et  al.,  2008; 
Shannahan et al., 2013).
1.2.3. Reticuloendothelial system  
The  reticuloendothelial  system,  also  called  mononuclear  phagocyte  system 
(MPS), represents another physiological barrier that an introduced therapeutic 
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by  immune  cells  such  as  monocytes  and  macrophages.  These  cells  are 
distributed into the reticular connective tissues of organs such as liver, spleen, 
bone marrows, lungs and lymph nodes. The RES has  the role to  protect our 
body from the  penetrations  and  consequent diffusion of external potentially 
dangerous  elements  such  as  toxins,  virus  and  bacteria  (Hume,  2006). 
Furthermore,  also  drug  formulations  introduced  into  the  bloodstream  are 
subjected at the  RES recognition and  consequent elimination. As  previously 
described (see Section 1.2.2), the interactions between the therapeutic agents 
and opsonins is at the base of the RES activation, leading to  the phagocytosis 
and destruction of the drug (Storm et al., 1995).
1.2.4. Vascular wall 
From the blood vessels, the drug formulation has to  be able to diffuse to the 
targeted tissue. To do this, the therapeutic agent has to overcome the vascular 
endothelium which has the function to  control the transport and exchange of 
nutrients, macromolecules, oxygen and fluids between the bloodstream and the 
surrounding interstitial space. The vascular endothelium can be divided in three 
different  categories  namely  continuous,  fenestrated  and  discontinuous, 
depending on its permeability. The continuous endothelium is present in organs 
such as skin, muscles, lung, fat, nervous system and several connective tissues 
(Pappenheimer et al., 1951). At the central nervous system level, the molecular 
diffusion from the blood vessels to the brain is controlled by  the so called blood-
brain barrier. This imposes a further selective molecular permeation (Pardridge, 
2012). On the other hand, organs such as kidney, intestine, exocrine glands and 
parts of the central nervous system (e.g. the choroid plexus) are characterised 
by a fenestrated endothelium that allow a more permissive molecular diffusion 
to  the  surrounding  tissues  (Gentile  et  al.,  2008).  The  discontinuous 
endothelium is  present  on vessels  that supply organs  such as  spleen,  bone 
marrow and liver. For this reason, the latter are naturally subjected to drugs 
passive diffusion and accumulation (Gentile et al., 2008). 
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The last barrier that a therapeutic agent has to overcome is represented by the 
cell itself. Indeed, a drugs formulation has to penetrate the cell membrane to be 
effective. Typically, the cell membrane allows the passage of  non-polar small 
molecules  and  stops  the  passage  of  polar  and  large  ones  (including  most 
biological macromolecules). The latter are transported within the cells either via 
specific molecular transporter (e.g. ion channels) or via the deformation of the 
cell membrane, in a process called endocytosis. The endocytosis is composed by 
a set of mechanisms that are fundamental for various activities involved on cell 
maintenance, including adhesion, migration, nutrient uptake, and signalling. 
This  cellular entry route  is  the most preferred by cellular parasite including 
most viruses and several bacteria. The endocytic process generally takes place in 
three principal subsequent steps that are:
I. interaction between cell membrane and extracellular compound;
II. membrane adaptive modification;
III. activations of specialised intracellular endocytic pathways.
The first step is defined as the binding step. Most of the endocytic mechanisms 
involve, at this stage, the mediation of specific extracellular receptor-proteins to 
bind the molecule of interest and to continue within the internalisation process. 
Most  endocytic  pathways,  with  the  exception  of  macro-pinocytosis,  involve 
specific membrane signalling events often activated by the binding.
The second step is the resulting membrane adaptive modification. This stage is 
promoted  by a concatenated  cascade of  events  that allow the recruitment of 
several  proteins  working  together  to  produce  the  necessary cell  membrane 
deformation, invagination and trafficking vesicle genesis.
Finally,  when  the  vesicular  cargo  is  internalised,  it  is  sorted  through  the 
appropriate  endocytic  pathway  having  the  function  to  sort  the  material 
accordingly. 
The most important endocytic pathways are summarised below: 
A. Clathrin-mediated
Clathrin-mediated endocytosis (CME) is implicated in the internalisation route 
for several different compounds in eukaryotic cells. Nutrients, synaptic recycled 
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works  thanks  to  the  assembly of  clathrin triskelion  proteins  into  polygonal 
structures, with the help of several other correlated factors (adaptor proteins - 
APs) that produce  the  vesicular internalisation of  the  cargo  (McMahon and 
Boucrot, 2011; Pearse, 1976; Schmid, 1997). 
B. Caveolae-mediated
Caveolae-mediated endocytosis is the mechanism that involves the membrane 
anchored caveolins proteins for the formations  of the endocytic vesicle. This 
route is implicated in several cellular mechanisms such as vesicular transport, 
lipid  regulations  and  cell  signalling.  Furthermore,  caveolae-mediated 
endocytosis is implicated in various diseases including cancer (Rothberg et al., 
1992).
C. RhoA-mediated
RhoA is a protein factor involved in the actin cytoskeleton recruitment and in its 
dynamics  modulation.  Since  the  F-actin  network  has  a  critical  function  in 
almost all the endocytic mechanisms, consequently RhoA assumes the role of 
principal actor across almost all of them (Robertson et al., 2009).
D. CDC42-mediated
Cell division cycle 42 (CDC42) belongs to the Ras superfamily of GTP-binding 
proteins. Its activity is associated with the cytoskeleton recruitment and F-actin 
polymerisation. Moreover, this factor is also correlated with the modulation of 
GRAF1. GRAF1 protein is, in turn, involved in the promotion of cell membrane 
deformations (Klein et al., 2009; Lundmark et al., 2008).
E. ARF6-mediated
ADP-ribosylation factor 6 (ARF6) is a member protein of ARF family, a group of 
6 GTPases. ARF6 function is correlated with membrane  curvature modelling 
through  its  interaction  with  the  phospholipids  bilayer  and  others  factors 
(Donaldson, 2008).
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Flotillin is a protein that present a structural conformation that have similarity 
to both caveolin-1 and clathrin proteins. Despite that, flotillin functions seems 
to be different and uncorrelated with these two class of proteins. Its role is most 
likely  related to membrane clustering formation and vesicular internalisation 
process (Glebov et al., 2006; Riento et al., 2009).
G. Macropinocytosis
Macropinocytosis  is  an endocytic  pathways  that  does  not  dependent to  the 
initial cargo-receptors interactions. This process exploits the actin cytoskeleton 
ability to model the plasma membrane in structures like: lamellipodia, circular 
ruffles  and  blebs.  The  macropinocytosis  allows  the  internalisation  of  a 
considerable  amount of  extracellular material  into  macropinosomes  vesicles 
(Lim and Gleeson, 2011; McNeil, 1984).
H. Phagocytosis
The phagocytosis process is a well used mechanism in specific cells belonging to 
the immune system such as: neutrophils, monocytes, macrophages, dendritic 
and mast cells. It is exploited mostly for the internalisation of pathogens, but it 
is also used for nutrients uptake. Phagocytosis is initiated by specific receptor 
“sensing”  of  the  extracellular  environment  and  it  progresses  through  the 
modulation of F-actin network. This in turn promotes the plasma membrane 
modification and the external element internalisation (Flannagan et al., 2012).
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eukaryotic cells (Canton and Battaglia, 2012).
Generally, the common destination for the internalised cargo during one of the 
above mentioned uptake processes is the endosomal pathway. During this route, 
the  internalised  vesicle follows  three  consecutive steps. Initially the  cargo  is 
accumulated into the so called early endosome where it can be processed into 
three different destinations: (i) delivered back to the cell membrane either via or 
not recycling endosomes, (ii) transported to the trans Golgi network (TGN) via 
specific modulator known as retromers, or (iii) sorted into multivesicular bodies 
(MVB). From the MVB, the internalised cargo can be included within the late 
endosomal compartments where is, in turn, vehicled to the lysosome organelle. 
In this  compartment  the  presence  of  enzymes  called  lysosomal  hydrolases, 
induce an acidic pH with an average value between 4 and 5. In these conditions, 
the  internalised  cargo  is  finally degraded  and  the  resulting constituents  are 
sorted to the appropriate cellular site (Canton and Battaglia, 2012).
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As  herein  described,  the  cancer  development  and  tumour  progression  is 
characterised by the acquisition of an abnormal functionality of a population of 
cells. The latter thus becomes able to highly proliferate and to further modulate 
the surrounding environment to support this process. Over the years, different 
approaches  were developed aiming to  stop this degenerative disease, and the 
most important strategies besides surgery and radiotherapy  can be divided in 
chemotherapy and biotherapy.  
1.3.1. Chemotherapeutic approach  
Chemotherapeutic drugs  were  first used  in the 1940’s  with the  discovery of 
alkylating agents  and their effects on mice tumours (DeVita and Chu, 2008; 
Goodman et al., 1946). Although different in their clinical activity, all alkylating 
agents  such as  nitrogen mustards  (e.g.  cyclophosphamide,  mechlorethamine 
and  uramustine),  nitrosoureas  (e.g.  carmustine  and  lomustine)  and  alkyl 
sulfonates  (e.g.  busulfan)  share  the  same  biochemical  mechanism.  This 
mechanism of action is therefore based on their cross-linking with DNA, thus 
causing abnormal base pairing and preventing cellular division. 
Besides  the alkylating agents  and the alkylating-like  drugs  such as  cisplatin, 
others chemotherapeutic molecules were developed. Thus, depending on their 
mechanism  of  action,  chemotherapeutic  agent  can  be  divided  into  three 
principal groups: antimetabolites, anthracyclines and vinca alkaloids / taxanes.
The  antimetabolite  drugs  have  chemical  structure  similarity  to  natural 
molecules such as vitamins, amino acids, and precursors of DNA or RNA. Once 
these agents are incorporated in the cell metabolism, they inhibit the synthesis 
of DNA or RNA therefore interfering within the cell division process. Examples 
of  molecules  that belongs  to  this  class,  include  methotrexate  (Abitrexate®), 
fluorouracil  (Adrucil®),  hydroxyurea  (Hydrea®),  and  mercaptopurine 
(Purinethol®).  Others  popular  antimetabolite  chemotherapeutic  drugs  are 
thioguanine, cytarabine, cladribine, alimta, gemcitabine, and fludarabine (Grem 
and Keith, 2005). 
The second mentioned group, namely anthracyclines, are able to induce direct 
chemical damage on DNA and RNA molecules through the production of free 
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RNA replication process and consequently lead to the production of nonsense 
nucleic acid sequences (i.e. the new DNA or RNA does not code for anything 
functional). These chemotherapeutic agents can also inhibit the topoisomerase 
II enzyme. The topoisomerase exploits its functionality supercoiling the DNA, 
thus allowing its repair, transcription and replication. Drugs that belongs to this 
class of chemotherapeutic antibiotics  include molecules such as  daunorubicin 
(Cerubidine®), doxorubicin (Adriamycin®), etoposide (VePesid®). Furthermore, 
epirubicin (Pharmorubicin®) and mitoxantrone (Novantrone®) are others two 
examples of commonly used anthracycline in anticancer therapy (Minotti et al., 
2004).
The  last  group  of  therapeutic  agents  is  represented  by  vinca alkaloids  and 
taxanes. This drugs produce their effect interacting within the mitotic spindle 
during the M-phase of the cell cycle. They induce either the inhibitions of its 
formation or the breakdown of it, thus causing the arrest of the cellular division.
Examples of mitotic disrupting drugs include: vinblastine (Velban®), vincristine 
(Oncovin®) and  paclitaxel (Taxol®) (Dumontet and Jordan, 2010; Rowinsky, 
2003). The mechanism of action of this classes of anticancer drugs is in overall 
based on the fact that cancerous cells do not respond to normal growth patterns 
and  proliferate  much  faster  than  normal  cells.  Hence,  the  basic 
chemotherapeutic  approach  is  to  target  highly  dividing  cells  without  any 
specificity. Consequently, this  leads to  the typical side effects associated with 
cancer chemotherapy. Because the general aim of chemotherapeutic agents is to 
decrease the growth rate of the highly dividing cancerous cells, side effects are 
mainly  seen in organs and tissues that naturally have a rapid turnover of cells 
and these include: skin, hair, gastrointestinal and bone marrow. 
1.3.2. Negative aspects of chemotherapy 
Dosage  is  a  critical  problem  that  affect  the  current  chemotherapy  based 
treatments. Due  to  the  lack  of  specificity of  these  agents, chemotherapeutic 
molecules are linked to severe off-target toxicity, serious reduction in patients 
life quality and even death. Furthermore, therapies  with a decreased dosage, 
aimed to reduce side effects, could instead lead to an inactive and incomplete 
treatment via induction of drug resistance. Despite several progress are over the 
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still a number of challenges which need to be addressed: 
I. to  specifically target  to  the  tumour  to  reduce  toxicity and  improve  the 
therapeutic efficacy;
II. to overcome the biological barriers for the delivery  of drugs to the location 
where they need to act (often intracellular targeting); 
III. to  increase  the  solubility  of  hydrophobic  chemotherapeutics  enabling  a 
lower administered dose;
IV. to improve the drug circulations times avoiding its premature degradation 
and clearance by the body. 
Newer technologies in nanomedicine may  be able to tackle these problems and 
thus change the chemotherapy based treatment of cancer. 
1.3.3. Biotherapy  
The  progressive  understanding  of  biological processes, including cell cancer 
molecular biology, is promoting nowadays the development of new avenues in 
cancer  treatment.  In  the  last  decade,  many research  efforts  were  made  to 
develop innovative biological based therapies, designed to be more selective on 
cancerous  cells. This new anticancer approach is  defined as  biotherapy. The 
final goal of biotherapy, similarly to the classic chemotherapy, is the cancerous 
cells  eradication from the  treated patient. To  do  so, biotherapy exploits  the 
possible modulations and controls of biological pathways implicated in tumour 
progression  that  are  over-expressed  in  cancerous  cells.  In such a  way,  the 
specificity of  the  biotherapy action  aims  to  reduce  the  side  effects  usually 
occurring in patients treated with unspecific chemotherapeutic drugs (NHS-UK, 
2013). The most important biotherapeutic approaches are listed below:
A. Gene therapy
The  use  of  genetic material  to  kill cancerous  targeted  cells  define  the  gene 
cancer  therapeutic  approach  (McCormick,  2001).  Various  strategies  were 
studied and developed to stop the tumour progression. 
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I. Gene supplementation therapy:  with this technology, cancerous cells  are 
supplemented  with a wild  type  gene. The  aim is  to  restore  the  normal 
cellular ability to start the apoptotic process in response to severe biological 
malfunctions.  For  this  reason,  p53  was  extensively  evaluated  in  this 
approach since  its  well  know  function  for the  cell  cycle  and  apoptosis 
regulation (Tazawa et al., 2013).   
II. Gene-directed  enzyme  prodrug  therapy:  in  this  case  the  intracellular 
delivered gene encodes for an enzyme that provides the conversion of an 
internalised  inefficient drug substrate  into  an extremely toxic  molecule. 
This  approach  could  thus  promote  an  enhanced  selectivity  of  the 
therapeutic  drug  treatment.  The  genetically  modified  cancerous  cells, 
expressing the exogenous enzyme, should became in this way vulnerable to 
the drug actions (Both, 2009).
III. Immunogene-therapy:  here  the  strategy  is  to  induce  in  cancer  cells 
(through  genetic  transfection)  the  expression  and  external  plasma 
membrane  exposition of  proteins, that  can  be  easily recognised  by the 
immune  system.  The  obtained  enhanced  immunogenicity  of  these 
genetically modified cancerous cells will promote the migration of immune 
effectors to the tumour site and consequently its eradications (Lichtor and 
Glick, 2012).
B. Cytokines
These are proteins produced by the immune system after antigen recognition. 
These  proteins  work  as  signaling  factors,  triggering  the  differentiation, 
activation  and  chemotaxis  of  white  blood  cells.  The  lymphocytes  cytokines 
production, resulting after the immune cell activation, is followed by a cascade 
of events that finally  promotes the elimination of the uncovered antigen (Khan, 
2008).  An important  example  of  cytokine  approved  for  the  used  in cancer 
therapy is  represented  from the interferon-α. Interferon-α  is  commercialised 
with the name of INTRON®A and its activity  is associated with the activation of 
memory T-Lymphocytes (T cells), natural killer (NK) cells and B-Lymphocytes 
(B  cells)  (Pasquali  and  Mocellin,  2010).  The  general  aim of  the  cytokines 
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functionality. In such a way it is exploited the ability of the immune system to 
recognise and subsequently destroy the identified cancerous cells.    
C. Cell-based immunotherapy
Cell-based  immunotherapy   represents  an  other  biotherapeutic a p p r o a c h  
correlated with the activations of  the  immune system (Alderton and Bordon, 
2012). The consecutive steps characterising the cellular immunotherapy can be 
summarised as follows: 
I. Antigen presentation to  the  immune  system (the  antigen  has  to  be  an 
externally exposed protein characterising cancerous cells).
II. Activation and recruitment to the tumour site of effectors cells.  
III. Recognition and destruction of abnormal cancerous cells.
Different  approaches  are  adopted  in  cell-based  immunotherapy  and  they 
includes protocols aimed to stimulate immune cells such as dendritic cells and T 
lymphocytes to mediate the cytotoxic action versus cancerous cells. 
An example of cell-based immunotherapy  treatment approved in the 2010 from 
the U.S. Food and Drug Administration (FDA) is a therapeutic prostate cancer 
vaccine, commercialised with the named of PROVENGE®. This vaccine involves 
the  patient dendritic  cells  activation  against the  prostatic acid  phosphatase 
(PAP) antigen. PAP is an enzyme which is over-expressed in cancerous prostate 
cells. For this reason it is used to stimulate the action of effector cells that can 
synergically act  to  destroy the  abnormal  tissues  that  present  this  antigen 
(Plosker, 2011).  
D.Antibody
Albeit therapeutic proteins are still in a pioneristic stage, they nowadays have a 
significant role in several fields of medicine.
Nevertheless, therapeutic biomolecules, such as antibodies, have to reach their 
site  of  action  to  be  effective.  Although  antibodies  are  of  great  interest  as 
therapeutics, their pharmacokinetics  is  very much  limited. For this  reason, 
antibodies  has  to  be  associated  with an appropriated  delivery method. This 
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protease, which are abundant in biological fluids. 
Monoclonal  antibodies  (mAb)  are  currently developed  for the  treatment  of 
immunological diseases and  cancer, with a particularly increasing interest on 
the  latter  application  (Nelson  and  Reichert,  2009).  An  example  of  this  is 
Herceptin®, a therapeutic mAb against the Human Epidermal Growth Factor 
Receptor-2 (HER2,  also  known as  Neu,  ErbB-2 and  CD340  receptor). This 
protein is implicated in cell survival, adhesion, differentiation and migrations 
(Pegram et al., 2000b). 
Antibodies are produced by immune cells known as B–Lymphocytes (B-cells), 
and their function is the recognition and neutralisation of foreign-body targets, 
named antigens. The immunoglobulin G (IgG) is a complex protein composed of 
four  peptide  chains.  The  full  IgG  antibody  has  a  distinctive  Y  shape 
configuration composed of a complex of two identical light chains (Molecular 
weight (MW) ~25 KDa). These present a constant and a variable domain, and 
two heavy  chains (MW ~50 KDa) that are composed by three constant domains 
and one variable domain. Disulphide bonds are also  presents in the structure 
with the role to interconnect the light chain to each heavy chain, and to bridge 
the gap between the two heavy chains (see Figure 1.4). 
The  IgG  structural  regions  can  be  moreover  defined  in  respect  to  their 
functionality.  In  this  way,  the  IgG  variable  region,  namely Fab  fragment, 
represents the antigen binding portion of the protein, while the Fc fragment, 
correspond  to  the  inactive,  glycosylated  and  conserved  portion  of  it.  Two 
constant and two variables domains characterised the IgG-Fab region and each 
of  them  belongs  respectively to  the  light  and  heavy chains  of  the  protein 
(Putnam et al., 1979). Both light chain variable (VL) and heavy chain variable 
domains (VH) are formed by three β-strands  loops that have the function to 
recognise  the  antigen.  Furthermore,  the  variables  domains  constituting  the 
protein  structure  (VL  and  VH)  changes  between  different  IgG  molecules 
depending on their antigen specificity (North et al., 2011).     
On the other hand, the conserved Fc region has the important role to mediate 
the antibody interactions with other proteins, such as the complement factors 
and the Fc receptors. The latter is a class of receptors that belongs to competent 
immune cells such as  natural killer cells (NK), macrophages, neutrophils and 
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aimed to eliminate the IgG identified antigen (Heyman, 1996).    
Figure 1.4. IgG structure. 
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Nanomedicine in cancer therapy is a rapidly expanding field, which is heavily 
involved with pharmacokinetics improvement of existing drugs. Indeed, most of 
the therapeutic drugs  applied in anticancer therapy are affected  by problems 
such as  poor  water  solubility and  wide  range  of  side  effects.  Nevertheless, 
tackling side effects in cancer therapy is not an easy task to achieve. 
In this context, nanomedicine applied in cancer therapy has the important role 
to increase drug accessibility  to the tumour site, decreasing the distribution of 
the latter in healthy tissues, thus reducing the correlated drug side effects. 
To achieve this purpose, defined as targeting, two distinct mechanisms can be 
used, and they are termed as (i) passive targeting and (ii) active targeting.
The  passive  targeting  exploits  the  modified  structural  anatomy  of  tumour 
vasculature. Growing tumours  require  a  big supply of  nutrients  and  this  is 
achieved through the extensive promotions of angiogenic process. Nevertheless, 
the new formed abnormal vessels do not have the typical barrier properties that 
belongs to normal tissues, and they are characterised by large fenestrations that 
can reach up to 800 nm. This enables the permeation into the tumour site of 
large macromolecules that would be otherwise restricted. This process, known 
as enhanced permeability and retention (EPR) effect, is  also  characterised by 
the  local impairment of  the  lymphatic system, with a consequent decreased 
drainage from the tumour site (Maeda et al., 2000; Matsumura and Maeda, 
1986). Thanks to the EPR effect, macromolecules with molecular mass above 40 
kDa (value above the renal excretion threshold) can be accumulated into solid 
tumours.  This  was  reported  in  experimental  studies,  where  the  quantified 
concentration at the tumour site of such macromolecule resulted 10-30 times 
superior compared with the systemic blood (Maeda et al., 2009; Maeda et al., 
2000). Furthermore, the EPR effect is common in all hypervascular tumours, 
and hence it become a typical target strategy  in nanomedicine (Maeda et al., 
2009).
On the other hand, the second targeting mechanism, defined as active targeting, 
implies the use of nanocarriers presenting properties that enables their direct 
recognition by cancerous cells. The use of polymeric formulation constituted, 
for  example,  by hyaluronic  acid, can promote  the  recognition promoted  by 
CD44 receptors  that are over-expressed  in cancerous  cells  (Platt and  Szoka, 
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moieties, such as folic acid or arginyl-glycyl-aspartic acid (RGD) peptide, can be 
exploited for active targeting. Also in this case, it was established that cancerous 
cells over-express the folic acid and integrins receptors on their surfaces. This, 
in turn, promotes the  accumulation at the  tumour site  of vectors  presenting 
these molecules (Moghimi et al., 2001).      
1.4.1. Strategies in drug delivery
Many  different  strategies  were  developed  over  the  years  to  enhance  the 
effectiveness  of  a therapeutic agent. These technologies  aim to  improve  the 
pharmacological  properties  such  as  drug  solubility,  drug  distribution, 
bioavailability, targeting, and controlled release of the therapeutic agent over 
time. All these approaches are defined as drug delivery systems. This definition 
includes  a  broad  range  of  carriers  such  as  polymer-drug  conjugates, 
dendrimers, polymeric micelles, carbon nanotubes, non-viral vectors for intra-
cytoplasmic transport, liposomes, polymersomes  and  others  (LoPresti et al., 
2009; Markman et al., 2013). 
To  describe  the  drug  delivery  systems,  it  is  possible  to  begin  from  the 
structurally  simplest  approach,  which  is  represented  by  the  polymer-drug 
conjugates. A typical polymer-drug conjugate is constituted by a single polymer 
chain covalently bounded to  a drug. This  therefore produces a new chemical 
entity  that has different characteristics compared to the initial free drug, and it 
is defined as  prodrug (Kopeƒçek, 2013). In such a way, the pharmacological 
properties belonging to the active molecule can be considerably increased. 
These chemical modifications, can improve pharmacological aspects of a given 
drug, such as increased solubility  at physiological conditions, escape from the 
RES, bioavailability, etc.  
A  more  complex  drug  delivery  system  is  represented  by  dendrimers. 
Dendrimers  (dendros from ancient greek-tree)  are  tree-like  macromolecules 
formed by the oligomerisation of multifunctional units that can grow to form 1, 
2, 3 up to 10 generation of branches with consequent amplification of the single 
unit valency. The end groups of those branches  allows controlled conjugation 
with the therapeutic agents and / or with targeting moieties. Also in the case of 
dendrimer  conjugates,  the  final  pharmacological  aspects  of  the  drug  are 
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as drug delivery system is also characterised by downsides. Criticisms arise from 
the high costs behind their synthesis. Furthermore, several studies associated 
this delivery system with cells  toxicity, including cases  of  serious  haemolytic 
activity on  red  blood  cells  (Chen et  al.,  2004).  All  together,  these  negative 
factors  about the  use of  dendrimers, hinder their commercialisation as drug 
delivery platform in cancer therapy.          
Polymer-drug  conjugates  and  dendrimers  are  examples  of  classes  of 
nanocarriers, whose structural assembly  is mediated by covalent bonds. Besides 
this class of drug delivery systems, another category is represented by  inorganic 
nanocarriers such as carbon nanotubes, quantum dots, gold, silica and magnetic 
nanoparticles. Gold nanoparticles can be applied for thermal therapy and can be 
further conjugated  with therapeutic molecules  (Jain  et  al.,  2012). However, 
excluding carbon nanotubes, the other nanocarriers belonging to the category  of 
inorganic  nanocarriers  can  only  be  externally  functionalised  with  the 
therapeutic compound of interest. For this reason, they presents the limitation 
to  expose  on  their  surface  the  active  agent  that  can  then  be  subjected  at 
unfavourable physiological conditions and be further recognised by the RES.
Furthermore, there is still some concern in the scientific community about the 
in vivo toxicity of this class of nanocarriers (Soenen et al., 2011). 
In  addition  to  these  technologies,  a  very important  class  of  drug  delivery 
systems is represented by  self-assembled nanocarriers. These nanocarriers can 
be formed by supramolecular forces between their constituents that range from 
polymer  chains  to  lipids.  Indeed,  hydrophobicity,  aromatic  interactions, 
hydrogen bounds and coulomb forces can be all implicated for the molecular 
self  assembly process  that characterised  this  class of  nanocarriers. The main 
self-assembly drug delivery systems  can thus  be  summarised  in liposomes, 
micelles and polymersomes (Figure 1.5).
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liposome; (B) micelle; (C) polymersome. 
In the following the main characteristics that belongs to the (A) liposomes and 
(B) micelles are reported, while the (C) polymersome delivery system will be 
extensively discussed in the next chapters of this thesis.
A. Liposomes
The liposome is a vesicular nanocarrier with approximately 100 nm in diameter. 
This nanoconstruct is made by lipids that naturally self-assemble into a bilayer 
which enclosed the aqueous lumen space. This particular conformation allows 
the  encapsulations  of  both  hydrophilic  (into  the  aqueous  core)  and 
hydrophobic  /  amphiphilic  (into  the  bilayer)  molecules.  Two  different 
doxorubicin liposome  formulations  such as  Doxil®  (pegylated) and  Myocet® 
(non-pegylated) are nowadays commercially available for cancer treatment and 
several others are undergo clinical trials (Allen and Cullis, 2013).
However, there are still some  limitations  concerning liposomal preparations. 
These limitations are mainly due to the liposomes lack of stability and shelf life 
overtime, and to their eliminations from the blood circulation produced by the 
RES activity. Furthermore, an adequate liposomal drug release profile is not an 
easy task to achieve. To this respect, reported experimental data have described 
liposomal formulations unable to release the cargo at physiological conditions 
or, vice-versa, they  are affected by a too fast release of the drug (Discher et al., 
2007; Duncan, 2003; Lasic, 1997). 
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The micelle is a spherical nanostructure with a diameter ranging between 10 to 
50 nm. This  nanocarrier is formed by the self-assembly of amphiphilic block 
copolymers  in  aqueous  solution.  In  contrast  with  liposomes,  micelles  are 
characterised  by   a  hydrophobic  central  core  which  is  surrounded  by  a 
hydrophilic  corona.  Anticancer  drugs  can  be  chemically conjugated  to  the 
polymer  chains  that  form  the  micelle  or  physically   trapped  inside  the 
hydrophobic  core.  Several  clinical  trials  are  underway  for  micelle  based 
anticancer therapies (Gong et al., 2012). Furthermore, recently South Korea has 
approved  a  paclitaxel  loaded  micellar  formulation  made  by  poly(ethylene 
glycol)-poly(D,L-lactide)  with  antineoplastic  activity named  as G e n e x o l ®PM 
(Lee et al., 2008).
Nevertheless,  also  in  the  case  of  micelle  formulations,  problems  such  as 
inadequate drug release profile can affect the final activity of the delivered drug   
(Trivedi and Kompella, 2010). 
Both  liposomes  and  micelle  represent  very interesting  delivery systems  for 
enhancing the activity of therapeutic drugs. Liposomes are able to entrap both 
hydrophobic / amphiphilic compounds within their membrane and hydrophilic 
molecules  into  their lumen space.  Nevertheless, this  delivery system is  also 
characterised  by negative  aspects  such as  limited  loading efficiency, lack  of 
chemical  /  physical  stability  overtime,  and  restricted  chemical  versatility 
(Barenholz, 2001). 
An alternative to liposome formulations is a drug delivery  system made by block 
copolymers. Block copolymers with amphiphilic properties allows the assembly 
of  nanocarriers that, compared with liposomes, show an enhanced structural 
stability and chemical versatility (Bermudez et al., 2002; LoPresti et al., 2009). 
The superior structural stability of bock copolymer assemblies is mainly due to 
the major length of the amphiphilic copolymers chain, compared with lipids. 
This  favours  the  so  called  entanglement  effect  between  polymer  molecules 
constituting  the  formed  nanostructure,  hence  promoting  the  stability  of 
polymeric carriers. Furthermore, block copolymer posses also  a lower Critical 
Aggregate Concentration (CAC), which make the derived polymeric assemblies 
non-ergodic (Won et al., 2003).   
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block copolymer based delivery system. The micellar nano-vector is particularly 
efficient  for  the  encapsulation  and  subsequent  delivery  of  hydrophobic 
compounds trapped inside the hydrophobic-micellar core (Werner et al., 2013). 
However,  the  impossibility  to  use  this  nano-vector  for  the  delivery  of 
hydrophilic therapeutic molecules is an important limitation of this approach. 
For this reason, the development of polymeric vesicular assemblies, defined as 
polymersomes,  represents  a  promising  progress  on  drug  delivery. 
Polymersomes combine the multi-cargo properties that belongs to liposomes to 
the enhanced structural stability and chemical versatility that derives from the 
constituents block copolymer units.   
  
1.5 POLYMERSOME 
The polymersomes are in essence very similar to liposomes. They are membrane 
enclosed  structures  made  from  the  self-assembly  of  amphiphilic  block 
copolymers  in aqueous  solutions  (Discher et al., 1999). However,  they have 
many advantages  over  liposomal  formulations.  The  synthetic  nature  of  the 
amphiphilic block copolymers, which make up polymersomes, allows a greater 
control over their properties (Discher and Eisenberg, 2002), including stability 
(Photos  et  al.,  2003),  reduced  or  selective  permeability of  the  membrane 
(Battaglia et al., 2006;  Discher et al., 1999), long circulation times  in blood 
(Photos et al., 2003) and response release of cargo according to stimuli (Ben-
Haim et al., 2008; Cerritelli et al., 2007; Du et al., 2005; Meng et al., 2005; 
Rameez et al., 2008). 
Polymersome  leads  the  encapsulation  of  hydrophobic  and  amphiphilic 
molecules within their synthetic membrane, and hydrophilic molecules in their 
central aqueous enclosed  space (see Figure 1.6)(Discher et al., 1999; Discher 
and Eisenberg, 2002; Onaca et al., 2009).
The  combination  of  all  the  chemical  and  physical  properties,  which  give 
flexibility and stability to those particles, makes them good candidates for a vast 
range of applications, from drug delivery to diagnostic (Discher et al., 2007). 
Polymersomes  are  stable  vectors  for long  retention time  and  protection  of 
hydrophilic cargoes. This because the loading of hydrophilic molecules occurs 
by encapsulation, rather than a complexation or a conjugation. Ironically, the 
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perhaps  their biggest disadvantage.  Indeed,  often  the  drugs  encapsulations 
inside these polymeric vesicles is  affected by  low efficiency (when there is  no 
interaction with the  polymers),  especially considering hydrophilic  molecules   
(Photos et al., 2003). In many cases this is not an issue, as it is validated that 
cells uptake polymersomes very rapidly and in big numbers (Massignani et al., 
2009). However, the optimisation of protocols for hydrophilic drug loading is 
very much recommended.
Chapter 1
55Figure 1.6. Descriptive illustration about the three main self-assemblies delivery 
systems namely liposome, micelle and polymersome. Both, polymersomes and 
liposomes  are characterised  respectively by a  synthetic  and lipid membrane 
that  encloses  a  central  aqueous  space.  On  the  other  hand,  micelles  do not 
present  an  internal  lumen,  instead  they are  characterised  by a  hydrophobic 
core.  
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chemical properties that belongs to the polymersomes unit are discussed below. 
These  properties  are fundamental to  control and mediate  the polymersomes 
assembly mechanism.  
1.5.1 Block copolymers 
Block copolymers  are macromolecules  that are constituted from two or more 
different polymeric units. Furthermore, depending on the number of distinct 
polymerised  constituents  characterising  the  copolymer,  the  latter  could  be 
defined  in  different  ways.  For  instance,  a  polymeric  chain  of  a  single 
polymerised  monomer is referred as one block. With this  logic, the chemical 
synthesis  of  a copolymer of  two  unequal repeated  blocks  of  monomers  will 
result  in  a  diblock.  Thus,  a  copolymer  is  defined  as  triblock  when  it  is 
constituted from three different blocks of monomers, and a tetrablock when it 
presents four unequal polymeric blocks. Thus, a diblock copolymer is defined 
with the following scheme: Am-b-Bn. Where A and B represent the two distinct 
polymeric  blocks,  whilst  m a n d  n  described  the  final  average  degree  of 
polymerisation  that  belongs  to  each  copolymer  constituents.  This  brief 
definition of block copolymer can give an idea about the different advantages on 
the use of the latter as an initial moiety for the assembly of derived vectors. 
To this respect, properties such as molecular weight, degradation under specific 
conditions,  conjugations  with  targeting  moieties  and  many  others 
characteristics  can  be  controlled  and  modified  depending  on  the  final 
requirements.  This  enhanced  chemical  versatility  (LoPresti  et  al.,  2009),   
combined with the high chemical and mechanical stability (Bermudez  et al., 
2002), favoured the development of block copolymers as new important tools, 
applicable in several research fields, including drug delivery.  
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Figure  1.7.  Illustration  representing  different  obtainable  block  copolymer 
architectures following diverse synthetic approaches. 
1.5.2. Self-assembling process of block copolymers
Taking inspiration from nature, the synthesis of block copolymers can be aimed 
to obtain synthetic molecules that presents physical / chemical properties that 
mimic  biological  molecules,  such as  the  phospholipids.  The  design  of  such 
amphiphilic block copolymers will result in artificial macromolecules that have 
different behaviour depending on the solvent. The solubilisation of the latter in 
an aqueous solution, for example, could promote a spontaneous self-assembling 
process that can drive the formations of structures with high complexity. The 
self-assembling process of dissolved block copolymers directly depend on their 
concentration  on  the  solution.  While  the  polymer  chains  are  singularly 
dispersed  on  the  solvent  at  low  concentration,  as  the  concentration  value 
increases and reaches the CAC, the polymer chains becomes close enough to 
reciprocally  interact.  This  interaction  is  driven  by  supramolecular  forces, 
including the  hydrophobic  effect  and  hydrogen  bonds  and,  in special cases, 
aromatic forces and coulombic attractions. 
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grade  of  curvature  are  defined  from  one  important  parameter  termed  as 
molecular packing factor (p).   
The p value is directly dependent on the molecular properties that characterise 
the relative copolymer, and it is  calculated taking into  account three distinct 
factors:  v,  a0 a n d  l.  Where  v  is  the  molecular  volume  occupied  by  the 
hydrophobic part of the polymer chain, a0  is the optimal surface area on the 
interface  between  the  hydrophilic  and  hydrophobic  portions  of  it,  and  l 
corresponds to the length of its hydrophobic part (Nagarajan, 2002; Smart et 
al., 2008). 
The p value equation is expressed as follow:  
 
Figure 1.8. Visualisation of the geometrical variables namely (l) length and (V) 
volume of the hydrophobic  block  and (a0)  optimal  surface area  per  molecule 
that determine the (p) packing factor  of a single amphiphilic copolymer  chain. 
The hydrophobic block is represented in red while the hydrophilic one in blue.
Considering the p value, amphiphilic block copolymers can mostly allows the 
formations  of  three  different  categories  of  structures:  spherical  micelles 
(p≤1/3), cylindrical  micelles  (1/3≤p≤1/2) and  membranes  (1/2≤p≤1) (Figure 
1.9)(Bates  and  Fredrickson, 1990;  Fredrickson and  Bates, 1996; Matsen and 
Bates, 1996a; Matsen and Bates, 1996b). 
The spherical micelles presents the hydrophobic copolymer part condensed into 
the  core  of  the  structure.  Vice  versa,  the  hydrophilic  block  is  distributed 
externally, directly interacting with the aqueous environment.
Cylindrical micelles have high similarity with the spherical shaped. Also in this 
case, the hydrophobic part is  condensed  into  the core, while the hydrophilic 
block  is  distributed  externally. Nevertheless,  in this  case, the  higher  length 
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structures.
Finally, spherical vesicular structures, termed as polymersomes, differ from the 
others  two  tridimensional  arrangements  by  the  formations  of  a  polymeric 
membrane that spatially   confine an internal aqueous lumen. The size represents 
an other physical difference between micellar like structures and vesicles. The 
micelles  polymeric arrangement  produces,  in fact,  particles  that  in aqueous 
solution have an average in diameter between 10 to 50 nm. On the other hand, 
at the same solvent conditions, the vesicular particles diameter, ranges from 50 
nm up to a micron.  
The Figure 1.9 shows schematic representations of these three copolymer based 
structures.
Figure  1.9.  Schematic  of  different  self-assembly  structures  derived  from 
amphiphilic  block-copolymer.  (1)  Spherical  micelle, (2)  cylindrical  micelle,  (3) 
polymersome (Discher et al., 1999).    
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PMPC-PDPA  (Poly(2-methacryloyloxyethyl  phosphorylcholine)-co-poly(2-
(diisopropylamino)ethyl methacrylate)) block copolymer is  a well established 
polymeric constituent for obtaining pH sensitive polymersomes-like structures.   
The  first  block  of  the  copolymer,  PMPC,  is  well  known  to  be  highly 
biocompatible, and characterised by non-fouling proprieties. For this reason, it   
is  approved  for  many  medical  uses  and  it  is  conventionally   applied,  in 
combinations with other polymers, for coating stent implants to avoid thrombus 
formation,  and  in  contact  lens  to  prevent  eye  irritation  (Lewis,  2000). 
Furthermore, it is studied as lubricant to mimic the native cartilage extracellular 
matrix that covers the synovial joints surface (Kyomoto et al., 2014). One of the 
main  advantage  of  MPC  monomers  is  that  they  can be  polymerised  using 
controlled  radical  polymerisation,  in  order  to  lead  to  several  copolymer 
combination  including:  poly(2-dimethylamino)ethyl  methacrylate  (PDMA) 
(Yuan et al., 2006), poly(oligo(ethylene  glycol)  methacrylate) (PEO), poly(2-
hydroxypropyl  methacrylate)  (PHPMA)  (Madsen  et  al.,  2009),  poly(2-
hydroxyethyl  methacrylate)  (HEMA)  (Madsen  et  al.,  2006)  and  2-
(diisopropylamino)ethyl methacrylate (DPA) (Ma et al., 2003). 
The  DPA  repeated  unit,  constituting  the  hydrophobic  part  of  PMPC-PDPA 
copolymer, has a pH responsive behaviour. The DPA indeed has a pKa of 6.4 at 
physiological conditions (Bories-Azeau et al., 2004; Pearson et al., 2013). 
This gives to the DPA different solubility behaviour depending on the pH of the 
aqueous.  At pH  lower than  its  pKa (pH  ~6.4),  its  tertiary amine  group  is 
protonated. Consequently, the PDPA is  positively charged and water soluble. 
When the pH of the solution increases over its molecular pKa (pH ~6.4), it loses 
the protonations on the amine group and it becomes hydrophobic. 
MPC and DPA monomers can be then combined with the aim to obtain pH-
responsive copolymers that allow the molecular self assembly, depending on the 
solvent pH value. 
Furthermore, it is also possible to customise the block ratio between PMPC and 
PDPA to control the type and the size of the structures that the copolymer will   
form in solution. In this context, it is shown that pH sensitive PMPC30-PDPA60, 
produces  a pH ~7.2 micellar structures with an average diameter of ~40 nm 
(Ma et al., 2003). On the other hand, a considerable increase on the DPA degree 
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(polymersome) and  of other more complex macromolecular assemblies, with 
size  correlated  with  the  final  length  of  the  DPA  block.  Indeed,  at  room 
temperature and at neutral pH, copolymers such as: PMPC25-PDPA77, PMPC25-
PDPA94 a n d  P M P C 25-PDPA147  allows  the  formations  of  polymeric  structures 
with respective diameter of: ~100, ~150, ~250 nm (Pearson et al., 2013). 
The figure below aims to explain the PMPC-PDPA polymersomes self-assembly 
process in aqueous solution. 
Figure 1.10. Illustration explaining the polymersomes self-assembly process. At 
acidic pH (lower than 6.4) the PDPA block is water soluble, instead when the pH 
solution increase over  the PDPA molecular pKa (pH ~6.4), the latter loses the 
protonations on its amine group and it becomes hydrophobic,  thus promoting 
the polymersome assembling.   
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As discussed before, the polymersome-based nanocarrier can be exploited for 
the  encapsulation and  subsequent delivery of  various  cargoes,  ranging from 
hydrophilic to hydrophobic / amphiphilic molecules. In this section, the most 
common approaches  used to  efficiently include functional cargoes  inside the 
vector are explained. 
1.6.1. Polymersome cargo encapsulation during vesicle formation
The cargo loading can be obtained during the vesicular formation, following two 
distinct strategies: the top-down or the bottom-up approach.
A. Top-down approach
Top-down  approach  defines  a  technique  that  allows  the  encapsulation  of 
hydrophilic / hydrophobic-amphiphilic molecules within polymersomes during 
their formations. This approach includes first the creation of a thin polymeric 
film on a flat surface. For the encapsulation of hydrophilic molecules in such a 
way,  the  new-formed  polymer layers  are  initially placed  in  an  appropriate 
buffered  solution (e.g. water), containing the hydrophilic cargo  aimed  to  be 
encapsulated. At this stage, it is necessary to rehydrate the polymeric film for   
producing enough energy to trigger the self-assembly mechanism.  
Good examples of some of these methods are ultrasounds, alternating current, 
and share rate stirring. In such way, the polymeric film progressively  detaches 
from the basal supporting surface. At the same time, it begins to assemble in a 
range of subsequent phases. These phases  are tightly dependent on the final 
polymer concentration. 
High polymer concentrations, for example, push the formations of lamellar like 
structures,  while  low  polymer  concentration  induces  the  vesicles  assembly 
(Battaglia and Ryan, 2006). In any case, with this procedure, the new-formed 
polymeric structures will include the hydrophilic cargo within the lumen space. 
This method was largely assessed by  Ahmed and collaborators for the efficient 
encapsulation of doxorubicin-hydrochloride (Ahmed et al., 2006). 
The  top-down  approach  can  be  further  used  for  the  encapsulation  of 
hydrophobic / amphiphilic compounds. In this case, hydrophobic therapeutic 
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together with the block copolymer in organic solvent, and then trapped within 
the polymeric film during its formation. Subsequently, the film rehydration will 
allows the polymersome assembly, resulting in the inclusion of the previously 
added drug between the copolymer membrane (Chierico  et al., 2014; Lee and 
Feijen, 2012; Li et al., 2007b).
B. Bottom-up approach
The bottom-up approach is another strategy that consists in a set of techniques 
that involves the cargo loading together with the vesicular formations. 
Nevertheless, despite the top-down approach, both the cargo and the copolymer 
have to be first solubilised in an appropriated solvent.  
This  technique  is  widely  used  for  the  encapsulation of  complex hydrophilic 
molecules such proteins and DNA (Canton et al., 2013; Lomas  et al., 2007). 
However, also small hydrophilic and hydrophobic drugs can be loaded within 
the vesicles in such a way (Ahmed et al., 2006; Yassin et al., 2012). Using this 
approach for the blocks constituents, the copolymer is initially  dissolved in a 
suitable solvent. Afterward, the initial solvent can be progressively exchanged 
with a different one. Alternatively, pH and temperature can be also modified to 
promotes  the  vesicular  formations  (Brown et al., 2010; Luo  and  Eisenberg, 
2001; Zhang and Eisenberg, 1995). One example of this process is given by the 
solvent switch  method.  This  method  involves  the  use  of  copolymers  whose 
building blocks have different solubility depending on the organic solvent. Thus, 
the  exchange  between  one  organic  solvents  to  another  induces  different 
solubility properties  on the subject copolymer, finally promoting its vesicular 
assembly. Since this protocol involves the use of organic solvents, the latter is 
restricted for the vesicular encapsulation of hydrophobic / lipophilic molecules, 
which are stable in these conditions (van Dongen et al., 2009). Another method 
that  belongs  to  the  bottom-up  approach  includes  the  use  pH  sensitive 
copolymers. In this case the self-assembly process is driven by the change of pH 
of  a buffered aqueous  solution. The  progressive  increase of pH, from acidic 
conditions (pH = ~6.4) to the neutral one (pH = ~7.4), decreases the solubility 
of  the pH sensitive block of the copolymer, thus  promoting the formation of 
amphiphilic  polymer  chains.  In  these  conditions  the  copolymer  units  self 
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lumen. In this method, the use of buffered aqueous solution makes it suitable 
for the encapsulation of hydrophilic biomolecules such proteins, which cannot 
be exposed to organic solvents. 
The further development of these two bottom-up techniques (i.e., the solvent 
exchange  and  pH  switch)  allows  the  evolution  of  other  more  complex 
methodologies.  In  this  context,  for  example,  the  elaborations  of  the  basic 
solvent switch approach has  led  to  obtain the polymersomes  formation and 
cargo encapsulations via the emulsion / centrifugation method. An example of 
this technique is given by the work of Marguet and colleagues. They proved the 
possibility  to  obtain the encapsulations  of small  drugs, such as  doxorubicin, 
within polymersomes, and  subsequently the encapsulations of the latter into 
giant polymeric vesicles (vesosomes) (Marguet et al., 2012).  
Furthermore, concerning the pH switch development, an interesting approach 
is  represented  by  microfluidic.  This  technique,  like  the  other  bottom-up 
approaches, combines  the simultaneous  vesicular formations  with the  cargo 
encapsulations. Compared to the standard pH switch formation / encapsulation 
method, microfluidic allows a higher control in terms of reproducibility of the 
new-formed  polymersomes,  and  gives  the  potential  of  a  constant  vesicular 
production over time (Brown et al., 2010; Thiele et al., 2010).    
1.6.2. Polymersome cargo encapsulation after vesicle formation 
A completely different approach for the payload encapsulations is based on to 
starting from an opposite way. This means that the cargo can be loaded after 
polymersomes formations. Techniques that exploit this strategy belongs to the 
so  called  post-formation approach. One  applied  method  that  works  in this 
direction takes inspiration from nature, and more precisely from the endocytic 
process. 
The “synthetic” endocytic approach is based on the initial interaction between 
the  polymeric  vesicle  surface  and  the  cargo  of  interest.  Therefore,  the 
established surfaces-surface interaction can culminate with the internalisation 
of  the latter. The endocytic approach is driven by the spontaneous curvature 
deformations occurring at the interface between the cargo and the polymeric 
membrane.  This  membrane  deformation  process  yield  the  endocytic-like 
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membrane-polymersome.  In  literature,  Kroeger and  colleagues  reported  the 
successful application of this system using poly(dimethylsiloxane)-block-poly(2-
methyloxazoline)  (PDMS-b-PMOXA)  polymersomes.  In  this  case,  SiO2  and 
polystyrene (PS) nanoparticles were used as prove of concept for the mechanism 
(Jaskiewicz et al., 2012a; Jaskiewicz et al., 2012b). 
Besides  the  endocytic  approach,  the  electroporation  (also  called 
electropermeabilisation) is another post-formation procedure applied to achieve 
the cargo encapsulation after the polymersomes formation. This technology is 
widely  used  in  molecular  biology  to  introduce  molecules  dissolved  in 
appropriate media into the cells.
Electroporation generally consists in an externally  applied electrical field. When 
a cell is subjected to an electric shock, it produces at the plasma membrane level 
a consistent increase of the electrical conductivity, and thus an enhancement on 
its  permeability (Ho  and  Mittal,  1996b;  Neumann et al.,  1982). Nowadays, 
electroporation is used also as a consistent and reproducible way  to introduce 
different cargoes  into  polymeric  vesicles. The  method  was  developed  in this 
directions during this research project (Wang et al., 2012) and it will be further 
discussed in this thesis (see Chapter 3).  
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66Figure  1.11.  The  cargo  can  be  loaded  within  polymersomes  during  their 
formation  (A) or  after  that (B). The polymersomes assembly can  be obtained 
starting from the copolymer bulk  (e.g. ﬁlm rehydration; top-down approach) or 
alternatively starting from a solution containing the free block-copolymer chains 
(e.g. pH switch; bottom-up approach).  
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A critical step for an efficient drug delivery system, beside the achievement of an 
efficient cargo encapsulation, is represented by the release of the latter on the 
site  of  action.  The  strategies  that could be  applied  for this  purpose, with a 
delivery vector such  as  polymersome, are  typically divided  in  three  distinct 
release  mechanisms.  The  first one  exploits  the  reverse  bottom-up  assemble 
approach, and it is driven, in this case, by the polymersome disassembly under 
specific  chemical  conditions.  The  second  approach  takes  advantage  from 
external physical stimuli, which would force the drug release. The latest herein 
described mechanism exploits a tuneable release. In this case, the encapsulate 
drug is released from the synthetic vesicles, with a controlled profile. Therefore, 
in the tuneable release, the polymersomes gradually increase their membrane 
permeability. This, in turn, promotes the drug diffusions between intra-  and 
extra-vesicular space.          
1.7.1. Polymersomes chemical driven cargo release
One of the most effective and used mechanism to trigger the polymersome cargo 
release in a specific site (intracellularly for example) is through its disassembly. 
The  polymersome  disassembly  could  be  mediated  by  simply reversing  the 
assembly  process.  Depending  on  that,  the  progressive  change  of:  pH, 
temperature,  CO2  concentration  and  eventually  the  presence  of  oxidative 
molecules  could lead the  copolymer chains dissociation (Lomas et al., 2007; 
Napoli et al., 2004; Qin et al., 2006; Yan et al., 2013). This dissociation occurs 
because  the  chemical  /  physical  properties  belonging  to  the  copolymer are 
modified in these changed conditions. More precisely, the hydrophobic block, 
composing the  latter, switches  and  becomes  hydrophilic. This  promotes  the 
elimination  of  the  previous  hydrophobic-hydrophobic  forces  of  interactions 
between  different  polymer  chains,  and  finally  leads  to  the  nano-vector 
disassembly.
Therefore, in the case of pH sensitive polymersomes, it is shown that the pH 
switch occurring at the intracellular endosomal compartment (organelle where 
the polymeric carrier is accumulated after the intracellular uptake) is sufficient 
to  yield  the  cargo  release (Akinc and Battaglia, 2013;  Canton and  Battaglia, 
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polymersomes, and it will be discussed in details in Section 1.8.  
Depending on the chemical nature that constitutes the used block copolymers, 
polymersomes  can  exploit  other  external  modifications,  such  as  light  or 
temperature, to achieve the in-situ drug release (Cabane et al., 2010).  
1.7.2. Polymersome cargo release under physical stimuli
Beside the chemical driven release approach, other external factors can be use 
to induce a targeted drug delivery. Physical stimuli, for instance, can be applied 
to reach this scope. One of these physical factors is defined by the shear forces 
occurring within the blood vessels. The increase of pressure characterising the 
capillaries can actually be exploited to  produce temporal fenestrations on the 
subjected polymersomes membrane. This finally leads  the outside leakage of 
internalised drugs (Gaitzsch et al., 2012a; Yassin et al., 2012). 
Another release mechanism that responds to physical stimuli works through the 
vesicular  sensing  of  externally  applied  UV  irradiations.  Polymersomes 
developed to respond to this source of energy possess copolymer chains cross-
linked between each other that reinforce their membrane stability. In this case, 
the UV irradiation, which exposes the delivery  site, causes the polymer cross-
linking reduction with a consequent increase on the membrane permeability 
value of the nano-carrier. This would culminate with the cargo release in the 
external space (Blasco et al., 2013; Cabane et al., 2010; Wang et al., 2014; Yassin 
et al., 2012).   
1.7.3. Polymersome cargo tuneable release
The last way, discussed herein to favour a controlled cargo release, is through a 
delivery system that  combines  the  characteristics  of  both  the  nano-vehicles 
previously discussed.  This  means  that  it  would  acts  by a  combination  of 
chemical and physical responses (Chen et al., 2006; Du and Armes, 2005; Yu et 
al., 2009). Such complex system allows  a tuneable  drug release  that can be 
controlled over time. The chemically  cross-linked membrane of these “swelling” 
polymersomes  are  able  to  react  to  the  changing  environment  (e.g.  pH, 
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(Yassin et al., 2012). 
Polymersomes defined as nanoreactors belongs to this class of delivery system. 
Nanoreactors are thus vesicles that enclose within their lumen space an enzyme 
that can be metabolically activated under specific conditions. (Gaitzsch et al., 
2012b;  Kim  et  al.,  2009).  The  characteristics  belonging  to  these  swelling 
polymersomes  can thus  favour the  enzyme  substrate  permeations  in certain 
physiological conditions, thus  triggering the metabolic machinery activations. 
Referring to this typology of vectors, cross-linked synthetic membrane reacting 
to external stimuli, such as CO2-controlled acidification, pH, temperature, are 
exploited to achieve a controlled release. Other reported nanoreactors instead 
exploit a tunable release, including channels proteins within their membrane. 
Such transmembrane proteins can thus make the polymersomes lumen space 
accessible for the cargo diffusion under specific external stimuli (Onaca et al., 
2008).     
Figure 1.12. The polymersome cargo release can be achieve in different ways 
and  depending  on  the  nanocarrier  properties.  Chemical  release  (left),   
mechanical  release  (centre)  and  ﬁnally  by  a  combination  of  chemical  and 
physical responses (right).   
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RELEASE  
A fundamental property characterising an effective drug delivery system is its 
capacity  to  be  up  taken  from  a  targeted  cell.  Furthermore,  after  its 
internalisation,  the  nano-carrier should  allows  the  escape  of  the  functional 
cargo intracellularly thus allowing its action.  
The biological process that defines the cellular internalisation of extracellular 
compounds, as previously explained, is called endocytosis (see Section 1.2.5). 
The endocytosis of synthetic nanocarriers depends from several characteristics 
that belongs to the latter. The chemical copolymer nature, for example, is one of 
these important properties that can affect the final vector uptake. In the case of 
PMPC-PDPA it was recently demonstrated its specific interaction with a precise 
class  of  cell  membrane  receptors.  These  transmembrane  receptors,  called 
scavenger, recognise modified low-density lipoprotein (PrabhuDas et al., 2014). 
The  phosphorylcholine  based  chemistry  (Poly(2-methacryloyloxyethyl 
phosphorylcholine)-co-poly(2-(diisopropylamino)ethyl  methacrylate),  which   
belongs  to  the  PMPC-PDPA  polymersomes,  is  responsible  for the  selective 
interplay of these with the specific scavenger receptor class B member 1 (SR-
B1). The recently reported  data from Colley et al. correlated the  role  of this 
transmembrane protein with the  polymersomes  interactions  within the  cells. 
Moreover,  Colley  and  colleagues  correlated  the  over-expression  of  SR-B1 in 
cancerous cells with an enhanced polymersomes uptake (Colley et al., 2014).   
Furthermore, not just the copolymer chemistry  nature is important to obtain an 
efficient cellular uptake. Another fundamental parameter that has also  to  be 
considered is the final particle size and shape. Several studies already reported 
that the optimal uptake range size is approximately  around 40 nm for polymeric 
micelles and spherical gold nano-particles (Chithrani et al., 2006; Nakai et al., 
2003). The size parameter is critical also for the polymersomes uptake. Recent 
studies  shows  that  polymersomes  uptake  is  facilitated  when  these  have  an 
average in diameter of 100 nm (Massignani et al., 2009). 
Furthermore,  is  proved  that  also  the  nano-vector  shape  can  affect  its 
internalisation  within  the  cells.  In  this  respect,  the  obtained  results  from 
Robertson  et  al.  shows  that  tubular  polymersomes  are  affected  by  an 
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(Robertson et al., 2014). 
1.8.1. PMPC-PDPA polymersome intracellular cargo release
PMPC-PDPA  polymersomes  are  biocompatible  synthetic  vesicles  that  self-
assemble  at  pH  7.4,  formed  by pH-sensitive  polymer  blocks  that  allows  a 
controlled cargo release inside the cells upon acidification (Massignani et al., 
2010b).  The  highly  biocompatible  block  poly(2-(methacryloyloxy)ethyl 
phosphorylcholine) (PMPC) is based on phosphorylcholine. The pH-sensitive 
poly(2-(diisopropylamino)ethyl methacrylate) (PDPA) block (with a pKa o f ~  
5.5-6.5) controls the release in the endo-lysosomal compartment (Massignani et 
al.,  2010b).  For  this  reason,  these  polymeric  vesicles  are  included  in  the 
nanocarriers  category that  exploit  the  chemical  driven  cargo  release.  Once 
cellularly internalised,  the  natural  acidification,  occurring  in  the  endocytic 
pathway, rapidly overcomes the pKa of the DPA block copolymer, forcing the 
polymersomes  to  dissociate into  the single  polymer units. This  consequently 
causes  an increased  osmotic  pressure  inside  the  early  endosomes,  which is 
compensated  by  the  formation of  a temporal membrane destabilisation that 
allows the cargo release (Massignani et al., 2010b). Rhodamine octadecyl ester 
loaded vesicles were used to validate this mechanism. LoPresti and colleagues 
exploited  the  polymersomes  internalised  cargo  release  using  two  different 
vesicular formulations. One formulation presented the DPA pH sensitive block, 
while the other formulation was deprived of it. The two copolymer formulations 
were thus in vitro tested with separate groups  of Human Dermal Fibroblasts 
cells  (HDF).  Afterward,  the  cargo  release  mechanism was  evaluated  under 
confocal microscopy. 
The  reported results  shows that the  rhodamine loaded vesicles  were able  to 
release  the  cargo  within  the  cytosol  just  in  the  case  of  pH  sensitive 
polymersomes. On the other hand, in non pH sensitive vesicles, the delivered 
dye was found to be accumulate in limited areas across the fibroblasts cytosol 
(LoPresti et al., 2009).  
These  results  strongly proved  the biological selective functionality of PMPC-
PDPA polymersomes as intracellular delivery system.   
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Figure  1.13.  Illustration  describing  the  consecutive  steps  that  allows  the   
cytosolic  cargo  delivery  of  PMPC-PDPA polymersome.  (1)  Endocytosis;  (2) 
polymersomes accumulation into the initial trafﬁcking vesicle; (3) sorting into the 
endosome  organelle;  (4)  temporal  membrane  osmolysis  of  the  acidic  endo-
lysosomal  compartment;  (5)  cargo  escape  into  the  cytosol;  (6)  intracellular 
distribution of the delivered cargo.    
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AND PROTEINS 
In the  last  decades,  the  continuous  progression  of  both biotechnology  and 
nanotechnology  has  allowed  important  steps  for  the  development  of  new 
biopharmaceutical entities. Since the discovery and productions of recombinant 
human insulin in the in the early ‘80s (Crea et al., 1978), biopharmaceutical 
drugs  such  as  therapeutic  proteins,  anti-tumour  enzymes  (able  to  degrade 
amino  acids  essential for the  tumour progression),  anti-angiogenic  peptides 
(angiogenesis  inhibitors), antibodies  and other biomolecules with therapeutic 
activity were developed. In 2012, the ~70% of the revenue generated from the 
first ten most important pharmaceutical industries in the world was obtained by 
selling biotechnology products (Tufts-CSDD-Impact-Report, 2013).     
Compared with small chemical drugs, biotechnology drugs have the potential to 
be  highly  specific  for  their  therapeutic  target.  Nevertheless,  these  active 
biomolecules are affected by important negative aspects  correlated with their 
structural  complexity.  The  lack  of  stability at  physiological  conditions,  fast 
eliminations from the blood circulation (i.e. via RES) and poor permeability of 
biological barriers (i.e. skin, mucosa and cell membrane) affects the therapeutic 
action of peptides and proteins. 
For this reason, the latter has to be associated with an appropriate drug delivery 
system able to overcome the mentioned obstacles. In this direction, over the last 
years,  various  delivery  approaches  were  progressed  in  nanotechnology   to 
optimise  the  therapeutic activity of biotechnology  drugs. Below the principal 
ones are briefly described.   
A. Injectable implants 
Injectable implants of drugs are used to achieve a continuous drug release over 
time of the bioactive molecule within the treated patient. An important example 
of  this  category  is  represented  by   the  Zoladex®,  which  is  a  formulation 
composed by  poly(lactic-co-glycolic acid) (PLGA) and gonadotropin releasing 
hormone superagonist (GnRH agonist). This formulation is mostly used for the 
treatment of breast and prostate cancer (Kotake et al., 1999). 
Other biocompatible polymers  such as hyaluronic acid were studied  for their 
applicability  in depot formulations  (Burdick and Prestwich,  2011). However, 
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incisions, the patient compliance represents a significative limitation on their 
use. Furthermore, the free-biomolecules released within the blood circulations 
are  exposed  to  the  RES  activity,  therefore  subjected  to  renal  clearance. 
Moreover, free peptides and proteins are characterised by poor permeability of 
biological barriers, such as the cell membrane, thus limiting their applicability 
to targets intracellular pathways.
B. Modification of peptides and proteins  
In order to decrease the injections frequency and to increase the plasma half-life 
of  therapeutic  biomolecules  (Meibohm, 2012), peptides  and  proteins  can be 
chemically  modified. Hydrophilic polymers such as polyethylene glycol (PEG), 
sialic acid, hydroxylethyl starch and hyaluronic acid are nowadays widely used 
for this purpose in combinations with peptides and proteins, and some of these 
formulations  are  currently clinically investigated  (Constantinou et al., 2009; 
Mero et al., 2013; Pasut and Veronese, 2012). Furthermore, also the fusion of 
therapeutic biomolecules with albumin represent a promising way  to increase 
the plasma half-life of a therapeutic modified biomolecule. Indeed, in 2014, the 
US Food and  Drug Administration (FDA) have approved the  albumin fusion 
peptide GLP1(7-36) for the treatment of type 2 diabetes (Bush et al., 2009).
Peptides and proteins can also be modified to achieve their specific intracellular 
delivery. To  reach this  scope,  different technologies  can be  used, and  these 
include  the  Presenting  Transduction  Domain  sequence  (PTDs)  (Prochiantz, 
2000) and chemical modifications with positively charged polyamines (Hervé et 
al.,  2008;  Kitazoe  et  al.,  2005;  Triguero  et  al.,  1989).  However,  these 
modifications, which result with the creations of a new molecular entity, can 
generate disadvantages compared with the native compound, including reduced 
solubility and decreased therapeutic activity.
C. Cationic lipids or polymers formulations  
Formulations based on the complexation between proteins and cationic lipids or 
polymers can be exploited to achieve proteins delivery, and their internalisation 
within the cells. An example of cationic lipid mixture evaluated for this purpose 
is  the  trifluoroacetylated  lipopolyamine  (TFA-DODAPL)  /  dioleoyl 
phosphatidylethanolamine  (DOPE).  Experimental  evaluations  show that  the 
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the uptake of the latter in different cell models (Zelphati et al., 2001).
On the other hand, polyethyleneimine (PEI) represents an example of cationic 
polymer  used  for  the  complexation  with  proteins  (Didenko  et  al.,  2005). 
Although  the  proteins  complexation  with  cationic  polymers  or  lipids  can 
facilitate their cellular internalisation, these approaches are however affected by 
downsides  such  as  low  plasma  half-life  (eliminations  mediated  via  RES), 
inadequate cargo release and cellular toxicity.
D. Nanoparticles  
In  the  last  years,  various  nano-delivery  systems  were  developed  in 
nanotechnology  to  deliver peptides and proteins. These include viral vectors, 
liposomes  and polymersomes. The first approach consists  in the  use  of viral 
vectors as delivery systems that can be loaded with the desired protein. In this 
way, the viral structure can protect the cargo  from the external physiological 
conditions, and release  it intracellularly (Kondo  et al., 2008). However, this 
approach is also characterised by negative aspects such as immunogenicity. 
The second two delivery systems, previously discussed in Section 1.4.1, namely 
liposomes  and  polymersomes,  enable  proteins  internalisation  within  their 
hydrophilic  core. In this  way the  cargo  is  protected  from the  physiological 
conditions, thus increasing its plasma half-life. Both these vectors can also be 
characterised by  pH sensitive properties that enable the intracellular release of 
the cargo, upon acidification at the endosomal level (Diego dos Santos Ferreira, 
2013;  LoPresti  et  al.,  2009).  Indeed,  the  possible  intracellular  delivery  of 
biomolecules  is  still  one  of  the  most  difficult target to  be  achieved.  In this 
context, delivery systems  such as  pH  sensitive  liposomes and  polymersomes 
represent  promising  technologies  to  introduce,  and  subsequently  release, 
therapeutic biomolecules such as  antibodies (Canton et al., 2013). Antibodies 
are able to target specific epitopes and, for this reason, they could represent a 
promising  and  powerful  biomolecule  to  be  exploited  intracellularly  as  a 
potential therapeutic tool also  in cancer therapy. The possibility to  introduce 
these  active  proteins  in a live  cell could  be used  to  precisely interfere  with 
aberrant intracellular pathways, otherwise inaccessible for the free IgG (Ren et 
al., 2009). Furthermore, the  promising pharmacological  properties  listed  in 
Section 1.5, which belong to the polymersome nanocarrier, can elect it as an 
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protein delivery. 
1.10.  Ki-67  AS  INTRACELLULAR  TARGET  IN  ANTICANCER-
THERAPY
As  discussed,  antibodies  can  be  potentially used  to  interfere  with  mutated 
intracellular pathway, if combined with an appropriated delivery system. 
In this context, mutated epitopes such as Rb, Bcl-2 and the enzyme telomerase,   
which are associated with uncontrolled cell cycle progression, could represent 
interesting targets  for future  anticancer therapies  based  on the  intracellular 
delivery of IgG. Among the listed factors, another protein demonstrated to play 
a  pivotal  role  in  cell  proliferation  (Bullwinkel  et  al.,  2006;  Jakobsen  and 
Sørensen, 2013) is Ki-67. Ki-67 is a nuclear protein, encoded by the gene MKI67 
on the chromosome 10 (10q26), which is present in two  main different splice 
variants of 320 and 359 kDa (Schlüter et al., 1993). The expression of Ki-67 is 
strongly promoted during the phases G1, S, and G2 of the cell cycle (namely, the 
active  states),  while  the  protein,  and  its  codifying mRNA,  are  both  rapidly 
down-expressed when cells exit the active cell cycle (i.e., the G0) (Bullwinkel et 
al., 2006; Gerdes et al., 1984; Gerdes et al., 1983). The cell transit, via mitosis, is 
promoted  by  the  cyclin  B  /  cdc2-dependet  phospho-  and  Ki-67 
dephosphorylation pathways  (Endl and  Gerdes, 2000b). The Ki-67 exclusive 
expression in specific phases of the cell cycle, combined with an overall short 
half-life, made this protein an ideal candidate for the development of specific 
antibodies useful for quantifying the cell proliferation, a crucial topic in cancer 
research (Endl and Gerdes, 2000a; Scholzen and Gerdes, 2000; Yerushalmi et 
al., 2010). It should be, in fact, mentioned that several studies highlighted Ki-67 
as a strong prognostic biomarker for both breast and non-small cell lung cancer 
(Jakobsen  and  Sørensen,  2013;  Pathmanathan  and  Balleine,  2013). This,  in 
turn, has important implications for the further selection and improvement of 
follow-up protocols / treatments based on radiation, chemotherapy, and / or 
surgery. Despite these promising data, there are however still a high level of 
uncertainty, regarding both (i) the exact Ki-67 molecular function, and (ii) its 
definitive  and  reliable  application  for  histopathological  grating  of  different 
cancer types (Jakobsen and Sørensen, 2013; Pathmanathan and Balleine, 2013). 
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exploration of Ki-67 as a specific structural nuclear element. Ki-67 was found to 
interact, for instance, with the fibrillarin-deficient region of the dense fibrillar 
components, the nucleoli (in the S phase), and the condensed chromosomes 
(through metaphase) and chromatin (during the anaphase) (Endl et al., 1997; 
Gerdes  et  al.,  1984;  Gerdes  et  al.,  1983;  Kill,  1996;  Starborg  et  al.,  1996). 
Furthermore, Ki-67 is associated also with the perichromosomal compartment 
assembly in human cells (Booth et al., 2014). However, there are not specific 
studies available on potential extra-nuclear Ki-67 pathways, in order to better 
understand its  possible fate beyond the  nucleus  as  well. With respect to  the 
second point, an unanimously  accepted agreement on the prognostic value of 
Ki-67 is still not available among the published works, mainly because of the 
different  methods  used  for  quantifying  the  Ki-67  labeling  index  (which 
estimates the mitotic activity of a cell population as a ratio between cells in S 
phase over the total cells) (Jakobsen and Sørensen, 2013). Taken together, all 
these evidences highlight the overall need to increase the current understanding 
on  the  molecular  action  and  regulation  of  Ki-67,  especially  regarding  its 
potential extra-nuclear pathways, which are almost unexplored.
In  this  framework,  the  possibility  to  uncover  the  intracellular  fate  and 
regulation of  Ki-67  could  be  crucial to  develop  a new targeted  approach in 
cancer therapy. Indeed,  the results  of  this  investigation can be  exploited  to 
develop  an  innovative  anticancer  therapy  based  on  the  polymersomes 
intracellular delivery of anti Ki-67 antibodies.
Chapter 1
78Project Aims
The  aim of  this  project is  to  use pH  sensitive  polymeric vesicles, known as 
polymersomes, to achieve the intracellular delivery  of antibodies for anticancer 
therapy. In this study, the polymersome system used is based on PMPC-PDPA 
block  copolymer.  Several  studies  already  proved  that  the  PMPC-PDPA 
polymersomes  can be  up  taken and  internalised  by  cells  (Massignani  et al., 
2010a). Moreover, the pH sensitive properties that belong to  the PDPA block 
allow the cargo escape from the endocytic pathway after cellular internalisation 
(LoPresti  et  al.,  2009).  Therefore,  the  antibodies  encapsulation  within 
polymersomes  gave  the  opportunity  to  target  sensitive  intracellular  sites, 
otherwise  inaccessible  for biological molecules  such as  immunoglobulins. In 
this work, the polymersomes stability in biological fluids (and, more precisely, 
the so called protein fouling process potentially occurring on their surface) was 
initially  investigated.  Furthermore,  a  technique  named  electroporation  was 
explored to achieve a reproducible and reliable encapsulation of proteins within 
the nanocarrier. Finally I looked for important intracellular epitopes associated 
with cell proliferation, cell cycle regulation and the tumorgenesis in cancer cells. 
This biomolecular investigation highlighted new interesting differences between 
cancerous  and  non  cancerous  cells,  regarding  the  expression  and  the 
subsequent degradation of the intracellular protein Ki-67, which is commonly 
used  in  diagnostic as  a proliferation marker. This  protein  was  furthermore 
evaluated as therapeutic target for the development of new selective anticancer 
treatments, by the  intracellular delivery  of  polymersomes  loaded  with anti-
Ki-67-antibody.  
The principal objectives of the project are:
I. Polymersomes stability in biological fluids.
II. Antibodies encapsulation within polymersomes. 
III. Intracellular delivery of antibodies.  
IV. Identifications  of  new  potential  intracellular  targets  for  anticancer 
applications.
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Results and Discussion
SURFACE INTERACTIONS BETWEEN 
POLYMERIC ASSEMBLIES AND PROTEINS 
2.1. Preparation and characterisation of copolymer assemblies
The  protein  fouling  process  defines  the  interactions  between  proteins  and 
synthetic surfaces.  When this  process  occurs  on the  surface  that belongs  to 
nanocarriers, it promotes the formation of a protein “corona”.  Such a process, 
schematised in Figure 2.1, is critical in dictating the final fate of nanoparticles 
injected within biological fluids.
Figure  2.1.  Schematic  of  protein  corona  formation  on  the  surface  of  a 
nanocarrier injected within biological ﬂuids.
These  are  aqueous  fluids  rich in proteins  and  other molecules  with protein 
concentration up to 10% in volume. For example ~8% of blood plasma volume 
is  constituted  by  proteins  (Vogler,  2012).  Such  a  crowded  environment 
promotes the interactions between proteins and nanoparticles, thus controlling 
the  protein  fouling  process  becomes  very  difficult.  Indeed,  a  nanocarrier 
covered  by  proteins  has  higher probability to  be  recognised  by the  immune 
80system and consequently be eliminated (Vonarbourg et al., 2006). Often the 
ability to avoid unspecific interaction with proteins is the key to achieve longer 
circulations times, targeting and consequently achieve efficient delivery. 
In this research project, the proposed polymersome nanocarrier aims to be used 
for  the  encapsulation  of  therapeutic  proteins  and  for  its  evaluations  as 
nanocarrier that can be applied in anticancer therapy. Hence, it is critical to 
evaluate  the  possible  interaction  of  polymersome  with  proteins  since  the 
adhesion of the latter on its external surface can result in overestimating the 
effective  protein loading and can further affect its  in-vivo pharmacokinetics. 
The  protein corona  formation on  the  surface  of  nanocarriers  is  affected  by 
various  properties  including electrostatic  interaction, hydrophobic effect and 
more specific interactions  associated with defined chemical moieties  such as 
hydroxyl groups which can interact with thioester groups (Pfeiffer et al., 2014; 
Tenzer  et al., 2013). Protein fouling  can be  prevented  by  a  combination  of 
chemical and  physical  properties. From a  chemical  point of  view,  the  ideal 
surface chemistry that characterise a nanocarrier should have a neutral nature 
that  favours  interaction  with  water  molecules  rather  than  other  solutes. 
Polymers  such  as  PEG  (polyethylene  glycol),  PMPC  (poly  (2-
methacryloyloxyethyl  phosphorylcholine)),  PVA  (polyvinyl  alcohol),  PVP 
(polyvinylpyrrolidone), Dextran, and many  others have the ability to  strongly 
interact with water (Träubel, 1999). Such a preferential interaction hinders the 
protein adsorption since the latter have to first displace the water molecules to 
be able to bind to the polymer. However, when it comes to use this approach to 
coat either surfaces or nanoparticles, the chemical nature of the applied polymer 
is not sufficient to prevent the protein fouling. In fact, a surface coated with a 
dense polymer brush is required to form a steric hindrance. In presence of such 
surface coating, proteins will have first to deform the polymeric layer to access 
and interact with the underlying substrate. Thus, parameters such as molecular 
weight and grafting density are also critical to limit the protein fouling.
At the nanoscale, the interaction between protein and synthetic surfaces are 
strongly  affected  by   the  surface  curvature.  Several  studies  have  reported 
considerable  differences  in  protein  adsorption  between  flat  surfaces  and 
nanoparticles in terms of kinetics and protein composition (Rahman, 2013). As   
the nanoparticle size approaches the size of proteins the protein / nanoparticle 
interaction  decreases.  Furthermore  as  the  surface  curvature  increases,  the 
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(Lynch and Dawson, 2008). As schematised in Figure 2.2-A as the nanoparticle 
decreases  in size, the  effective  polymer coating with adequate brush density 
becomes the critical factor. Two surfaces with different curvatures and with the 
same graft density  will have very different brush density with the less curved 
being denser (Daoud and Cotton, 1982; Nagarajan and Ganesh, 1989). Typically 
as  the  curvature  approaches  zero  the  highly  grafted  polymer  coating  has 
conformations approaching the Alexander-De Gennes limit (i.e. with the single 
chains fully stretched). Such a condition gives the densest brush conformation 
and hence is the most effective in creating steric repulsion (de Gennes, 1980).
As summarised in Figure 2.2-B, for structures where the polymer that form the 
brush is also a structural unit that control the final geometry  such as in micelles 
and vesicles, the brush density depends on the single copolymer packing density 
(i.e. the packing factor). Spherical micelles have the least dense configuration 
with packing factors, p<1/3, and vesicles have the densest configuration with 
packing factor approaching the unit (e.g. p=1) (Bates and Fredrickson, 1990; 
Fredrickson and  Bates,  1996;  Matsen and  Bates,  1996a;  Matsen  and  Bates, 
1996b; Rahman, 2013). 
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coated nanoparticle, where decreasing the particle size,  decrease also the d 
value. (B) Schematic of copolymer assemblies and the factors that in this case 
contributes on the ﬁnal brush density. Micelles are characterised by a smaller p 
(<1/3) and thus smaller  size compared to polymersomes (p=1), consequently 
they presents also a lower d value.
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polymers that are known to prevent protein fouling: the PEG and the PMPC. 
These  are  co-polymerised  with  hydrophobic  poly(2-(diisopropylamino)ethyl 
methacrylate) (PDPA) in two different compositions to form polymersomes and 
micelles  respectively. PMPC25-PDPA70 a n d  P E G 45-PDPA80  were  used  for the 
polymersomes  formations. PMPC30-PDPA30 a n d  P E G 113-PDPA56 w e r e  u s e d  t o  
obtain  micelles.  The  relative  protocols  for  the  assemblies  preparations  are 
described in the materials and methods section (Section 7.1.2). Polymersomes 
and micelle dispersions were characterised by  Dynamic Light Scattering (DLS) 
and Transmission Electron Microscopy (TEM) as shown in Figure 2.3.
Figure 2.3. DLS and TEM analysis of  micelle and polymersome assemblies 
derived from PMPC-PDPA and PEG-PDPA block  copolymers. Scale bar:  150 
nm.
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average  diameters  of  the  two  PMPC-PDPA and  PEG-PDPA assemblies.  The 
PMPC-PDPA polymersomes have an average diameter of approximately 150±10 
nm, while the micelles have average diameter of 30±10 nm. The PEG-PDPA 
polymersomes and micelles have an average diameter of 145±5 and 40±15 nm 
respectively.  Proteins  such  as  the  Bovine  Serum  Albumin  (BSA), 
Immunoglobulin G (IgG), and lysozyme were chosen as a models. BSA and IgG 
are  two  abundant  proteins  found  in  the  blood  plasma and  they are  widely 
studied as models for opsonisation (Giacomelli et al., 2012). Lysozyme is one of 
the very few globular proteins to have positive net charges and it was used to 
evaluate  the  effect  of  electrostatic  interactions.  All  these  proteins  were 
fluorescently  labeled with Cy5 (Cyanine5) dye as described in the materials and 
methods section (Section 7.1.4).   
2.2.2. Characterisation of protein fouling process
To evaluate the interaction between proteins and micelles and vesicles we used 
Size Exclusion Chromatography (SEC) to quantify  the amount of protein bound 
and  confirmed  this  binding  using  both  TEM  and  Isothermal  Titration 
Calorimetry (ITC). 
SEC, initially developed by  Moore and colleagues (Moore, 1964), is extensively 
used  for  the  purification  of  macromolecules  in  solution and  it can also  be 
applied as analytic tool. The SEC principle is based on the use of a highly porous 
cross-linked resin that is settled in an appropriate column eluted with solvent 
(typically aqueous). Such a technique allows the separation of macromolecules 
and / or particles as a function of their size. The gravitationally driven elution 
through the resin of  small particles requires longer time  compared to  larger 
ones.  This  is  because  small  particles  can  access  more  volume  than  larger 
particles with consequent longer retention (Figure 2.4).
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puriﬁcation  of  different macromolecules and /  or  particles depending on  their 
size. Small macromolecules and / or  particles have a longer  retention volume 
compared to bigger particles, thus allowing their separation from the latter.
The concentration used for each experiment of the three tested fluorescently 
labeled protein; BSA, IgG and lysozyme, was set at 15 µM to avoid unwanted 
protein  /  protein  interaction  and  yet  enable  enough  sensitivity   for  their 
detection. 12 µM of PMPC-PDPA or PEG-PDPA were used for both, micelles and 
polymersomes  which  correspond  to  at  least  100  proteins  per  particle 
(polymersome or micelle). Three different samples: free protein, polymersomes 
and micelles were also prepared at the described concentrations and evaluated 
separately as controls.
As shown in the chromatograms in Figure 2.5 A-B-C-D-E-F, the elution time 
resulting from the SEC analysis for micelles and vesicles (either PMPC-PDPA or 
PEG-PDPA) is respectively of ~35 and ~34 min. Instead, the protein peak is 
detected after ~78 min. The stationary phase used, (Sepharose 4B) was unable 
to  separate particles larger than 40 nm, but with it was possible to separate 
effectively smaller sizes. Looking at the resulting spectra at both wavelengths 
(UV-Vis absorbance at 220 nm and fluorescence emission intensity at 669 nm) 
it is  clear  that  polymersomes  and  micelles  are  detected  in the  fluorescent 
channel. Since  the  PMPC-PDPA or PEG-PDPA were not associated with any 
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86inherent fluorescence is most likely that the signal detected by  the spectrometer 
is derived from light scattering. 
It is important to notice that no  interactions were revealed for the mixture of   
protein (BSA, IgG and lysozyme) plus polymersomes. This result was confirmed 
in  both  PMPC-PDPA  and  PEG-PDPA  polymersomes.  In  either  cases,  no 
differences in the proteins retentions time (~78 min) were found compared to 
the free proteins controls (~78 min).
On the other hand, the mixed samples between protein and micelle yields to a 
protein detected peak that appeared characterised by a different retention time 
(~38 min) and shape compared to the free protein control. The results reported 
in  Figure  2.5  A-B-C-D-E-F,  shows  this  effect  in  particular considering  the 
fluorescence channel. It is important to notice, that the protein peak detected in 
mixed samples of protein plus micelle is characterised by a shape that follows 
the tailing trend that belongs to the micelles chromatogram measured at 220 
nm. Taken together,  these  observations  indicate  that  in a mixed  micelles  / 
proteins sample, part of the protein fraction is binding to the micelles. However, 
not relevant modifications  on the micelles retention time are herein detected 
when these particles are mixed with proteins. 
It is  believed  that this  result is  due  to  the small hydrodynamic volume  that 
belongs to the proteins in comparison to the micelles. Thus, the interaction of 
the  former  with  the  micelles  could  be  not  sufficient  to  induce  a  relevant 
increment on the  complex's size (micelle plus  proteins) that can be detected 
using SEC.
To  better explore this  hypothesis, a DLS analysis was  performed before and 
after micelle  incubation  with  protein. However,  the  results  of  this  analysis 
revealed no  difference in terms of average diameter between the two samples 
(data not shown). 
Nevertheless, experiments reported by Giacomelli and colleagues showed using 
both Small-Angle X-ray Scattering (SAXS) and Static light scattering (SLS) the 
correlation between minimal increase (~4 nm) on the micelle average diameter 
with the formation of a protein monolayer (Giacomelli et al., 2012). 
It is further necessary to remark that the same results were obtained in presence 
of either PMPC-PDPA or PEG-PDPA structures. 
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Figure 2.5-A. SEC analysis of PMPC-PDPA polymersomes and micelles mixed 
with  BSA.  The  chromatograms  were  obtained  measuring  the  UV-Vis 
absorbance at 220 nm (left side) and the ﬂuorescence emission intensity at 669 
nm (right side).  
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88Figure 2.5-B. SEC analysis of PMPC-PDPA polymersomes and micelles mixed 
with IgG. The chromatograms were obtained measuring the UV-Vis absorbance 
at 220 nm (left side) and the ﬂuorescence emission  intensity at 669 nm (right 
side).
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89Figure 2.5-C. SEC analysis of PMPC-PDPA polymersomes and micelles mixed 
with  lysozyme.  The  chromatograms  were  obtained  measuring  the  UV-Vis 
absorbance at 220 nm (left side) and the ﬂuorescence emission intensity at 669 
nm (right side). 
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90Figure 2.5-D. SEC analysis of PEG-PDPA polymersomes and micelles mixed 
with  BSA.  The  chromatograms  were  obtained  measuring  the  UV-Vis 
absorbance at 220 nm (left side) and the ﬂuorescence emission intensity at 669 
nm (right side). 
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91Figure 2.5-E. SEC analysis of PEG-PDPA polymersomes and micelles mixed 
with IgG. The chromatograms were obtained measuring the UV-Vis absorbance 
at 220 nm (left side) and the ﬂuorescence emission  intensity at 669 nm (right 
side).
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92Figure 2.5-F. SEC analysis of PEG-PDPA polymersomes and micelles mixed 
with  lysozyme.  The  chromatograms  were  obtained  measuring  the  UV-Vis 
absorbance at 220 nm (left side) and the ﬂuorescence emission intensity at 669 
nm (right side). 
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93To have a direct visualisation of the described micelles / proteins interactions a 
TEM analysis was also performed. For this purpose, the used model protein is a 
IgG  labelled  with 5  nm gold  nanoparticle  (AuNP-IgG). The  presence  of  the 
electron dense gold  nanoparticle allows  the  facile identification of  the  latter 
under the TEM. To perform this experiment, a final concentration of 1.5 µg/ml 
AuNP-IgG  was  placed  in 300  µl  of  PMPC-PDPA micelles  or polymersomes 
sample  (10 mg/ml). Assuming a molecular mass  of  the gold nanoparticle  of 
about 5 MDa (i.e. about 25,000  gold  atoms  per particles),  these conditions 
corresponds to about 1 AuNP-IgG per micelle. Note that higher concentrations 
were inaccessible by the experimental set-up. The samples were incubated for 
about 10 min and purified by SEC. As shown in Figure 2.6, only  the micelles 
show the presence of gold attached to their surfaces with configuration of about 
AuNP-IgG per micelle confirming the original calculation. On the contrary no 
gold was detected for the polymersomes sample confirming that polymersomes 
do not interact with the proteins.    
Figure  2.6.  TEM  characterisation  of  PMPC-PDPA  (A)  micelles  and  (B) 
polymersomes aimed to visualise their possible interaction with 5 nm AuNP-IgG. 
As  it  is  possible  to  see  in  (A),  AuNP-IgG  bound  the  micelles  after  SEC 
puriﬁcation,  while this  is not the case considering the polymersomes sample 
(B). Scale bar: 60 nm.
To establish the equilibrium between micelles and proteins, a thermodynamic 
characterisation  of  the  system  was  performed  by  Isothermal  titration 
calorimetry  (ITC).  This  technique  is  usually   applied  to  describe  binding 
processes, for example between an enzyme and its substrate. The ITC device is 
generally   constituted  of  two  cells,  containing  separately  in  each  one  the 
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reference cell, is thermally  controlled and capable to sense minimal temperature 
variations.  Thus,  for  the  thermodynamic  interaction  analysis  between  two 
different  molecules,  the  temperature  into  the  reference  cell  has  to  be 
continuously  tracked  during sequential injections  of a species into  the  other. 
These injections are then repeated over time, until the investigated interactions 
analysis  reach  a  point  of  saturation.  Herein  the  ITC  measurement  was 
performed  to  disclose  the  energetics  of  the  binding  between IgG  /  BSA  to 
polymersomes  or micelles  made  by  PMPC-PDPA or PEG-PDPA. 15.2 µM  of 
analysed protein was initially introduced into the reference cell, and 47.6 µM of 
polymeric micelles or polymersomes (either PMPC-PDPA or PEG-PDPA) were 
in turn placed into a syringe (second cell) and injected 10 µl per time at regular 
intervals into  the protein solution. The polymer molarity of the micellar and 
polymersomes sample, was calculated as a function of the single polymer chain. 
This would result as a more realistic situation, since the binding effect should be 
proportional to  the surface  area per micelle or polymersome rather than the 
total micelles or polymersomes number on the solution. The obtained ITC data 
are shown in Figure 2.7. 
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95Figure  2.7.  ITC  analyses  of  PMPC-PDPA  /  PEG-PDPA  micelles  and 
polymersomes  with  two  different  proteins:  IgG  and  BSA.  The  red  line 
corresponds to the baseline of the measurement.   
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96From the ITC data presented in Figure 2.7 it is evident that the polymersome 
samples do not show any detectable activity. No peaks were revealed analysing 
mixed samples of polymersomes plus proteins. On the other hand, the micelles 
ITC  measurements  displayed,  depending  on  the  experiment,  positive  or 
negative  areas,  indicating  the  detections  of  exothermic  (negative  areas)  or 
endothermic (positive areas) contributions. It is important to  observe that all 
the  registered  peaks  (either  positive  or  negative)  have  dissimilar  area  of 
integration,  which  indicates  different  occurring  reactions,  in  terms  of 
thermodynamic properties. This  analysis result is  quite difficult to be clearly 
interpreted and the actual measurements are quite noisy. In order to measure 
and assess the actual interaction between the micelle and the protein, one would 
have to repeat the experiment using an opposite configuration, i.e. adding small 
amount of proteins to a fixed amount of micelles. However, this experimental 
condition would  not show the  real  case  scenario. In  fact,  polymersomes  or 
micelles exposed at normal physiological conditions would be diluted into fluids 
rich of proteins. While more ITC characterisation is underway, it is only possible 
to conclude here that the ITC measurements confirm that micelles interact with 
proteins while polymersomes do not show any detectable binding. 
On the  basis  of  these  data, is  confirmed  that proteins  interact strongly with 
micelles and do not interact with polymersomes. 
Using the  SEC  analyses  it is  possible  to  parameterise  the  micelle  / protein 
interaction as an apparent binding constant, Ka:
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This value is different for every interaction is only dependent on temperature. 
For  an  ideal  reaction  this  truly  stays  a  constant  and  thus  dictates  the  rate  and 
direction of the reaction when subjected to change. A decrease in the concentration 
of the reactants will cause the products to dissociate to maintain this equilibrium. It is 
important to note that in the previous equation, the stoichiometry between reactants 
is assumed to be unitary. Given the large relative surface area of the micelles, this is 
highly unlikely, however this gives us a starting point on which to continue further 
calculations. 
Looking  at  the  SEC  curve  of  BSA  and  PMPC25-PDPA70,  one  peak 
corresponds to the amount of bound protein and one to aqueous protein and dividing 
them by each other gives us a simplified ratio. To obtain the actual affinity constant, 
we would then have to divide this ratio by the unbound micelle concentration. This is 
very difficult to experimentally detect, so a further simplification can be made. If we 
assume the concentration of the micelles to be proportionally larger than the protein, 
it will not be greatly affected by the binding protein and so will remain a constant. 
The  affinity  constant  then  simplifies  into  the  simple  ratio  of  bound  and  unbound 
protein with the added benefit that this relationship is the same no matter what the 
true stoichiometry of the reaction is. 
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For the sake of simplifying the calculations, this reduced version of the affinity 
constant will be used. Any deviations from ideal behaviour could be attributed to this 
approximation and will be taken into account. 
 
4.3 General Case: Proteins with Micelles 
  Protein Characterisation. There are many different ways to characterize 
proteins  as  they  are  highly  complex  polymers,  however,  there  are  two  specific 
metrics  that  are  valuable  for  this  discussion:  charge  and  surface  hydrophobicity. 
Starting with charge: all proteins are a collection of bounded amino acids which can 
Where [P]bound is the concentration of protein bound to the micelles, while [P]free 
is the concentration of the free protein. The [P]bound a n d  [P]free values can be 
calculated  by  measuring  the  area  under  the  peaks  obtained  in  SEC 
chromatography evaluating the injected mixed sample (micelles / proteins) on 
the fluorescence channel. Since the most part of the analysed peaks resulted 
overlapping,  the  relative  areas  are  integrated  applying  an  exponentially 
broadened Gaussian (Attila, 1998) as reported in Figure 2.8.
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97Figure 2.8. Areas of integration  for  the obtained SEC peaks.  The integration 
was obtained measuring an exponentially broadened Gaussian. 
It is important to emphasise that this analysis can only be performed for the 
micelles  samples  as  the  polymersomes  samples  show  no  sufficient  bound 
protein  and  Ka e q u a l  t o  z e r o .   The  summarised  Ka  data  calculated  at  the 
equilibrium between PMPC-PDPA / PEG-PDPA micelles and the tested proteins 
are shown in Figure 2.9. 
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98Figure 2.9. Afﬁnity constant (Ka) extrapolated from the SEC analyses regarding 
the  PMPC-PDPA /  PEG-PDPA micellar  binding  with  three  different  proteins 
namely BSA, IgG and lysozyme. (t-test, p-value * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 
0.001;  ****  P  ≤  0.0001).  The  experimental  error  is  expressed  as  standard 
deviation (N=3).
The  PMPC-PDPA micelles show a similar grade of  interaction within all the 
tested proteins. The resulting Ka values appears to be very similar, ranging from 
~0.6 (lysozyme) to ~0.9 (IgG). The PEG-PDPA micelles instead show smaller Ka 
for the IgG  and  BSA (Ka  = ~0.2; ~0.4) and similar values, compared to  the 
PMPC-PDPA data, for the lysozyme with a resulting average Ka of ~0.7. 
Figure  2.10  shows  the  different properties  of  the  proteins  evaluated  in this 
study, using either values extracted from the Protein Data Bank (PDB) or from 
the literature. The table lists the hydrodynamic radius (RH, nm), molecular mass 
(kDa),  the  protein  net  charge  expressed  as  ζ-potential  (mV) a n d  t h e  
hydrophobic Solvent Accessible Surface Areas (SASAs) percentage calculated as 
reported  from  Fraternali  and  colleagues  (Fraternali  and  Cavallo,  2002; 
Giacomelli et al., 2012).    
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99Figure 2.10. Schematic  showing the PDB references and physical / chemical 
properties  such  as hydrodynamic  radius (RH,  nm),  molecular  mass  (kDa),  ζ-
potential  (mV)  and  hydrophobic  Solvent  Accessible  Surface  Areas  (SASAs) 
percentage that belongs to the proteins evaluated in this study. Scale bar: 2 nm.
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hydrophobicity and  yet the  data in Figure 2.9 show little differences  on the 
binding effect revealed between the latter and PMPC micelles. Lysozyme shows 
in  that  case  a  slightly   lower  interaction  with  the  micelles,  however  not 
statistically different from the other two models. On the other hand, the PEG 
micelles bind considerably less  to  IgG and BSA than the PMPC counterparts, 
but the binding to lysozyme is still equally  detectable. The correlation with these 
data and  the protein properties listed in Figure 2.10, would suggest that the 
electrostatic interaction between the residual positive charge of the PDPA (being 
10% at pH 7.4 (Pearson et al., 2013) and the proteins are not involved since also 
the  lysozyme  (ζ-potential  = +6)  binds  to  the  micelles. On  the  other  hand, 
referring  to  the  PMPC-PDPA  micelles,  a  correlation  between  proteins 
hydrophobicity and obtained Ka values can be stipulated. Indeed, the greater the 
hydrophobicity of  the  protein,  the  greater the  interaction  with  the  micelle. 
Nevertheless, considering PEG-PDPA micelles, the described  Ka  trend is not 
maintained, and the lysozyme represent the protein more interacting. Clearly 
the data presented shows that PEG is superior to PMPC to protect the micelle 
from protein fouling. It is important to notice that PEG-PDPA micelles have a 
size of 40 nm compared to 30 nm for PMPC-PDPA micelles. This difference is 
due to the difference in the degrees of polymerisation of the hydrophilic block 
that characterise the two copolymers used. PMPC has a polymerisation degree 
of 30 while the PEG of 113. Previous studies based on PEG assemblies, show 
that  increasing  the  degree  of  polymerisation  of  the  hydrophilic  block 
consequently increase the  stealth properties  of the  nanocarrier reducing the 
protein  adsorption  (de  Castro  et  al.,  2014).  This  occurs  because  longer 
hydrophilic polymer chains can shield the hydrophobic core of the nanocarrier 
better than shorter chains and protect it from its interaction with the protein. 
Furthermore, a recent study from Giacomelli and collaborators, highlighted the 
importance  of  the  hydrophilic  copolymer chains  density (Giacomelli  et  al., 
2012). They observed that micelles formed by PEG as hydrophilic block have a 
chain surface density per nm2 equal to ~0.1, which is a considerably higher value 
compared to PMPC (as hydrophilic block) micelles which are characterised by  a 
value of chain surface density equal to ~0.05. Giacomelli et al., showed that this 
parameter is a critical factor that strongly  affects the interactions between the 
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the  hydrophilic chain surface  density of  the polymeric  assemblies, the more 
exposed the hydrophobic micellar core is. 
This  increases  the  possibility  for  the  proteins  to  penetrate  the  external 
hydrophilic  shield.  For  this  process  to  occur,  the  protein  size  represents  a 
determining factor. Small proteins  can penetrate  external  hydrophilic shield 
more easily compared to bigger one (Giacomelli et al., 2012).    
These  assumptions  were  confirmed from the obtained  results  where  PMPC-
PDPA micelles are equally interacting with all the tested proteins while PEG-
PDPA micelles presents lower adsorption considering IgG and BSA compared 
with the higher absorption detected  for the  lysozyme. Thus, it is  possible  to 
rationalised the data for the PEG system as a function of the protein size, with 
lysozyme being considerably smaller than the IgG and BSA and therefore able to 
penetrate the polymer brush and interact to the hydrophobic core of the micelle. 
However,  the  most  striking  observation  is  that  the  same  copolymer  stops 
protein interaction when assembled as polymersomes and fail to  do  so when 
assembled as micelles. As  schematised in Figure 2.11, this of course suggests 
that the  copolymer conformation has  a fundamental role in this process and 
that the brush density correlated with the copolymer assemblies play a pivotal 
role. 
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102Figure  2.11.  Illustration  to  explain  the  binding  protein  effect  detected  in 
presence of micelles. The different copolymer conﬁguration is speculated to be 
the causing factor  for the studied binding equilibrium. The lower brush density 
characterising  the  micellar  conformation  possibly  allows  the  proteins 
penetrations  of  the  external  hydrophilic  polymer  brush,  thus  permitting their 
interactions  with  the  hydrophobic  core  of  the  micelle.  As  experimentally 
conﬁrmed,  this  is  not  occurring  in  presence  of  polymersomes,  which  are 
assemblies characterised by a higher brush density compared to micelles.  
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Results and Discussion
ELECTROPORATION FOR PROTEIN 
ENCAPSULATION WITHIN POLYMERSOMES
3.1. Electroporation principles
The electroporation technique, also called electropermeabilisation, is a process 
widely applied in Molecular Biology. It is used with the aim of introducing into 
cells external molecules that are dissolved in an appropriate media. With this 
procedure it is possible to  obtain the intracellular delivery of  a vast range of 
different  compounds,  characterised  by very different  chemical  and  physical 
properties,  including:  proteins,  DNA,  and  mRNA  (Neumann  et  al.,  1999). 
Electroporation consists of an externally applied electrical field that induces an 
increase in the electrical conductivity and, consequently, permeability of the cell 
plasma  membrane  (Ho  and  Mittal,  1996b;  Neumann  et  al.,  1982).  Herein, 
electroporation was studied and developed as a consistent and reproducible way 
to introduce proteins into polymersomes. 
Electroporation  is  based  on  an  oscillatory electrical  field  occurring  in  an 
electrode chamber that produces ions displacement and the formation of charge 
poles across  the  subjected membrane. This, in turn, leads  to  an unbalanced 
concentration  of  fluid  ions  between  the  internal  membrane  enclosed 
environment  and  the  external  one.  In  such  a  way,  the  generated  osmotic 
pressure  induces  the  formation of  pores  and  consequent diffusion of  water 
soluble species across  the membrane  (Escoffre et al., 2009; Neumann et al., 
1999).
The effectiveness of the electropermeabilisation technique is based on various 
parameters that range from the strength of the electrical field, the number of 
104pulses  applied  and  the  duration  of  a  single  pulse  (Ho  and  Mittal,  1996a; 
Knutson and  Yee,  1987). The  electrical  filed  strength value  results  from the 
contributions  of  both  the  voltage  used  (Va)  and  the  distance  between  the 
electrodes. This parameter is responsible for the pore formations on the subject 
membrane.  On  the  other  hand,  the  number  of  pulses  applied  and  their 
durations  determine  the  size  and  number  of  the  resulting  pores.  Studies 
performed using cell models, have shown that the temporal formation of pores 
at the cytoplasmic membrane level can be induced by adjusting both parameters 
(Escoffre et al., 2009; Neumann et al., 1999). Besides these parameters, other 
factors such as the type of membrane, the temperature of the system and ion 
concentrations  can also  influence  the  results  of  the  electroporation process. 
Furthermore, the surface charge of the molecule that is to be permeated affects 
its internalisation process (Wang et al., 2012).  
The  polymersome  membrane,  as  well  as  the  lipid  one, is  held  together  by 
supramolecular forces  and  indeed  is  sensitive  to  electrical  fields.  Hence,  as 
schematised  in  Figure  3.1,  it  was  hypothesised  that  the  application  of  an 
electrical field will cause the temporary formation of pores that will in turn be 
used to load proteins within the polymersomes. However from a physical point 
of  view,  Aranda-Espinoza  and  coworkers  (Aranda-Espinoza  et  al.,  2001) 
compared  the  electromechanical  properties  of  a  poly(ethylene  oxide)-block-
polybutadiene  (PEO-PBD)  polymersome  membrane  with  a  lipid  one.  They 
clearly  demonstrated  that  the  polymersome  membrane  can  porate  as  a 
consequence  of  an electrical field, albeit with a voltage  almost one order of 
magnitude larger than the required one for lipids. Precisely, they defined that 
the membrane breakdown potential value (Vc) is  directly proportional to  the 
membranes thickness (d). Thus, they calculated that a polymersome with a d 
value of 15 nm is characterised by  a Vc  = 9 V. Instead, liposome with a much 
smaller d value, equal to 3 nm, presents  a Vc  = 1 V (Aranda-Espinoza et al., 
2001;  Discher  et  al.,  1999).  Furthermore,  the  higher  robustness  that 
characterises a polymersome membrane compared to a lipid one is due to the 
entanglement effect that occurs between the hydrophobic polymer chains. For 
this reason, and in order to obtain the polymersome membrane poration and 
cargo  encapsulation  via  electroporation,  different  parameters  were  herein 
explored. These parameters range from the number of repeated pulses to the 
ion concentration and the initial potential-cargo  concentration in the sample 
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105solution. Importantly, the structural integrity of both vesicles (morphology and 
size distributions) and encapsulated cargo (biological activity) was tested after 
the  electroporation  process.  Furthermore,  the  encapsulation  efficiency  of 
complex  bio-molecules  such  as  Immunoglobulin  G  (IgG)  achieved  with 
electroporation was compared with other encapsulation methods  such as pH 
switch and polymer-film rehydration.
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106Figure  3.1.  Schematic  representation  of  the  four  steps  required  for  the 
encapsulation of biomacromolecules within polymersomes, via electroporation. 
In  the  ﬁrst  step (1),  polymersomes  and  the  cargo  are  both  loaded into  the 
electroporation  cuvette.  Afterwards  (2),  the  applied  electric  pulse  leads  the 
formation  of  transient  pores  on  the  polymersomes  membrane,  allowing  the 
cargo  encapsulation.  The  third  step  (3)  represents  the  polymersomes 
membrane recovery, and the consequent intra-vesicular trapping of the loaded 
cargo. Finally, in the fourth step (4), the loaded polymersomes are puriﬁed from 
the non-encapsulated biomolecules.
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First of all, it is important to note that in all the performed experiments, the 
PMPC-PDPA  (Poly(2-methacryloyloxyethyl  phosphorylcholine)-co-poly(2-
(diisopropylamino)ethyl  methacrylate) p o l y m e r  c o n c e n t r a t i o n  w a s  k e p t  
constant  at  10  mg/ml  in  phosphate-buffered  saline  0.1 M  (1X  PBS).  The 
polymersome  samples  were  prepared  with  film rehydration  method,  which 
requires 8 weeks, under high shear rate stress (magnetic stirring at 200 rpm) 
(Robertson et al., 2014). The  used  electroporation protocol  included  a fixed 
voltage value (Va) of 2500 V. This is in accordance with previous studies that 
reported  that  micrometer /  nanometer vesicles  require  a  considerably high 
voltage  to  be  temporally  affected  by  pore  formation  on  their  membrane 
(Schoenbach et al., 2001). Furthermore, 20 electrical pulses were applied. To 
confirm the vesicular formation and stability, before and after this high energy 
transfer,  Dynamic  Light  Scattering  (DLS)  and  Transmission  Electron 
Microscopy  (TEM)  analyses  were  performed.  These  two  techniques  show 
respectively the average intensity of the particle diameter in solution (DLS) and 
a dehydrated representation of their morphology (TEM). As  shown in Figure 
3.2, no differences were observed in the polymersome sample before and after 
the electroporation process. Thus, TEM and DLS analyses confirmed that the 
size distribution and the structural particle integrity was maintained unaltered 
after electropermeabilisation. These results strongly corroborate the hypothesis 
of  a transient pore formation on the  polymersome membrane, which can be 
recovered after the electroporation process. 
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108Figure 3.2. (Left) TEM analyses before (A) and after (B) electroporation, which 
includes the intensity against distance plot proﬁle (the dark  magniﬁed region 
corresponds  to  the  minimum  revealed  intensity).  (Right)  DLS  analyses 
(correlation  function  and  size  distribution  intensity  graphs)  of  PMPC-PDPA 
polymersomes before ( ) and after ( ) electroporation. Scale bar: 150 nm.
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1093.3. Antibody stability after electroporation process
Any potential damage caused by the electroporation process on the IgG stability 
and  bioactivity was  assessed  by (i) Enzymatic Linked  Immunosorbent Assay 
(ELISA) and (ii) immunohistochemistry. The first test used for this purpose was 
the  ELISA assay  (Engvall  and  Perlmann,  1971).  This  sensitive  method  is  a 
quantitative  sandwich immunoassay based  technique.  For normal  biological 
applications, this  colorimetric assay is  utilised  for the  detection of a specific 
antigen solubilised in media. This test, in fact, involves the use of well plates 
that  are  pre-coated  with  a single-type  of  immobilised  IgG  antibody that is 
selectively  able to bind the corresponding antigen (if it is present in the added 
liquid sample). After the first step of the ELISA protocol, that correspond to the 
antibody-antigen  detection,  to  avoid  any   contamination  from  unbounded 
molecules,  the  latter are  removed  from the  plate  with consecutive  washing 
steps. The subsequent step concerns the addition of a secondary enzyme-linked 
antibody, able in turn to detect if present, the previously  immobilised antigen. 
After that, another washing step is necessary  to exclude any unbound secondary 
IgG. The last part of the ELISA procedure is the reaction between the enzyme 
linked  secondary  IgG,  with  the  appropriate  substrate  (see  Figure  3.3). 
Importantly,  the  product  derived  from  this  colorimetric  reaction  can  be 
quantified via spectroscopy and can be proportionally correlated to the amount 
of unknown antigen present in the sample.
For the  validation purposes, the  ELISA secondary  enzyme-linked IgGs  were 
initially  subjected to the electroporation procedure. Subsequently to that, these 
IgGs  were used in a standard ELISA assay. In such a way, it was  possible to 
evaluate the IgGs ability to detect the presence of a previously absorbed antigen 
(bound to the primary  antibodies) and thus to characterise their integrity after 
the  electroporation  process.  These  antibodies  were  compared  to  native 
untreated IgGs (negative control) and to  degraded immunoglobulins (positive 
control obtained by placing the protein at 90°C for 15 min).  
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customised  ELISA  assay,  used  to  evaluate  the  antibody  stability  after 
electroporation.  (1) In the ﬁrst step of  the protocol, the secondary IgG-linked 
enzyme is subjected to electroporation. (2) Subsequently, the pre-coated well 
plate, presenting the immobilised IgG, is exposed to the antigen solution. (3-4) 
In  the last two steps of the protocol, antigen recognition  of the electroporated 
IgG is evaluated through a colorimetric enzymatic reaction.  
The  second  test  performed  to  validate  the  antibody  stability  after 
electroporation was based on immunohistochemistry (Odell and Cook, 2013). 
This is a technique that involves  the use of specific fluorescently  labeled IgG 
able to recognise singular epitopes displaced on an appropriately  permeabilised 
and fixed  cell. The cellular permeabilisation and fixation steps are critical to 
allow penetration of the antibody into the targeted cell model; otherwise it is 
inaccessible to extracellular proteins such as free IgGs. After the fluorescently 
labelled-antibody epitope  recognition,  the  targeting protein  mechanism was 
assessed through confocal microscopy analysis. Also in this stability test, as in 
the ELISA, structural impairment of the antibody  can affect the capability of the 
latter to  bind  the  intracellular  target.  For  the  immunohistochemistry  IgGs 
stability  characterisation  fluorescently  labelled-antibodies  were  initially 
subjected  to  electroporation  and  their  ability  to  target  the  corresponding 
epitope was compared (at equal concentrations) with a negative control (non-
treated antibody) and a positive one (degraded antibody). 
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immunohistochemistry, regarding the IgGs stability after electroporation.
It is possible to notice in Figure 3.4-A, which shows the ELISA immunoglobulin 
stability data (using a detection kit against Interleukin 8 (IL-8)), there is not 
statistical  difference  when  comparing  the  electroporated  IgGs  (enzyme 
conjugated IgG anti IL-8) with the native untreated control. Furthermore, no 
difference in the IgGs activity  was observed after subjecting it to  5, 10 or 20 
pulses. Indeed, after 20 electroporation pulses, more than 93% of the antibodies 
were capable of binding to the immobilized antigen, demonstrating the overall 
protein  resilience  to  the  process.  On  the  other  hand,  the  positive  control 
antibody (obtained  by placing the protein at 90°C for 15 min)  indicated the 
expected protein degradation. Indeed, just 8%  of  the  IgGs  were  still able  to 
detect the corresponding antigen. 
In the second stability test, an anti α-tubulin AlexaFluor®647 antibody was used 
as a model for the immunohistochemistry test after electroporation. Also in this 
case,  the  antibodies  were  subjected  to  20  pulses  during  the  encapsulation 
process simulation. After that, their ability to recognise the α-tubulin epitope in 
Human Dermal Fibroblast (HDF) was tested. The α-tubulin was exploited as a 
target  model,  since  its  tubular  structure  it  is  well  established  and  easily 
recognisable  in  confocal  microscopy  analysis  (Saxton  et  al.,  1984).  This 
facilitates the evaluations of the antibody structural stability. Also in this case, 
the  results  in  Figure  3.4-B  shown  that  the  activity  of  the  electroporated 
antibodies was similar to the control native protein. The control IgG and treated 
protein presented the same capability of interacting with the α-tubulin epitope, 
confirming that there was essentially no degradation after electroporation. On 
the other hand, the positive control antibody (obtained by placing the protein at 
90°C for 15 min) as expected was unable to stain the α-tubulin.
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112Figure 3.4. (A) ELISA assay results regarding the antibody stability evaluation 
after different electroporation pulses (t-test, p-value * P ≤ 0.05; ** P ≤ 0.01; *** 
P  ≤  0.001;  ****  P  ≤  0.0001).  (B)  Immunohistochemistry  assay  in  HDFs  to 
validate  antibody  stability  after  20  electroporation  pulses  of  anti  α-tubulin 
AlexaFluor®647 antibody. In both experiments the IgG stability was compared to 
a negative control (untreated IgG, -CTRL) and a positive control (IgG placed at 
90°C for  15  min,  +CTRL). The experimental  error  is expressed as  standard 
deviation (N=3). Scale bar: 20 µm.   
3.4. Protein encapsulation within polymersome
Herein  the  evaluation  of  antibody   (anti  α-tubulin  AlexaFluor®647  IgG) 
encapsulation  within  polymersomes  was  calculated  using  the  encapsulation 
efficiency percentage (E) and  loading efficiency (L). E is  defined as the ratio 
between  the  final  mass  of  encapsulated  protein  within  polymersomes  after 
purification and the initial mass of antibody and it is expressed as it follows:
E = 
n 
n 
(1)  x 100 
p 
p0 
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113where nP0 is the initial moles of protein and nP is the moles of protein after SEC 
purification (see materials and methods section). nP is given by:
 = [P]    x V       (2)  m  s  n p 
where [P]m is the molar concentration of protein measured by reversed phase 
high-pressure liquid chromatography  (RP-HPLC) after purification (materials 
and methods Section 7.2.3) and Vs is the solution volume, while the initial moles 
of protein, nP0, is calculated as follow:
n  p0 
  = [P]    x V       (3)  0  s 
where [P]0 is the initial protein molar concentration. Combining equation 2 and 
3 it is possible to re-write the encapsulation efficiency as follows:
   
(4)  x 100  E = 
[P]    x V  m  s 
  [P]    x V    0  s 
The loading efficiency, L, is the ratio between the measured number of proteins 
encapsulated  per  polymersome  divided  by   the  number  of  proteins  that 
theoretically can be packed within the polymersome lumen. L can be expressed 
as it follows:
L = 
P 
P
(5)  M 
T 
where  PM  is  the  experimental  number  of  proteins  encapsulated  with  the 
polymersome  and  PT  is  the  theoretical  number  of  proteins  that  can  be 
encapsulated. PM is given by:
 = [P]   x V  x N       (6)  P  M  m  s  A 
where NA is the Avogadro’s number. The theoretical number of proteins, PT, can 
be calculated as it follows:
P    = [P]   x V   x N   x N       (7)  T 0  l  A  V 
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polymersomes in the sample. Vl can be calculated as it follows:
Hydrophilic core
Membrane
l
d
d
r
V =  4 
3
  (r-2d-l)
3
(8)  l 
where r is the polymersome radius, d is the hydrophilic layer thickness and l is 
the hydrophobic membrane thickness, while NV is calculated as:
N   = [C] x V  x N  /N    (9)  V  s  A 
where [C] is the final copolymer concentration (measured by RP-HPLC), and N 
is the number of copolymer aggregates per polymersome and is given by:
N=  (10) 
V    
v
M 
PDPA 
where VM is the membrane volumes and is calculated as:
V   =  4 
3
  (r-d-l)
3 (11)  (r-d)
3
- (                          ) M 
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115while  vPDPA  is  the  molecular  volume  of  a  single  chain  of  PDPA  and  it  is 
calculated as:
vPDPA =
MWPDPA 
A  N  PDPA  x  (                          )
(12) 
where MWPDPA is the PDPA molecular mass, and ρPDPA is the PDPA bulk density. 
Combining equations 6-12 the loading efficiency can be re-written as a function 
of experimentally accessible parameters as:
L=  (13) 
x N    
(         x [C] x     )
 [P]m 
[P]0    Vl 
Using such a formula, it is possible to determine if the encapsulation process is 
driven by simple diffusion between solution bulk and the polymersome lumen 
upon  pore  formation  (i.e.  statistical  encapsulation,  L=1),  or  if  there  is  an 
external force  that actively promotes  /  hinders  protein  diffusion within the 
polymersomes and overcomes the entropic barrier to concentrate / dilute them 
within the lumen. When L value is higher than the unity, an external applied 
force  promotes  the  cargo  encapsulation.  Looking  at  the  obtained  L v a l u e s  
summarised  in  Figure  3.5,  it  is  clear  that  for  all  the  tested  conditions, 
electroporation  promotes  the  protein  encapsulation  within  polymersomes. 
Indeed, all the calculated L values appear to  be much higher than the unity, 
ranging from 6 to 76. 
IgG  encapsulation  was  studied  using  different  experimental  conditions, 
including pulses  number, initial amount of IgG and finally by increasing the 
solution  ionic  strength.  It  is  important  to  remark  that  the  polymersome 
concentration was kept constant for each experiment at 10 mg/ml in terms of 
PMPC-PDPA.
No  significant effects  were  here  detected  on  the  protein  and  polymersome 
structure (see Section 3.2 and 3.3) when applying 20 pulses at 2500 V each, 
these  experimental conditions  were  thus  kept for the  protein encapsulation 
studies. In this context, four different experiments  were performed. In all of 
them, the protein and ion concentrations were kept constants at 5 µg/ml (IgG) 
and 0.1 M (1X PBS). On the other hand, the four samples  were subjected  to 
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116different numbers of electroporation pulses: 5, 10, 15 or 20. As explained at the 
beginning of this chapter, the pulses number affects the size, the number, and 
the lifetime of the resulting membrane pores (Escoffre et al., 2009; Neumann et 
al., 1999). The second  variable herein tested, that has  the potential to  affect 
protein encapsulation within polymersomes is the initial protein concentration 
present  within  the  sample.  An  increase  of  this  variable  will  consequently 
increase  the  statistical probability  for the  protein  to  be  trapped  within the 
polymersomes  when  the  pores  are  formed.  For  this  experiment,  the  PBS 
molarity and the number of electric pulses applied were kept constant at 0.1 M 
PBS and 5 (at 2500 V each). Instead, four different protein concentrations: 5, 
10, 20 and 40 µg/ml were  tested. The last parameter changed was  the PBS 
molarity. Previous studies performed using cell models, already  correlated the 
ion concentration in the sample solution, as a critical variable that has to  be 
considered to obtain the maximal internalisation of extracellular compounds via 
electroporation  (Ho  and  Mittal, 1996a;  Knutson  and  Yee, 1987;  Wolf et al., 
1994).  In  this  work,  the  protein  encapsulation  within  polymersomes  was 
evaluated  using three  different  PBS molarities: 0.1, 0.2 and  0.5 M,  keeping 
constant the initial amount of IgG (5 µg/ml) and the pulses number (5 pulses at 
2500  V  each).  The  experimental  results  expressed  as  L a n d  E  for  all  the 
mentioned variables, are summarised in Figure 3.5.
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117Figure 3.5. Encapsulation efﬁciency percentage (E), loading efﬁciency (L) (top 
graphs) and encapsulated amount of IgG (μg/ml, bottom graphs) within PMPC-
PDPA polymersomes obtained by electroporation using different parameters. A-
B,  reports  the  results  of  samples  subjected  to  different  number  of 
electroporation pulses: 5, 10, 15 and 20, keeping constant the protein and ion 
concentration at 5 μg/ml (IgG) and 0.1 M (PBS). C-D shows the data obtained 
from testing four different initial protein concentrations: 5, 10, 20 and 40 μg/ml. 
In  C-D the PBS molarity and the number of electric  pulses applied were kept 
constant at  0.1 M (1X PBS) and 5. Finally,  E-F  shows the data  achieved by 
keeping constant the initial amount of IgG (5 μg/ml) and the number  of pulses 
(5) and testing three different  PBS molarities:  0.1,  0.2 and 0.5 M.  In  all  the 
experiments, the applied voltage per single pulse was set at 2500 V (t-test, p-
value * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental 
error is expressed as standard deviation (N=3). 
The first relevant outcome shown in Figure 3.5 is that the immunoglobulin G 
was  successfully   encapsulated  within  polymersomes  via  electroporation. 
Furthermore, analysing the results for all the different tested conditions, the 
maximum L value was obtained with 20 pulses, keeping constant the protein 
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118and ion concentration at 5 µg/ml (IgG) and 0.1 M (1X PBS) (Figure 3.5 A-B). It 
is  important  to  notice  that  subjecting  the  sample  at  increasing  number  of 
electroporation  pulses  (from  1  to  5),  results  in  a  statistically  significant 
increased in internalisation of protein cargo within the polymersomes (t-test, P 
≤ 0.05). In fact, a single electroporation pulse leads to a loading efficiency of 
~40, and this increases to ~70 as the number of electric pulses increases. No 
statistical significant difference between loading efficiency from 5 to 20 pulses 
was observed. The same trend was also  observed by calculating the µg/ml of 
antibodies  encapsulated per sample. More precisely, in such experiments the 
encapsulated amount of IgG was calculated, which ranged from 0.42 µg/ml (5 
pulses)  to  0.51  µg/ml  (20  pulses).  Whereas,  after  one  pulse  the  protein 
concentration value  calculated  was  0.29 µg/mL  These  results agree with the 
theoretical principle behind the electroporation. As explained at the beginning 
of this chapter, the pulse number is the factor that determines the size and the 
number of pores resulting on the subjected membrane. The obtained data show 
that  increasing  the  number  of  pulses  increases  the  amount  of  protein 
internalised  per  vesicle.  Therefore,  these  results  indicated  that  1  pulse  is 
sufficient to induce the formation of pores with diameter superior of ~10 nm, as 
this is the average size of a single IgG molecule (Marquart et al., 1980; Wells et 
al., 1992).   
The second variable herein tested was the initial amount of protein added to the 
polymersome dispersion (Figure 3.5 C-D). Despite the significant variations in 
L, with values ranging from 66 to  6 going from 5 µg/ml to  40 µg/ml of IgG 
initial concentration, the final amount of antibodies encapsulated using the four 
different initial IgG concentrations (5, 10, 20 and 40 µg/ml), was approximately 
always the same and corresponded to ~0.4 µg/mL. This result indicates that at 
the used experimental conditions (voltage value 2500 V, 5 pulses), all the tested 
IgG  concentrations  allowed  the  achievement  of  the  maximum  protein 
encapsulation within polymersomes. This result would suggest that L and E can 
be further improved  by both increasing the  polymersomes  size and numbers 
and further experiments are ongoing to assess this.  
Concerning the last analysed variable, the PBS molarity, it is evident that the 
obtained IgG encapsulation within polymersomes is not statistically affected by 
this factor within the protein concentrations measured herein (Figure 3.5 E-F). 
As previously explained, the cargo encapsulation via electroporation is mediated 
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it was expected a correlation between ion concentration on the sample solution 
and protein encapsulation.  
Despite  the  obtained  results,  further  experiments  should  be  performed  to 
confirm this possibly spanning across larger ionic strengths. 
Similar conclusions can be drawn using the encapsulation efficiency to analyse 
the data. Indeed, for the tested conditions the obtained E values ranges from ~2 
to ~12%. It is important to consider that the total polymersomes volume percent 
(ϕp)  is  estimated  to  be ~1%  of  the total sample  volume  (data derived from 
equation  (5)).  Thus,  if  the  encapsulated  proteins  were  loaded  within 
polymersomes by simple diffusion (L=1) the resulting E should be around 1%. 
Because the obtained L value is considerably higher that 1 (>70), by  applying 
electroporation  the  protein  internalisation  within  polymersomes  is  forced, 
leading to an increase of E value (~10%) of one order of magnitude. One should 
expect  to  potentially  reach  100%  efficiencies  by  either  increasing  the 
polymersome numbers or by changing their size.
On these premises it is possible to speculate that protein encapsulation occurs 
via two possible mechanisms. On one hand, it is necessary to remark that highly 
charged proteins were used; the IgG has ζ-potential equal to -13.9 mV at neutral 
conditions and room temperature. This would suggest the possible implication 
of an electrophoretic push from the outside to the inside of the polymersomes. 
This  hypothesis  was  partially verified  in  my  original  contribution  using  a 
different protein, the lysozyme (Wang et al., 2012). This enzyme is positively 
charge at neutral pH (ζ-potential = 3.2 mV at pH  7.3) while it is negatively 
charged in alkaline conditions (ζ-potential = -7.8 mV at pH 11). Interestingly, 
the  different  charges  correspond  to  very different  loading  efficiencies  with 
values close to the unity at neutral conditions and values of about 20 at pH 11. 
This would confirm the electrophoresis hypothesis, however, in the same work   
(Wang et al., 2012) also  nucleic acids DNA and RNA were encapsulated with 
very  different loading efficiency  of 20 and 2 respectively. These molecules have 
similar net charges  to  the IgG and lysozyme at pH 11 and one should expect 
similar  trend.  Hence,  it  is  hypothesised  that  there  is  further  a  possible 
entrapment effect, where the diffusion into the polymersomes is considerably 
more efficient that the diffusion out of the polymersomes. This would justify the 
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smaller RNA. Furthermore, such a hypothesis would be in agreement with other 
works ongoing in the Battaglia research group, where it was demonstrated that 
encapsulated proteins within polymersomes have higher stability and unfolding 
kinetics  which are considerably hindered compared to  when they  are free  in 
solution (Cecchin et al., Nat. Commun., under review).  
3.5.  Electroporation  encapsulation  comparison  with  other 
techniques
To  promote  electroporation  as  the  elective  method  to  achieve  protein 
encapsulation within polymersomes, it is necessary  to  compare it with other 
encapsulation methods such as solvent switch and polymer film rehydration. 
The results of this analysis, and in particular the obtained values of L and E for 
each technique, are shown in Figure 3.6. In all cases, the polymersome samples 
were prepared using the same initial amount of PMPC-PDPA (10 mg/ml) and 
IgG (5 µg/ml -  anti α-tubulin AlexaFluor®647 IgG). Furthermore, for all the 
experiments the polymersomes were formed in 0.1 M 1X PBS, as described in 
the materials and methods section (Section 7.2.4).  
Figure 3.6-A and B, show the TEM and DLS characterisations analyses for the 
polymersomes  formed  by  the  three  different  encapsulation  methodologies 
(electroporation, solvent switch and polymer film rehydration). These data are 
critical to explain the final L and E values achieved for each method (see Figure 
3.6-C).  However,  for  such  a  comparison  it  is  important  to  state  that 
electroporation is a post-polymersome-formation protocol while the other two 
methods,  namely solvent  switch  and  polymer  film  rehydration,  allows  the 
protein encapsulation to occur during the polymersome formation (see Section 
1.6.1). For this reason, these techniques are affected by a limited possibility to 
control and modulate the  polymersome  self assembly  process. Therefore, the 
resulting protein encapsulation can be influenced from this lack of control. In 
fact, with these methods, it is  critical to  find  a balance in the experimental 
conditions in order to obtain an adequate polymer self-assembly and to preserve 
the stability of the protein cargo. 
Starting with the analysis of the TEM and DLS data obtained from the solvent 
switch encapsulation method (Figure 3.6-A and B), it is possible to notice the 
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structures. Furthermore, the L and E values resulting from this technique were 
respectively ~85 and ~12%. In this context it is thus necessary to remark that 
the  experimental  data  shown  in  Section  2.2.2  regarding  the  established 
interactions  subsisting between free  proteins  and  micellar structures.  These 
assessed  interactions  therefore  could  result  in  an  overestimation  of  the 
calculated L and E values achieved via solvent switch method.
On  the  other  hand,  the  physical  characterisations  (DLS  and  TEM)  of 
polymersomes  obtained  via  film rehydration shows  the  formation of  larger 
structures  with an average size of ~250 nm as opposed  to  about 150 nm for 
polymersomes used for the electroporation-based encapsulation. It is therefore 
necessary to  mention  that  the  different  size,  between  the  two  samples,  is 
certainly due to the minor shear time applied during the protein encapsulation 
via film rehydration (10 days for the film rehydration encapsulation technique 
compared  8 weeks  for the  preparation of  the  electroporation sample). This 
minor shear time was applied with the aim of preserving the protein stability 
overtime. Furthermore, the achieved data with regards to the protein L and E 
values were ~41 and ~23 % respectively. With this protocol it was possible to 
achieve a quite remarkable E value, which was double that of the one achieved 
via electroporation. However a previous study conducted using liposomes as a 
model,  revealed  that  this  techniques  leads  to  a  non  homogeneous  protein 
encapsulation (Luisi et al., 2010). This study carried out by Luisi and colleagues 
shows  that the obtained liposome sample was  characterised by two  vesicular 
populations, one presenting the trapped cargo while another one characterised 
by empty vesicles. In this context, despite the promising data that were achieved 
with  this  approach,  further  investigations  are  necessary to  reach  a  better 
understanding  on  the  encapsulation  mechanism  that  drives  the  protein 
internalisation  via  film  rehydration  using  PMPC-PDPA  block  copolymers. 
Nevertheless,  these  data  show  that  electroporation  has  the  highest 
reproducibility  and  its  post-polymersome-formation  nature  bodes  well  for 
future  technological  translation  of  polymersomes  compared  to  the  other 
techniques. 
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122Figure 3.6. (A) TEM, (B) DLS and (C) Encapsulation efﬁciency percentage (E) / 
loading efﬁciency (L) analyses regarding the IgG encapsulation within PMPC-
PDPA  polymersomes  obtained  using  three  different  methods  namely 
electroporation,  pH  switch  and  ﬁlm  rehydration.  The  experimental  error  is 
expressed as standard deviation (N=3).
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Results and Discussion
POLYMERSOMES AS A FUNCTIONAL ANTIBODY 
DELIVERY SYSTEM IN LIVE CELLS
4.1. Polymersome treatment and cells viability 
A first requisite for any delivery system in cells is to understand whether it can 
induce any adverse effects. Previous studies have already extensively assessed 
the  biocompatibility  of  PMPC-PDPA  (Poly(2-methacryloyloxyethyl 
phosphorylcholine)-co-poly(2-(diisopropylamino)ethyl  methacrylate) 
polymersomes in several cells types and in vivo; so far no adverse effects are 
reported (Massignani et al., 2009). However, to biologically validate once more 
PMPC-PDPA polymersome as a biocompatible delivery system and to ensure 
that  the  batch used  herein  was  not  deteriorated, a cyto-compatibility study 
using an in vitro MTT assay was performed. 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) is a 
molecule  that  can  be  reduced  by  two  types  of  cellular  enzyme,  namely 
dehydrogenases  and  NAD(P)H-dependent  oxidoreductases  (Berridge  et  al., 
2005).  This  enzymatic  reaction  is  proportionally  related  to  the  metabolic 
activity of  the cell, transforming the  yellow coloured MTT substrate into  the 
purple insoluble product formazan. This can be detected spectrophotometrically 
as it absorbs light with a peak at wavelength of 570 nm (van Meerloo et al., 
2011). The MTT assays is an in vitro test widely  used to verify the toxicity of 
drugs on cell models (Sadeghi Aliabadi et al., 2010). MTT assay  was performed 
after 24 h incubation with polymersomes at concentrations of 0.5, 1 and 1.5 mg/
ml.  Cells  were  treated  with  an  equal  volume  (compared  to  the  added 
polymersomes sample) of 1X phosphate buffered saline (PBS 0.1 M) in media as 
a negative control. 
124Five different cells models were used in this validation; primary  human dermal 
fibroblasts (HDF), a breast cancer cell line (MDA-MB-231), ovarian carcinoma 
cells  (SKOV3),  human  skin  melanoma  cells  (MEWO)  and  urinary bladder 
transitional carcinoma cells (RT112). 
The obtained results are shown in Figure 4.1.
Figure 4.1. Cells viability (%) was tested by means of MTT assay performed in 
5 different cell  types: HDF, MDA-MB-231, SKOV3, MEWO and RT112. Three 
concentrations  of  PMPC-PDPA were  evaluated  (0.5,  1  and  1.5  mg/ml)  and 
compared to the control cells incubated with 1X PBS (t-test, p-value *  P ≤ 0.05; 
** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental error is expressed 
as standard deviation (N=3).
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observed in the four cell models used at any tested polymersome concentration. 
Beside  the  anomalous  (yet  not  relevant)  data  from  the  RT112  cells  at 
polymersomes concentration of 0.5 mg/ml no detrimental effect on the cells (t-
test, p-value > 0.05) was observed. 
4.2. Polymersome uptake and cargo delivery in live cell 
The  polymersomes  ability to  deliver cargoes  into  live  cells was  evaluated  by 
encapsulating,  AlexaFluor®546  labeled  immunoglobulin  G  (IgG)  antibodies, 
using  the  electroporation  method  described  in  Chapter 3 .  A f t e r  t h e  
encapsulation and purification steps, the protein content within polymersomes 
was  quantified  by reversed phase  high pressure  liquid chromatography (RP-
HPLC)  (see  Section  3.4  and  7.2.3).  A  concentration  of  0.45  µg/ml  was 
determined. 
The cellular uptake of the polymersome formulations in HDFs was evaluated by 
confocal laser scanning microscopy analysis  (CLSM). For this  purpose, cells 
were seeded in a glass bottomed 96 well plate and grown for 24 h. Afterwards, 
the  cell  medium was  replaced  with fresh media containing antibody  loaded 
polymersomes,  at  a  concentration  of  0.1  µg/ml  IgG.  Cellular  uptake  was 
subsequently visualised at 0, 1, 5, 18 and 24 h incubation.  Control experiments 
were  performed  in  which  cells  were  treated  for  24 h with 5 µg/ml  of  free 
antibody solution.  All  cells  were  treated  with  a cell nucleus  staining probe 
(SYTO®9) 10 min before confocal analysis. The CLSM  results  in Figure 4.2, 
showed the increase of the IgG signal overtime. The fluorescence intensity is 
proportional to  the elapsed cellular incubation time. No  evident fluorescence 
was  revealed  in  cells  treated  with  free  antibody.  These  data  indicates  the 
effectiveness of polymersomes to deliver proteins within live cells.
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126Figure  4.2.  CLSM  analysis  of  HDF  cells,  showing  the  cellular  uptake  of 
polymersomes loaded with 0.1 μg/ml AlexaFluor-546 labeled IgG. The efﬁciency 
of polymersomes as an intracellular delivery system was compared to a control 
experiment in which cells were treated for  24 h  with  5 μg/ml  of free antibody 
solution in medium. Scale bar: 25 µm.
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The  resulting mean fluorescent intensity values  from one field of  view were 
normalised with the fluorescence intensity obtained from cells treated with free 
antibody solution.  The  measured  fluorescence  intensity  obtained  after  24 h 
incubation time with IgG loaded polymersomes was taken as the upper limit of 
the analysis. In such a way, the measured average IgG emission intensities at 
573  nm (calculated  using  ImageJ), corresponding  to  each  time  point  were 
plotted on a graph reported in Figure 4.3-A. The image analysis was confirmed 
by RP-HPLC detection of lysed cells and the final data are also plotted in Figure 
4.3-B.     
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128Figure 4.3. (A) CLSM and (B) RP-HPLC quantiﬁcations at different time points 
about the polymersome antibody (AlexaFluor-546 labeled IgG) delivery in HDF. 
In (C) the obtained results concerning the CLSM intensity (%) and the ng of IgG 
per cell are normalised (respectively to the maximum intensity or concentration 
value at 24 h) and compared. The experimental error is expressed as standard 
deviation (N=3).
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129As seen in Figure 4.3-C, both measurements are in close agreement, confirming 
the validity of the imaging method.
The data in Figure 4.3 show that after 1 h of polymersomes incubation, cells had   
internalised more than half the maximum, corresponding to ~12.5 x 10-5 ng of 
protein  per  cell.  Several  factors  are  implicated  in  the  cellular  uptake  of 
polymersomes.  Recent  works  produced  in the  Battaglia research group  has 
singled  out  a  specific  scavenger  receptor  SR-B1  for  the  initial  cellular 
recognition of the PMPC-PDPA polymersomes  (Colley et al., 2014). It is also 
established  that  PMPC-PDPA  polymersome  uptake  is  strongly  affected  by 
particle size, shape and surface topologies (LoPresti et al., 2011; Massignani et 
al., 2009; Robertson et al., 2014).       
It is important to note that polymersome uptake in HDFs reached a plateau at 
about 18 h, following which the amount of IgG detected  inside the cells was 
constant.  
To explain this result, two correlated hypothesis can be considered. The first one 
implicates the saturation of SR-B1 receptor on HDF. 
The second is the degradation of the internalised IgG molecules  involves the 
cytosolic IgG receptor, tripartite  motif-containing 21 (TRIM21). TRIM21 is  a 
cytosolic protein that  recognizes  the  fragment  crystallisable  (Fc)  domain  of 
internalised  IgG  molecules  (Mallery et al., 2010).  It  plays  a  crucial  role  in 
mediating the intracellular immune response that targets internalised viruses 
bound by IgG antibodies for proteasomal degradation. 
It is possible to speculate a synergistic effect between SR-B1 saturation resulting 
in  impaired  uptake  and  TRIM21  activity  promoting  IgG  degradation.  The 
combination of the two effects could justify  the observed plateau of uptake at 18 
h.
4.3. Polymersome cytosolic cargo release  
To  further validate the intracellular-delivery of antibodies  CLSM analysis was 
conducted in the presence of other fluid phase markers. 
In Figure 4.4, this analysis was used to visualise the sub-cellular distribution of 
internalised antibodies  (AlexaFluor®546 labeled unspecific rabbit IgG). HDFs 
were  incubated  overnight  with  antibody  loaded  polymersomes  at  a 
concentration of 0.1 µg/ml IgG  in medium and subsequently treated  with a 
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130lysosomal marker (LysoTracker®) prior to visualisation. The data suggest that 
while some of the antibody signal colocalises with the lysosome, the majority is 
well distributed within the intracellular volume, indicating endosomal escape.    
Figure 4.4. CLSM analysis (A) and z-stack micrograph (B) evaluating the sub-
cellular distribution of polymersome delivered AlexaFluor-546 labeled IgG. Live 
HDFs  were  exposed  overnight  with  the  polymersomes  formulations  and 
subsequently treated with lysotracker to stain the endolysosomal compartment.     
Scale bar: 20 µm.
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131Previous studies by Battaglia and coworkers demonstrated that the pH-sensitive 
polymersomes  disassemble  within  the  early  endosome  (Massignani  et  al., 
2009). The acidic pH that characterises endocytic organelles overcomes the pKa 
of PMPC-PDPA (6.4), subsequently driving polymersome disassembly. This, in 
turn,  produces  a  considerable  increase  in  the  osmotic  pressure  within  the 
endosome  that  eventually  causes  temporary  endosomal  membrane 
destabilisation and cytoplasmic release.       
It is likely that this mechanism of endocytic release is affected by the size of the 
delivered cargo, and the number of polymersomes accumulated within a single 
endosomal  compartment.  Moreover,  osmotic  lysis  is  a  temporary  event 
resulting from excessive endosomal concentrations, thus it is likely  that only a 
proportion of polymersome cargo will be released into the cytosol (Lomas et al., 
2008; Massignani et al., 2010a; Massignani et al., 2009).    
To  further  corroborate  the  obtained  findings  and  assess  the  protein  cargo 
escape  from  the  endocytic  pathway  after  polymersome  mediated  delivery, 
Transmission Electron Microscopy (TEM) using 15 nm gold labeled antibodies 
(AuNP-IgG)  encapsulated  within  polymersomes  were  employed.  HDFs  were 
incubated overnight with antibody  loaded polymersomes at a concentration of 
0.1 µg/ml AuNP-IgG in medium. The metallic particles attached to the delivered 
IgG can be visualised by TEM and subsequently their sub-cellular localisations 
revealed. Control experiments were performed in which cells were treated with 
medium containing free AuNP-IgG. 
Multiple images were acquired and the average amount of IgG escaped from the 
endocytic pathway quantified by image analysis (ImageJ). 
The results of this analysis are summarised in Figure 4.5.
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132Figure  4.5.  TEM  analysis  of  HDF  cells  which  were  exposed  for  24  h  to 
polymersomes loaded with 15 nm gold labeled IgG. In (A) a cell section at the 
cell membrane edge is shown, while in (B) the antibody release into the cytosol, 
as well  as antibodies still located within vesicular compartments can be seen. 
(C) Control experiment of cells treated with free antibody sample. (D) ImageJ 
quantiﬁcation regarding the vesicular trapped and released antibody (t-test, p-
value *  P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; ****  P ≤ 0.0001). The experimental 
error is expressed as standard deviation (N=3). Scale bar: 200 nm.
TEM  reveals  that  at  the  cell  membrane,  gold  labelled  IgG  molecules  are 
confined within spaces hundreds of nanometers in size. This would suggest the 
visualisation of the first step of polymersomes uptake, in which the protein is 
still encapsulated within the synthetic vesicles.
Midsections  of  the  cell  (Figure  4.5-B)  show,  dark  dots  located  both within 
vesicular  like  spaces  (likely  endocytic  organelles)  as  well  as  distributed 
throughout the cell cytosol. Quantification of antibodies located within cellular 
vesicles  (see Figure 4.5-D), established that they correspond to  ~30%  of the 
total antibody  per image, the remainder being found within the cytoplasmic 
space. 
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However, when considering intracellular antibody delivery as  a technique for 
live cell imaging, the presence of IgG within the endo-lysosomal compartments 
could prove problematic, since this may  hinder the visualisation of other sub-
cellular structures. Even though the majority of the proteins are delivered to the 
cytosol, those proteins remaining within the endo-lysosomal compartments are 
retained in compartments orders of magnitude smaller than cell cytosol. This 
translates to high endosomal antibody concentrations and stronger fluorescent 
signal than in the cytosol. Such a mismatch can be mitigated by co-delivering a 
membrane impermeable  quencher that  absorbs  the  fluorophores  signal only 
when  the  two  are  localised  into  smaller  compartment  (i.e.  at  high 
concentration). Such absorption occurs  by Förster resonance energy  transfer 
(FRET)  (Cheng, 2006). This  was  demonstrated  by co-encapsulating Brilliant 
Violet  421™  labeled  antibodies  with the  corresponding quenching molecule 
Trypan Blue. For this  experiment, anti γ-Tubulin IgG (Brilliant Violet 421™ 
anti-Tubulin-gamma)  was  used  as  a  model.  The  γ-Tubulin  is  a  structural 
intracellular  protein  that  functions  to  promote  microtubule  nucleation  and 
branching. It is  localised  throughout the cytoplasm, though under particular 
conditions  it  accumulates  within  the  nuclear  region  (Kollman  et  al.,  2011; 
Raynaud Messina and Merdes, 2007).  
Figure 4 . 6  s h o w s  t h e  c o m p a r i s o n  b e t w e e n  c e l l s  t r e a t e d  o v e r n i g h t  w i t h  
polymersomes loaded with only anti γ-Tubulin IgG antibodies (0.1 µg/ml IgG) 
(Figure 4.6-A), and polymersomes loaded with both antibody and Trypan Blue   
(Figure 4.6-B).             
In the latter instance, a considerable reduction in signal originating from the 
endo-lysosomal  organelles  is  apparent,  suggesting  that  the  Trypan  Blue 
quenches the Brilliant Violet 421™ dye. Trypan Blue was subsequently used in 
all successive microscopy experiments. 
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134Figure  4.6. ( A )  C L S M  a n a l y s i s  s h o w i n g  p o l y m e r s o m e  m e d i a t e d  l i v e  
immunolabelling  of  γ-Tubulin  (Brilliant  Violet  421™anti-γ-Tubulin  IgG)  in  live 
HDFs without the use of quencher  (A) or with Trypan-Blue as a quencher (B). 
Cells were co-stained with green RNA / DNA probe SYTO®9. Scale bar: 50 µm.
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1354.4. Delivery of functional antibody for sub-cellular targeting in live 
cells  
The ability to directly  visualise intracellular proteins in live cells without genetic 
manipulation, could  open many  possibilities  in the  research of  cell biology. 
Polymersomes  mediated  delivery of  antibodies  to  the  cell  cytosol  can  be 
exploited to target structural proteins and study their activity  without artefacts 
that  can  result  from  fixation  techniques.  This  was  demonstrated  using 
polymersomes  loaded  with  Brilliant  Violet  421™  anti-γ-Tubulin IgG, which 
enabled real time visualisation of  γ-Tubulin localisation during DNA damage 
caused by the nuclear stain SYTO®9. Though that γ-Tubulin is normally present 
on  the  cytoplasm,  previous  studies  have  reported  that  when  DNA  damage 
occurs, this  protein is translocated to the cell nucleus, interacting with other 
cellular factors involved in DNA-repair mechanisms (Höög et al., 2011; Hořejší 
B1, 2012; Lesca et al., 2005; Zhang et al., 2007).
Figure 4.7, show HDF cells stained by  SYTO®9 and γ-Tubulin either added to 
fixed cells (Figure 4.7-A) or delivered via polymersomes to live cells (Figure 4.7-
B).
In live cells, SYTO®9 (green), has the dual function to highlight the cell RNA /
DNA and to induce irreversible damages to DNA (Ferguson and Denny, 2007; 
Li et al., 2007a). In fixed cells, the anti γ-Tubulin is localised throughout the cell 
cytosol  and  concentrated  along  microtubule  networks  and  centrosomes. 
SYTO®9, highlighted  as  expected  the  cell  DNA  and  the  nucleoli  where  the 
rRNA / DNA is accumulated. 
Similar results were achieved in live cells imaged after 5 min incubation with 
high concentration  of  SYTO®9 (0.5 µM)  and  upon polymersomes  mediated 
antibody  delivery  (HDFs  were  incubated  overnight  with  antibody  loaded 
polymersomes  at a concentration of  0.1 µg/ml IgG in medium). Fluorescent 
signal from antibodies was found localised within the centrosomes, while the 
nuclear dye highlighted the cellular DNA and RNA. 30 min after SYTO®9 (0.5 
µM)  addition,  the  micrograph in  Figure  4.7-C  shows  a  different γ-Tubulin 
distribution,  with  a  strong  signal  coming  from  the  cell  nuclei.  It  was 
hypothesised that this  is  an attempt by  the cell to  recover the DNA damage 
induced by SYTO®9. Indeed, previous studies have reported the translocation of 
γ-Tubulin into  the  nucleus  with DNA repair mechanisms  (Hořejší  B1, 2012; 
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136Lesca et al., 2005; Zhang et al., 2007). These results demonstrate once more the 
ability of PMPC-PDPA polymersomes to  deliver antibodies in live cells and to 
use them to monitor internal dynamic.
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137Figure  4.7. ( A )  γ-Tubulin  (Brilliant  Violet  421™anti-γ-Tubulin  IgG) 
immunolabeling  of  ﬁxed  HDFs.  (B)  Polymersome  mediated  γ-Tubulin 
immunolabeling  in  live  HDFs.  (C)  Polymersome  mediated  γ-Tubulin 
immunolabeling in live HDFs after SYTO®9 DNA damage. Scale bar: 30 µm. 
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138The  proposed  mechanism  of  γ-Tubulin  translocation  after  DNA  damage   
induced by SYTO®9 is schematised in Figure 4.8. 
Figure  4.8.  Schematic  representation  of  γ-Tubulin  intracellular  distribution 
(revealed by the polymersomes delivery of functional Brilliant Violet 421™anti-
γ-Tubulin) before (1) and after (2) SYTO®9 DNA damage which promote the γ-
Tubulin translocation into the cell nucleus. 
To further corroborate these findings, Figure 4.9 shows the CLSM analyses of 
polymersome delivery of the same IgG (overnight cellular incubation with anti 
γ-Tubulin antibody  loaded polymersomes at a concentration of 0.1 µg/ml IgG in 
medium)  in  other  cells  including  human  embryonal  carcinoma  stem  cells 
(NTera2), human adenocarcinoma cells (HeLa), human melanoma cell (A375), 
murine fibroblasts (NIH-3T3) and murine brain endothelial cells (bEnd3). The 
distribution  of  γ-Tubulin  is  quite  different  form cell  model  to  cell  model, 
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139confirming the universality of polymersomes as protein delivery  system in live 
cells. 
Figure 4.9. Immunolabeling of γ-Tubulin obtained exposing different cell models 
to  polymersomes  loaded  with  Brilliant  Violet  421™  IgG-anti-γ-Tubulin.  Cells 
were co-stained with green RNA / DNA probe SYTO®9. Scale bar: 20 µm.
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Results and Discussion
Ki-67 AS INTRACELLULAR TARGET IN 
ANTICANCER-THERAPY
5.1. Quantification of Ki-67 expression in different cell models 
The first experimental approach aimed to quantify and localise the intracellular 
Ki-67 in non-cancerous and cancerous cells, as a function of their proliferative 
or quiescent phases. Confocal imaging investigations were carried out in fixed 
cells treated with SYTO®9 (green channel), to achieve the nucleolar staining, 
and Brilliant Violet™ 421 anti Ki-67 IgG antibodies (red channel), to quantify 
the Ki-67 protein. Different cell models were used for this purpose, including 
human dermal fibroblast (HDF) and  human umbilical vein endothelial  cells 
(HUVECs) (non-cancer cells), as well as on breast cancer cells (MDA-MB-231), 
human  pharyngeal  squamous  carcinoma  cells  (FaDu),  and  human 
adenocarcinoma  cells  (HeLa)  (cancer  cells),  upon  incubating  them  in  both 
normal  and  Fetal  Bovine  Serum  (FBS)  deprived  media  to  control  the 
proliferation status. 
In particular, Figure 5.1 shows that, immediately  after starvation (i.e., at time 
zero), HDF and HUVEC cells posses a high amount of Ki-67, which is located 
within the nucleus, as expected (top-left section of Figure 5.1). 
The amount of protein becomes significant less after 18 h of starvation time, and 
it is completely  undetected after 36 h of FBS deprivation, when cells enter the 
quiescent  phase. On  the  other hand,  confocal  microscopy investigations  on 
MDA-MB-231, HeLa, and FaDu cells demonstrated that Ki-67 is present even 
after 36 h of starvation time, and it is spread throughout the nucleus (top-right 
section of Figure 5.1). The graph in the bottom part of Figure 5.1, obtained with 
an ad hoc developed image software based on a MATLAB® platform, further 
141provides a quantification of Ki-67 in both non-cancerous and cancerous cells, as 
a function of starvation time. Also in this case, a strong decrease in the value of 
the fluorescence signal is evident for HDF and HUVEC cells, which shifts down 
of ∼70% after 18 h, and becomes c.a. 80% and 98% less after 36 h for HUVEC 
and HDF, respectively. This  condition is  significantly different in cancer cells 
undergoing serum starvation, which does  not lead  to  a down-expression  of 
Ki-67. The quantification of the protein signal was, in fact, roughly the same 
between t=0 and t=18 h of FBS deprivation, and slightly decreases of ∼25% after 
36 h of starvation time. The obtained data show that non-cancerous cells are 
able to control the down-regulation of Ki-67 when forced in a quiescent phase of 
the  cell  cycle,  while  the  same  experimental  conditions  do  not  affect  the 
regulation of Ki-67 in cancerous cells.
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142Figure  5.1.  Confocal  analyses  of  Ki-67  expression  in  HDF,  HUVEC,  MDA-
MB-231, HeLa and FaDu cells (analysed overtime after serum deprivation), and 
the relative ﬂuorescence signal  quantiﬁcation (average overlap value percent) 
(Two-way ANOVA,  p-value * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 
0.0001).  The  experimental  error  is  expressed  as  standard  deviation  (N=3). 
Scale bar: 10 µm.
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To  further  explore  the  cell  cycle  dynamics,  and  to  better  understand  and 
quantify the Ki-67 expression in HDF and MDA-MB-231 cells during the cell 
cycle (considered, for the next experimental approaches, as representative non-
cancer  and  cancer  cells,  respectively),  a  propidium  iodide  (PI)  based 
fluorescence cytometry (FC) analysis was performed.  
In particular, this characterisation confirmed that ~62% of HDF cells, incubated 
with a complete  growth medium, are  in the  G0/G1  phase (namely, they are 
quiescent  /  synchronised),  and  ~38%  are  in  the  S/G2/M  steps  (i.e.,  in  a 
proliferative status), as shown in Figure 5.2-A. Upon 36 h of serum starvation, 
~98% of  fibroblasts  are quiescent, in the G0/G1, and only 2% of cells  are  in 
active  S/G2/M  phases  (Figure  5.2-A).  On  the  other  hand,  the  same  FC 
investigations  on  MDA-MB-231 cells  revealed  that  a  significant  difference 
between normal cultured  and  starved  cells  is  not evident. As depicted  in the 
right side of Figure 5.2-B, in fact, ~54% of breast cancer cells incubated with 
complete medium were in the G0/G1  stage, and ~46% in the phases  S/G2/M. 
Similarly, after incubation with serum deficient growth medium, ~75% of MDA-
MB-231 cells were in the G0/G1 and ~25% of cells were in the S/G2/M (Figure 
5.2-B).  This  first evidence  confirmed  the  inability of  breast  cancer  cells  to 
control the cell cycle check points (even after serum deprivation), and enabled 
to set the starvation condition for the next experimental approach, where the 
presence  of  Ki-67 was  quantified  (in  both  HDF  and  MDA-MB-231),  as  a 
function of the cell cycle phase. As shown in Figure 5.2-A, in fact, FC analyses of 
HDF  cultured  in normal  medium displayed  the  presence  of  Ki-67 (the blue 
graph  does  not  overlap  with the  control  grey graph),  while  the  protein  is 
strongly down regulated during the cell stationary phase (G0/G1), induced by 
serum starvation. This is evident by  the strong overlap between the blue and 
grey graph of Figure  5.2-A, and by the relative signal quantification. On the 
other hand, MDA-MB-231 displayed a different behaviour. The expression of 
Ki-67 in breast cancer cells is, hence, rather similar for cells growing in both 
complete and FBS-deprived medium (Figure 5.2-B), thus in strong agreement 
with the previous findings of Figure 5.1. Taken together these data indicate a 
different Ki-67 regulation pathway between HDF and MDA-MB-231 cells.
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144Figure 5.2-A. (Left) Flow cytometry analyses of the cell  cycle in  HDF  before 
and  after  serum  starvation.  (Right)  Flow  cytometry  quantiﬁcation  of  Ki-67 
expression in HDF cells as a function of the cell cycle stages (t-test, p-value * P 
≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental error is 
expressed as standard deviation (N=3). 
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145Figure 5.2-B. (Left) Flow cytometry analyses of the cell cycle in MDA-MB-231 
before and after serum starvation. (Right) Flow cytometry quantiﬁcation of Ki-67 
expression in MDA-MB-231 cells as a function of the cell cycle stages (t-test, p-
value * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental 
error is expressed as standard deviation (N=3).
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To  further explore whether the regulation of Ki-67 expression is controlled at 
transcriptional level, a Ki-67 gene knock-down experiment was performed.
In particular, cells were transfected with a lentivirus, which codifies  for short 
hairpin RNA (shRNA) involved in the transcriptional degradation of the α and β 
splice  variants  of  Ki-67,  respectively (Figure  5.3).  The  confocal  analyses  in 
Figure 5.3 show that HDF cells do not display the fluorescence signal from the 
reporter GFP gene immediately after viral infection (t=0 h), while it is evident 
the  presence  of  Ki-67 as  red  spots.  After 24 and  48 h,  fibroblast  cells  are 
completely infected, as confirmed by the strong green signal, combined with the 
down-expression of  Ki-67 (the red spots completely lack in this  case). These 
outcomes are surprisingly different in MDA-MB-231 breast cancer cells. In this 
case, the viral infection with shRNA does not influence the down regulation of 
Ki-67, which is still present even after 24 and 48 h, as highlighted by  the red 
signals. The  graph in the bottom part of  Figure 5.3, which provides  a signal 
quantification, confirms  the  strong down-expression of  Ki-67 in  transfected 
HDF, together with the  impossibility to  repress  the  transcript expression in 
transfected MDA-MB-231 cells. In this latter case, the analysed signals are very 
close to  those belonging to  the control cells, which were  infected with a not 
codifying (scrambled) sequence.
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147Figure 5.3. Confocal analyses of  Ki-67 expression  in HDF and MDA-MB-231 
cells after  shRNA knock-down. Bottom  part:  graph  showing the Ki-67 protein 
quantiﬁcation (Two-way ANOVA, p-value *  P ≤ 0.05;  **  P ≤ 0.01; *** P ≤ 0.001; 
**** P ≤ 0.0001). The experimental  error  is expressed as standard deviation 
(N=3). Scale bar: 10 µm. 
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148In addition,  Reverse  Transcription  Quantitative  Polymerase  Chain  Reaction 
(RT-qPCR) analysis were carried out to precisely  quantify the amount of mRNA 
codifying for the two α and β splice variants, upon shRNA assays (Figure 5.4).
Figure 5.4. RT-qPCR quantiﬁcation of the α and β splice variants of Ki-67, and 
GAPDH (G), after  virus knock-down in  HDF and MDA-MB-231 cells (t-test, p-
value * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental 
error is expressed as standard deviation (N=3).
As confirmed in Figure 5.4, the level of mRNA of HDF cells is significantly   lower 
after 24 h of viral infection (the ΔΔCt was c.a. 0.7-0.8 for the β, and c.a. 0.3-0.4 
for the α), and became even less after 48 h (the green graph represents the 
internal control). In addition, the amount of mRNA for the β splice variants was 
found to be overall higher than the α after 24 h, while these levels were rather 
similar after 48 h (Figure 5.4). On the other hand, the level of Ki-67 transcript in 
MDA-MB-231 cells was slightly higher than the HDF, upon both 24 and 48 h of 
viral infection (the ΔΔCt was about 0.5 for the β splice variant and 0.7 for the α 
after 24 h, and 0.3 for the β and 0.4 for the α after 48 h). Interestingly, there is 
also a significant difference in the expression levels of the two splice variants 
between  HDF  and  MDA-MB-231 cells.  In  particular,  while  the  α  is  more 
expressed in fibroblast, the β is much more present in breast cancer cells.
The  ΔCt quantification in Figure  5.5 further corroborates  the  quality of  the 
analyses. In fact, both HDF  and MDA-MB-231 show that the internal control 
gene  glyceraldehyde  3-phosphate  dehydrogenase  (GAPDH)  is  not  affected 
during the overtime Ki-67 gene knockdown experiments. 
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149Figure 5.5. RT-qPCR ΔCt quantiﬁcation of GAPDH internal control at different 
time points during Ki-67 gene  knockdown  experiments  (t-test,  p-value * P ≤ 
0.05;  ** P ≤ 0.01;  *** P ≤ 0.001;  **** P ≤ 0.0001). The experimental error  is 
expressed as standard deviation (N=3).
The  are  two  hypothesis  that  can  be  considered  to  explain  the  different 
expression levels of the α and β isoforms between HDF and MDA-MB-231 cells. 
The first one refers to the fact that the two isoforms may undergo very different 
degradation pathways in non-cancer and cancer cells. In the second hypothesis, 
each  specific  cell  model  could  express  different  levels  of  the  two  variants. 
Furthermore, considering  the  data shown in  Figure  5.4,  another important 
outcome  should  be  highlighted.  Despite  the  Ki-67  transcript  is  degraded 
overtime by the action of the introduced shRNA, the protein is still present in 
MDA-MB-231 cells.  This  probably because  Ki-67 is  more  stable  herein  or, 
alternatively, its post-translational degradation fails to occur in cancer cells. 
5.4. Ki-67 expression in cancerous  and  non-cancerous  cells  before 
and after nutrients deprivation    
To have a deeper insight into the molecular bases of Ki-67 expression (and of 
the relative splice variants) and to  shed light on the different mechanisms of 
Ki-67  post-transcriptional  and  post-translational  regulation,  Western  blot 
assays was carried out with the automated Simple Western™ (or Simon™). This 
automated Western blot technology is based on capillary-electrophoresis-SDS   
(Sodium Dodecyl Sulfate) (CE-SDS).  The protein identification is  performed 
upon incubation with a  primary antibody, followed  by  an immunodetection 
based on a horseradish peroxidase (HRP), which is conjugated to the secondary 
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150antibody, together with a chemiluminescent substrate for the binding detection. 
This automated Simple Western™ combines several advantages, including the 
possibility  of quantification, together with the higher reproducibility  of results 
over time and between different users (Boge et al., 2012; Rustandi et al., 2012). 
This analysis was performed in both the cell models tested. In both cases, the 
Ki-67  protein  expression  was  quantified  before  and  after  36  h  of  FBS 
deprivation from the cell medium. As previously described in Figure 5.2-A and 
5.2-B, this leads the ~98% and ~75% of HDF and MDA-MB-231 in a quiescent 
(G0/G1) state respectively.
As shown in Figure 5.6, the Western blot analysis confirms that Ki-67 is present 
within fibroblast cells grown in complete medium, although in this case the two 
different splice variants were not noticeable. This is evident in both the profile 
of  expression, where the  relative peak of the  protein is  present, and  in the 
protein run lane in the inset (the dark spot above the profilometer analyses). 
On the other hand, Ki-67  lacks in HDF undergoing 36 h of serum deprivation, 
as confirmed by the absence of both the relative intensity peak and the protein 
band  in  Figure  5.6.  The  chromatograms  in the  graph of  Figure  5.6 further 
quantify that fibroblast forced to a quiescent state have c.a. 60% less amount of 
protein, compared  to  the  same  cells  in the  normal  medium. However, this 
represents a rather underestimation since the software detects also the signal 
coming from the background region of the lane.
Concerning the MDA-MB-231 cells, the expression of Ki-67 is demonstrated to 
be constitutive / constant in the presence of FBS, as well as after 36 h of serum 
starvation. This is in fact evident in the Simple Western™ quantification profile 
of Figure 5.6, together with the relative protein band spot in the inset, which 
both confirm the significant presence of Ki-67 (the α and β splice variants were 
both detected  in this  case). The  graph, in the  right side of Figure  5.6, also 
assessed the similar amount of the protein either when the cells are pushed to a 
quiescent stated (-FBS) and were they are in normal conditions (+FBS). 
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151Figure 5.6. Simple Western™ quantiﬁcation proﬁle of Ki-67 in HDF and MDA-
MB-231 breast cancer  cells, growing in both media supplemented (+FBS) and 
lacking of FBS (-FBS) (t-test, p-value * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** 
P ≤ 0.0001). The experimental error is expressed as standard deviation (N=3). 
To further validate the data obtained from the automated Simple Western™, the   
ERK  1/2 extracellular-signal-regulated  kinases  were  quantified  in  the  same 
cellular samples. ERK  1/2 are well conserved proteins  that are implicated  in 
essential functions  for the  cell  maintenance and,  for this  reason, they were 
chosen as internal controls (Roskoski, 2012). As shown in Figure 5.7-A, ERK 1/2 
resulted  equally expressed for both models  (HDF and  MDA-MB-231) and  in 
each cell culture conditions.
Moreover, to  further corroborate the Simple  Western™ analyses, a standard 
Western blot assay was also performed, confirming that the results are entirely 
comparable between the two methods (Figure 5.7-B).
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152Figure 5.7. (A) Simple Western™ quantiﬁcation proﬁle of ERK 1/2 in HDF and 
MDA-MB-231  breast  cancer  cells,  before  and  after  FBS  deprivation.  (B) 
Standard  Western  blot  analysis  of  Ki-67  in  HDF  and  MDA-MB-231  breast 
cancer cells, before and after FBS deprivation.  
5.5.  Ki-67  α a n d  β splice  variant expression  as  a  function  of  the 
nutrients deprivation    
In addition to the presented data, it is herein further explored and discriminate 
the level of genetic expression of the two main Ki-67 splice variants (namely the 
α and β), in the two  different cell models, as a function of the presence and 
absence of FBS. This approach may enable to better understand which subunit 
plays a key role in controlling the cell shifting in the different stages of the cell 
cycle. According to the obtained results, both subunits are present in HDF cells 
at  time  zero,  as  confirmed  by  the  Reverse  Transcription Polymerase  Chain 
Reaction (RT-PCR) investigations in Figure 5.8. 
After 18 h of serum starvation, the α subunit is still present, but the expression 
level is significant less comparing to time zero, while the β subunit is completely 
down  regulated.  Both  the  α  and  β  splice  variants  are  then  completely 
unexpressed in HDF cells after 36 h of FBS absence. 
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153On  the  other  hand,  RT-PCR  analysis  on  MDA-MB-231  proved  that  the 
expression of transcript for both the α and β subunits of Ki-67 does not undergo 
significant  modifications  after  18  h  (Figure  5.8).  However,  after  36  h  of 
starvation, only the β subunit seems to be slightly  down-expressed as compared 
to the α. 
All these RT-PCR outcomes were further corroborated by means of quantitative 
PCR analysis (Figure 5.8). In particular, the ΔΔCt quantification displays that 
the mRNA level for the β splice variant of Ki-67 (with a value < 0.5) is less than 
the transcript of the α splice variant (value > 0.5), for HDF cells undergoing 18 h 
of incubation with growth medium lacking of serum. 
Upon  36  h  of  starvation, the  ΔΔCt value  for both  the  α  and  β  variants  is 
significant  low,  confirming  that  control  fibroblasts  are  able  to  regulate  the 
down-expression of Ki-67 when they lie in the stationary  phase of the cell cycle 
(G0/G1). This condition is significant different in the breast cancer cells, where 
the FBS deprivation does not lead to a down-regulation of Ki-67. 
As shown in Figure 5.8, the MDA-MB-231 cells possess higher level of α and β 
variants with respect to the HDF (0.4<ΔΔCt<0.7 for the β, and 0.6<ΔΔCt<0.9 
for the α, respectively) after 18 h of FBS deprivation. 
Upon longer starvation time (36 hours), the mRNA level for the β splice variant 
is significantly down-regulated, while the transcript for the α variant is almost 
unvaried. However, the most interesting data here is that both the RT-PCR and 
RT-qPCR confirm a different regulation of the two splice variants, as a function 
of nutrient starvation. In particular, the α variant seems to be mainly present in 
both fibroblast and breast cancer cells, suggesting that this splice variant may 
play a much more important role in regulating the cell cycle, with respect to the 
β.  Alternatively, the  α  and  β  variants  may undergo  two  distinct  regulation 
pathways. 
A further validation comes from the ΔCt quantification, an important parameter 
concerning the internal reference control gene GAPDH. 
In Figure 5.8, the results of this validation are reported. It is  clear that there is 
not a  significant  difference  in  the  level  of  ΔCt signal  in  fibroblasts  during 
starvation time. Similar data are evident for breast cancer cells.
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154Figure 5.8. RT-PCR (left column), and RT-qPCR (right column) quantiﬁcation of 
the α and β splice variants of Ki-67, as a function of nutrient starvation in HDF 
and MDA-MB-231 cells. Bottom ﬁgure: (left) RT-PCR analysis of β-actin (A) and 
GAPDH (B) as internal  controls, before and after  nutrient deprivation.  (Right) 
RT-qPCR quantiﬁcation of the internal control GAPDH after serum starvation (t-
test,  p-value  * P ≤  0.05;  ** P ≤ 0.01;  *** P ≤ 0.001;  **** P  ≤ 0.0001).  The 
experimental error is expressed as standard deviation (N=3).
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With respect to  the data shown in Figure 5.1, a set of confocal colocalisation 
experiments were performed to better investigate the extra-nuclear detection of 
Ki-67, and its possible interaction with cytoplasmic pathways.    
In  this  respect,  the  first  explored  interaction  was  between  Ki-67 and  the 
proteasome,  which  is  one  of  the  most  important  cellular  quality  control 
mechanisms of proteins (Kish-Trier and Hill, 2013; Makino et al., 2013). 
To  do  this,  fibroblasts  and  breast  cancer  cells  were  co-stained  with  anti-
proteasome  20s  antibody  (which  specifically  bind  the  subunit  20s  of  the 
proteasome complex), with Ki-67 antibody for targeting the protein of interest, 
and treated with a modified baculovirus expressing a fusion construct of a Golgi 
marker (to recognise the Golgi apparatus). 
Then, confocal microscopy investigations enabled to  explore the intracellular 
colocalisation and  interactions  between  the  proteasome  complex,  the  Golgi 
apparatus, and Ki-67. As  shown in Figure 5.9, HDF  cells grown in complete 
medium display most  of  the  proteasome  system and  the  Ki-67 within  the 
nucleus (in agreement with previous data). This is much more evident in the 
colocalisation confocal analyses, where it is clear that Ki-67 is mainly present in 
the nucleus and locally interacts with the nuclear proteasome (albeit the latter is 
also spread in the cytosol). A quantification of the colocalisation event is also 
provided by  the graph in Figure 5.9, which confirms that fibroblasts growing in 
complete medium possess c.a. 50% less of Ki-67 interacting with proteasome at 
the cytosolic level, comparing to  the nucleus (with a normalised fluorescence 
signal at 100%), where the interaction resulted to be stronger. At the same time, 
there is not a significant difference in the colocalisation signal between Ki-67 
and  the  proteasome  system  both  at  the  cell  nucleus  and  the  cytosol,  for 
fibroblasts undergoing serum starvation. However, serum deprivation leads to 
an overall lower level of signal from Ki-67 in the nucleus. 
On the other side, the  confocal investigations  in Figure 5.9 show that MDA-
MB-231 cells display high levels of Ki-67 in the cytosol and nucleus (where it 
resulted more abundant), both for starved and non-starved cells. It is, in fact, 
evident that the protein is spread throughout the nucleus, and some spots are 
also present in the cytoplasm. 
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156The quantification of the fluorescence signal, in the graph of Figure 5.9, further 
supports the evidence that the overlap value between the proteasome complex 
and Ki-67 is ~40% lower in the cytoplasm as compared to the overlap value of 
the nucleus, in both the conditions tested.
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157Figure 5.9. Confocal  assays  and quantiﬁcation  graphs (on  the bottom of the 
picture) of the distribution  and interaction  between Ki-67 and the proteasome 
system, in both HDF (left column) and MDA-MB-231 cells (right column). The 
analyses were carried out with and without the presence of FBS (t-test, p-value 
* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental error is 
expressed as standard deviation (N=3). Scale bar: 10 µm. 
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158The  next  efforts  were  then  focused  on  exploring  the  possible  interaction 
between Ki-67 and the endoplasmic reticulum (ER) molecular chaperon Binging 
immunoglobulin protein (BiP). This chaperon is specifically located within the 
lumen of the  ER, and  it is  responsible  for binding the nascent polypeptides 
which are emerging in the lumen of the ER during co-translational translocation 
(Gething, 1999; Pimpl et al., 2006; Vashist and Ng, 2004; Zimmermann et al., 
2011).  BiP  plays  a  pivotal  quality  control  of  protein  folding:  it  hinders 
incomplete or unfolded proteins to reach their final sub-cellular compartments, 
by activating the  ER-associated  protein degradation (ERAD). The picture  in 
Figure 5.10 shows  the co-distribution of  Ki-67 and BiP  in active  fibroblasts 
growing into a complete medium. 
In this condition, Ki-67 is mainly   present in the nucleus (as expected) and only a 
small portion of the protein seems to interact with the BiP, whose fluorescence 
signal is randomly spread throughout the cytosol. The overall weak interaction 
is also confirmed by the graph on the bottom of Figure 5.10, which confirms a 
low level of overlapping fluorescence signal between the nucleus and the cytosol 
in proliferating cells. Starved fibroblasts, however, demonstrated to possess a 
stronger interaction between the cytosolic Ki-67 and BiP that, in this case, is 
much more precisely localised in the ER / Golgi compartment, as depicted by 
Figure 5.10 and the relative quantification of fluorescence signal. On the other 
hand, a significant difference in the Ki-67 and BiP coupling in starved and non-
starved breast cancer cells is less evident. Figure 5.10 shows, in fact, the weak 
interaction between the  two  proteins, as  well as  BiP  seems  to  be  randomly 
distributes in both the conditions tested, showing low accumulation at the Golgi 
compartment in FBS deprived cancer cells. It is worth also  mentioning that, 
after 36 h of starvation time, all the extranuclear Ki-67 was founded to localise 
within the Golgi apparatus, where  it may  undergoes  further modifications  / 
regulations. 
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159Figure 5.10. Confocal assays and quantiﬁcation graphs (on the bottom of the 
picture) of the distribution and interaction between Ki-67 and the chaperone BiP, 
in both HDF (left column) and MDA-MB-231 cells (right column). The analysis 
were carried out with  and without the presence of FBS (t-test, p-value * P ≤ 
0.05;  ** P ≤ 0.01;  *** P ≤ 0.001;  **** P ≤ 0.0001). The experimental error  is 
expressed as standard deviation (N=3). Scale bar: 10 µm. 
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160After uncovering the role of BiP  in the control of Ki-67 degradation, the next 
investigations  aimed  to  understand  the  possible  interaction  with  the 
cytoplasmic coat protein complex II (COPII), mainly  because of a preliminary 
observation of a fully Ki-67  loaded Golgi apparatus after a long starvation time 
of HDF cells (see Figure 5.1 and Figure 5.12). COPII is the main constituent of 
vesicles  that bud from the  endoplasmic  reticulum and  transport their cargo 
(namely, secretary  proteins) to the Golgi system (Brandizzi and Barlowe, 2013; 
Derganc et al., 2013; Zanetti et al., 2012).
As  depicted  in  Figure  5.11,  there  is  a  significant  difference  between  the 
distribution of COPII in normal and synchronised fibroblasts, particularly at the 
cytoplasmic level.  However,  the  overlap  of  fluorescence  signal  of  Ki-67 and 
COPII suggests that a proximity  between the two proteins is occurring in both 
the  two  growth  conditions.  Concerning  MDA-MB-231  cell  seeded  with  a 
complete media, the fluorescence signal of COPII vesicles displays a very well 
defined  distribution  pattern  around  the  nucleus,  together  with  a  poor 
interaction with Ki-67. Upon serum starvation, COPII seems to be widely spread 
within the cytosol instead. In addition, the overlap signal with Ki-67 is higher as 
compared to non-starved cells, although this interaction resulted significant less 
with respect to the same one occurring in fibroblasts.
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161Figure 5.11. Confocal assays and quantiﬁcation  graphs (on the bottom of the 
picture) of the distribution and interaction between Ki-67 and the COPII, in both 
HDF  (left column) and MDA-MB-231 cells (right  column). The analyses were 
carried out with and without the presence of FBS (t-test, p-value * P ≤ 0.05; ** 
P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001). The experimental error is expressed as 
standard deviation (N=3). Scale bar: 10 µm. 
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162Finally,  the  possibility of  Ki-67 translocation  into  the  Golgi  apparatus  was 
investigated. Figure 5.12 (left hand side) shows that the protein is present in the 
Golgi system for starved, as  well as  in non-starved  fibroblasts. However, the 
protein accumulation seems to be higher upon FBS deprivations, as confirmed 
by the  quantification graph (bottom side  of  Figure  5.12).  This  condition is 
dissimilar in breast cancer cells. As displayed in Figure 5.12 and  the  relative 
quantification analysis (bottom side of Figure 5.12), in fact, both starved and 
non-starved  MDA-MB-231 cells  have  a similar distribution  of  Ki-67 in  the 
nucleus,  as  well  as  in  the  Golgi.  In  addition,  two  other  possible  cellular 
clearance / degradation mechanisms for Ki-67 were investigated: the lysosome 
and the autophagosome (see Figure 5.13). However, no interaction between the 
protein and these two degradation machineries was found.
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163Figure 5.12. Confocal assays and quantiﬁcation graphs (on the bottom of the 
picture) of the distribution and interaction between Ki-67 and Golgi apparatus, in 
both  HDF  (left  column) and MDA-MB-231 cells  (right  column).  The analyses 
were carried out with  and without the presence of FBS (t-test, p-value * P ≤ 
0.05;  ** P ≤ 0.01;  *** P ≤ 0.001;  **** P ≤ 0.0001). The experimental error  is 
expressed as standard deviation (N=3). Scale bar: 10 µm. 
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164Figure 5.13. Confocal  analyses of  the  interaction  and cellular  distribution  of 
Ki-67 with  LAMPI and LC3B, in  HDF and MDA-MB-231 cells before and after 
serum starvation. Bottom part: graph showing the overlap signal between Ki-67 
with  LAMPI  and  LC3B,  for  HDF  and  MDA-MB-231  growing  in  both  serum 
supplemented and deprived media (t-test, p-value * P ≤ 0.05; ** P ≤ 0.01; *** P 
≤ 0.001;  **** P  ≤ 0.0001).  The experimental  error  is expressed as  standard 
deviation (N=3). Scale bar: 10 µm.
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165This  imaging investigations  confirm that Ki-67 is  transported  outside of the 
nucleus in proliferating HDF (i.e., during the S/G2/M phases of the cell cycle), 
where  it  interacts  with  the  proteasome  complex,  which  may,  in  turn,  be 
responsible  for  the  local  degradation  of  the  protein.  At  the  same  time, 
fibroblasts  in the  G0/G1  phase  have  a significant less  amount of  Ki-67  (the 
nucleus in this case completely lacks of the protein) that is mainly degraded by 
the nuclear proteasome. Despite fibroblasts, breast cancer cells seem to have a 
minor  ability  to  translocate  Ki-67  in  the  cytoplasm,  or  alternatively  they 
overexpress it in the nucleus. In addition, the proteasome system is unlikely  to 
regulate the degradation of the proteins in both the cytoplasm and the nucleus 
of cancer cells, resulting in an overall loss of control over the shifting through 
the different steps of the cell cycle.
Another important point is represented by the Ki-67 / BiP interactions. In this 
case, the translocation machinery of fibroblasts is able to effectively process the 
protein. In particular, HDF cells effectively control their ERAD, and this issue is 
also crucial for finely regulating the transit through the different steps of the cell 
cycle. This coupling with BiP should not be considered as trivial. Indeed, BiP is 
demonstrated to physically interact with Ire1α (inositol-requiring enzyme 1α), 
PERK (protein kinase RNA-like ER kinase), and ATF6 (activating transcription 
factor 6), which are the three signalling proteins important for the activation 
and regulation of the unfolded protein response (UPR) pathways (Bertolotti et 
al., 2000; Hetz et al., 2013; Kimata and Kohno, 2011; Onn and Ron, 2010). In 
particular, any ER-related  stress  leads  to  the  activation of  these  sensor like 
proteins, which, then, transduce the signals to the cytosol and nucleus in order 
to  restore protein-folding capacity through different and well-defined cellular 
adaptation pathways (usually, by  activating transcription factors which induces 
the  expression of  genes  involved  in aminoacids  metabolism, apoptosis, and 
authophagy)  (Hetz  et al.,  2013).  As  a consequence, fibroblasts  may “sense” 
misfolded Ki-67 through its coupling with BiP that, in turn, activate the UPR 
sensors Ire1α, PERK, and ATF6.
On the other side, breast cancer cells seem to fail to activate ERAD machinery, 
and  extranuclear Ki-67 is  not correctly degraded, with a consequent loss  of 
control over the cell cycle check points.
Same  considerations  should  be  inferred  for the ability  to  direct Ki-67 in the 
secretory  pathways. The strong evidence of interaction between the protein and 
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166COPII-coated  vesicles  further confirms  that fibroblasts  are  able  to  correctly 
deliver  the  protein  in  the  secretory  pathways.  Such  a  possibility  is  also 
confirmed by the considerable presence of Ki-67 at the Golgi level. These latter 
perspectives  further  support the  idea  that the  transfer  from an active  to  a 
quiescent phase (after a long starvation period) may be regulated by a dynamic 
degradation  process  of  Ki-67,  which  is  also  related  to  the  ability  of  non-
cancerous cells to deliver the protein in the secretory pathway.
On the other hand, experimental evidences suggest that breast cancer cells fail 
to  direct  Ki-67  to  the  correct  secretory  pathway  (the  protein  was  found 
considerably  less to be included in COPII-coated vesicles), which is crucial for 
controlling its degradation and / or regulation. In particular, serum deprivation 
does not lead to an increase of the protein in the Golgi complex, indicating that 
breast cancer cells may lose the control on Ki-67 turnover.
All these findings are summarised in the scheme in Figure 5.14, which finally 
shows  a  proposed  molecular  mechanisms  involved  in  the  extranuclear 
regulation of Ki-67.
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167Figure  5.14.  Scheme  representing  the  proposed  extranuclear  molecular 
regulation and pathways of Ki-67. Upon the transferring of the cell in the G0 of 
the cell  cycle, Ki-67 is ﬁrst  translocated  in  the ER  (1).  This  will  activate the 
ERAD signal pathway, which  lead BiP to bind the newly ER transferred Ki-67 
(probably activating the UPR). Then,  Ki-67 may interact  with the proteasome 
system, and this complex buds from the ER into speciﬁc COPII coated vesicles 
(2), which transport their cargo to the Golgi apparatus (3) where Ki-67 may be 
further recycled and / or degraded (4).
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1685.7. Ki-67 as intracellular target for anticancer applications   
In this chapter the biological investigation of Ki-67 in two cell models (HDF and 
MDA-MB-231)  is  presented.  These  data  shed  light  on  the  still  unexplored 
extranuclear translocation of this protein, as well as clarified its expression and 
intracellular localisation in cancerous and non-cancerous cells. 
Indeed,  while  most  of  the  Ki-67 is  translocated  outside  the  nucleus,  and 
consequently down regulated in serum deprived HDF, this  does  not occur in 
MDA-MB-231. 
Furthermore, by   quantifying the Ki-67 two principal splice variants (namely, the 
α and β), it is demonstrated that the α variant is the mainly expressed. 
Moreover, while the HDF did not present any  sign of either α or β isoform after 
36 h of  starvation, the  breast cancer cells  MDA-MB-231 showed  an evident 
expression of the α isoform (PCR analysis Figure 5.8).  
These results suggest the implication of the α isoform in playing an important 
role in the regulation of the cell cycle, and thus in cancer progression. Aiming to 
validate the Ki-67  potential as intracellular target for anticancer applications, 
fluorescently  labeled  (Brilliant Violet™  421)  anti  Ki-67 IgG  antibodies  were 
delivered  intracellularly,  by  exploiting  the  PMPC-PDPA  (Poly(2-
methacryloyloxyethyl  phosphorylcholine)-co-poly(2-(diisopropylamino)ethyl 
methacrylate) polymersome delivery system. MDA-MB-231 cells were used as a 
model  system,  and  the  ability of  the  introduced  IgG  to  target  Ki-67 was 
evaluated by means of confocal microscopy. The results of this investigation are 
reported in Figure 5.15. 
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169Figure 5.15. Z-stack versus mean intensity graphical reconstruction (Top ﬁgure) 
and  imaging rendering (bottom ﬁgure) of  the  intracellular  distribution  of  anti-
Ki-67  antibody  delivered  (Brilliant  Violet  421™anti-Ki-67  IgG)  in  live  MDA-
MB-231 cells with polymersomes. Cells were co-stained with green RNA / DNA 
probe SYTO®9. Scale bar: 10 µm.
As  shown  in  Figure  5.15,  the  polymersomes  delivered  anti  Ki-67  IgG 
(fluorescently labeled) are effectively up-taken and accumulated intracellularly. 
Evidently,  the  red  signal  revealed  that  most  of  the  delivered  proteins  are 
accumulated  within  the  cytoplasm.  Nevertheless,  the  SYTO®9  nucleic  acid 
staining (green channel) shows that part of the delivered IgG are penetrated 
within the cell nucleus, and are co-localised within the nucleolar region. These 
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170results proved the targeting efficiency of the polymersomes delivered anti Ki-67 
IgG. 
After this preliminary validation, the next experimental step aimed to test in live 
cells  the therapeutic potential of the delivered IgG, and  more  precisely their 
ability  to  interfere  with  the  Ki-67 functionality.  For  this  scope,  antibody 
targeting the N-portion of Ki-67 that corresponds to  the forkhead associated 
domain (FHA) were  used. The  FHA domain is  a well conserved  amino  acid 
sequence that mediate the interactions with factors involved on the cell cycle 
progression, DNA repair and transcription (Byeon et al., 2005). 
The FHA domain of Ki-67 allows the protein association with the kinesin-like 
protein Hklp2, and  with the  nucleolar protein interacting factor NIFK. The 
Ki-67 association with NIFK was described during the mitosis phase of the cell 
cycle, thus  supporting the possible implication of  these two  proteins for the 
regulation of the latter (Sueishi et al., 2000; Takagi et al., 2001).  
Moreover,  the  presented  results  showed  that  quiescent  non-cancerous  cells 
(upon serum starvation) express lower amount of Ki-67 comparing to cancerous 
cells (Figure 5.1). For this reason, it is expected that the intracellular delivery of 
anti  Ki-67 antibodies  should  produce  a considerable  and  selective  effect  in 
cancerous cells. To evaluate this therapeutic approach, HDF and MDA-MB-231 
cells  were used  as  a models. MTT assay was  exploited  to  evaluate  the  cells 
viability,  while  a  cell  counting  assay was  performed  to  assess  the  cellular 
proliferation after the treatment. In both cases, cells were starved for 18 h and 
subsequently incubated  24  h  with  the  respective  formulations,  and  finally 
analysed. More precisely, different groups of cells  were treated with antibody 
loaded polymersomes characterised by  different concentrations of PMPC-PDPA 
(0.5 -  1 - 1.5 mg/ml) and IgG (0.05 -  0.1 -  0.15 µg/ml). The total amount of 
PMPC-PDPA and IgG per single formulations was quantified by RP-HPLC (see 
Section 7.2.3).  Furthermore, two  separated  controls  were  used. One  control 
group  was  characterised  by  cells  treated  with  empty  polymersomes  using 
PMPC-PDPA concentrations of 0.5, 1 and 1.5 mg/ml. The other control group, 
was characterised by cells treated with an equal volume (compared to the added 
polymersomes sample) of 1X phosphate buffered saline (PBS 0.1 M) in media. 
All these analyses are summarised in Figure 5.16. The first relevant outcome is 
that  HDF  are  not  affected  by the  applied  polymersomes  formulations  (i.e., 
empty, and antibody  loaded polymersomes). This result was confirmed by both 
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171MTT assay and  cells  counting. Different results were achieved by  evaluating 
MDA-MB-231 cells.In particular,  both cellular viability and  the  proliferative 
capacity  of MDA-MB-231 cells decreased after the exposure to the polymersome 
formulations loaded with the antibody cargo. Indeed, cells treated with 0.5 and 
0.1 µg/ml of IgG show a reduction on their viability of ~20 and ~25% comparing 
with cells exposed to the empty  polymersomes. Furthermore, cells treated with 
0.15 µg/ml of antibodies show a ~25% reductions on their proliferative activity. 
Taken together, these data indicate that antibodies targeting the FHA domain 
may  inhibit the Ki-67 activity. Furthermore, only the cancerous cells resulted 
affected  by the  intracellular  delivery of  antibody with  significant  statistical 
validity, thus indicating the high specificity of the treatment. This result can be 
correlated  with the  higher expression of  Ki-67 occurring in cancerous  cells, 
compared  to  non-cancerous  one.  It  was  demonstrated  that  the  former 
constitutively express this protein also when their proliferation is inhibited via 
serum starvation.  Despite  these  promising results  further  investigations  are 
however needed to better elucidate the Ki-67 pathway and the contributions of 
other key factors on it. It is also necessary to point out that most part of Ki-67 
structural conformation is still unknown at the moment. This lack of knowledge 
strongly precludes, and makes difficult, the validations of others targeting sites 
on the Ki-67 structure (besides the FHA domain) that could be exploited for its 
inhibition.
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172Figure 5.16.	 ﾠCells viability (%) tested by means of MTT assay and cell counting   
assay,  performed  on  HDF  and  MDA-MB-23  cells.  Empty  PMPC-PDPA 
polymersomes  were  compared  to  polymersome  formulations  (at  the  same 
overall  amount  of  PMPC-PDPA,  i.e.  0.5,  1  and  1.5  mg/ml) containing three 
different concentrations of anti-Ki-67 antibody (0.05 - 0.1 - 0.15 µg/ml; antibody 
targeting the N-portion of the protein). Furthermore, another control cells group 
was incubated with PBS (t-test, p-value *  P ≤ 0.05; **  P ≤ 0.01; *** P ≤ 0.001; 
**** P ≤ 0.0001). The experimental  error  is expressed as standard deviation 
(N=3).
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General Conclusions and Future Directions
6.1. General conclusions 
In this  PhD  project, it was  exploited  the use  of  pH  sensitive  polymersomes 
based  on  poly(2-methacryloyloxyethyl  phosphorylcholine)-co-poly(2-
(diisopropylamino)ethyl  methacrylate  (PMPC-PDPA)  block  copolymer,  to 
achieve the intracellular delivery of antibodies for anticancer therapy.
As a first step, for the development of PMPC-PDPA polymersomes as efficient 
drug delivery system, the so called protein corona effect was initially studied.
This process was investigated using, as a model, three different proteins namely 
immunoglobulin G  (IgG),  Bovine  Serum Albumin  (BSA)  and  lysozyme  and 
evaluating it on assemblies derived from two different block copolymers namely 
PMPC-PDPA  and  poly(ethylene  glycol)-co-poly(2-(diisopropylamino)  ethyl 
methacrylate (PEG-PDPA). The characterisation of the fouling process, which 
defines the interactions between proteins and synthetic surfaces was evaluated 
with both, polymersomes and micelles using techniques such as Size Exclusion 
Chromatography  (SEC),  Transmission  Electron  Microscopy  (TEM)  and 
Isothermal  titration  calorimetry (ITC)  (see  Figure  2.6,  2.7  and  2.9).  The 
obtained  results  showed  the  binding  effect occurring between  proteins  and 
micelles when the latter are mixed together in solution. On the other hand, the 
same effect was not detected in the presence of proteins  and polymersomes. 
Aiming to describe the protein fouling, observed exclusively within the micelles, 
an  important  observation  correlated  with  the  polymer  chains  molecular 
organisation on the micellar structure has to be considered. 
174In fact, structural  assemblies  such as  polymersomes  and  micelles  made  by 
copolymer with the same graft density differ by different brush density.
In copolymer assemblies, the latter parameter depends on two distinct factors 
which are (i) the curvature of the particle and (ii) the copolymer packing factor 
(p).  Particles  such  as  micelles  that  posses  high  surface  curvature  and  low 
packing  factor  are  also  characterised  by  a  low  brush  density  (Bates  and 
Fredrickson,  1990;  Daoud  and  Cotton,  1982;  Fredrickson  and  Bates,  1996; 
Matsen and Bates, 1996a; Matsen and Bates, 1996b;  Nagarajan and Ganesh, 
1989;  Rahman,  2013).  Furthermore,  considering  two  distinct  micellar 
assemblies differing by the hydrophilic block, another determining factor on the 
occurring of the protein fouling process is represented by the hydrophilic chain 
surface density per nm2 (Giacomelli et al., 2012). The higher this value is, the 
more inaccessible is  the  hydrophobic micellar core. For this  reason micelles 
characterised  by the  presence of  PEG as hydrophilic block interact less  with 
proteins compared with micelles presenting the PMPC block.    
It is  possible to assume that the structural difference between polymersomes 
and micelles is the key factor to explain the revealed protein fouling process. As 
a conclusion, it can be assumed that the micellar hydrophilic brush it is in some 
way not sufficient to  prevent the proteins adsorption while the polymersomes 
higher brush density contributes the most to prevent this effect. Furthermore, 
the obtained data indicates that hydrophobic interactions and protein size are 
the driving factors  on the observed proteins fouling process with micelles. In 
fact, the Ka values obtained regarding the tested protein models, resulted in all 
the cases correlated with their hydrophobicity and size. Indeed, the smallest 
tested proteins, the lysozyme, has proved capable more that BSA and IgG to 
penetrate  the  highly  protective  brush  shield  of  well  established  anti-fouling 
polymers such as PEG.
After  confirming  that  protein  fouling  does  not  occur  in  the  presence  of 
polymersomes, the next step was focused on the investigation of a new approach 
to  achieve  a  reliable  and  reproducible  protein  encapsulation  within  these 
nanocarriers. For this  purpose, the development of  electroporation as  a new 
encapsulation technique is reported  herein. This  method, commonly used  in 
molecular biology to introduce biomolecules in live cells (Ho and Mittal, 1996b; 
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proteins within polymersomes. 
The overall data presented, indicates that the polymersome membrane is not 
permanently affected by the electropermeabilization energy applied. In fact, the 
nano-vector size and morphology remained unchanged after the process (Figure 
3.2), thus indicating a transient polymersomes membrane destabilisation that is 
afterwards  efficiently  recovered.  Moreover,  the  protein  stability  after 
electroporation, was evaluated with two  different methods namely Enzymatic 
Linked  Immunosorbent  Assay  (ELISA)  and  immunofluorescence.  Both 
techniques  proved  a  normal  antibody  functionality  and  integrity after  the 
process (Figure 3.4). 
With the aim of optimising the IgG cargo encapsulation using electroporation, 
different experimental  parameters  such as  pulses  number, initial  amount of 
protein  and  ion  concentration  in  the  solution  were  evaluated.  The  loading 
efficiency (L)  and  encapsulation  efficiency  percentage  (E)  values  showed  a 
particularly  consistent increment in correlation with the number of electrical 
pulses applied to the polymersomes sample. This was observed whilst keeping 
the protein and ion concentration constant at fixed values of 5 µg/ml and 0.1 M 
phosphate buffered saline (1X PBS) respectively. The  maxima L  (~76) and E 
(~12%)  values  were  reached  using  20  pulses  (Figure 3 . 5 ) .  Furthermore, 
electroporation  was  compared  with  other  encapsulation  methods  such  as 
solvent  switch  and  polymer  film  rehydration.  The  obtained  experimental 
findings showed that the higher reproducibility in terms of L and E values was 
generated using the electroporation technique. Moreover, electroporation also 
shows  the  possibility  to  have  better  control  over  the  final  vesicle  size 
homogeneity compared with the other encapsulation methodologies evaluated 
(Figure 3.6).
After establishing  electroporation as  a reliable  approach  to  achieve  the  IgG 
encapsulation,  functional  antibodies  were  delivered  into  live  cells  using the 
same  PMPC-PDPA  polymersomes.  Reversed  phase  high  pressure  liquid 
chromatography  (RP-HPLC),  confocal  laser  scanning  microscopy  analysis 
(CLSM),  and  TEM  were  all  exploited  to  characterise  the  effectiveness  of 
antibody delivery. It was demonstrated that PMPC-PDPA polymersomes allows 
the  endo-lysosomal  escape  of  the  delivered  cargo.  It  is  likely  that  the 
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endocytic organelles, induces an increase in osmotic pressure that causes the 
temporary formation of pores in the endosome membrane, thus facilitating the 
polymersome cargo delivery into the cytosol. 
The polymersome cargo  release is experimentally well supported by the TEM 
analysis shown in Figure 4.5, where the distribution of gold labeled IgG in both 
vesicular spaces (likely endocytic organelles) and throughout the cell cytosol. 
These results also support the use of polymersomes for the intracellular delivery 
of probes applied in TEM imaging applications. 
Fluorescently labeled antibodies, have shown an overall stability and targeting 
functionality after their introduction into the live intracellular milieu. In fact, in 
Figure 4.7 it is shown, through the use of fluorescently labeled anti γ-Tubulin 
IgG, sub-cellular targeting of this structural protein can be achieved and their 
intracellular dynamics in response to external stressors can be revealed.  
In  conclusion,  PMPC-PDPA  based  polymersomes  demonstrated  their 
applicability  for the  delivery of  complex  biomolecules  such as  IgG, without 
causing relevant perturbations to the cellular viability. 
Taken together, all these findings suggest that polymersomes can be used  in 
combination with imaging techniques for the study  of biological pathways  in 
live experiments.
The assessed ability of polymersome as nanocarrier for the intracellular delivery 
of  functional  antibody makes  them  an  important  tool  useful  for  targeting 
intracellular epitopes, associated  with cancer cell development. In particular, 
interesting  targets  are  represented  by  epitopes  implicated  with  cell  cycle 
regulation.  For this  reason, the  intracellular pathway of  the  nuclear protein 
Ki-67, which is associated with cellular proliferation and cell cycle regulations, 
was investigated in this project (Scholzen and Gerdes, 2000).  
In this  work,  it  is  demonstrated  that  Ki-67 undergoes  completely  different 
regulation / degradation pathways in non-cancerous and cancerous cells. This 
was specifically ascribed to the different expression of the two splice variants of 
the protein, combined with possible altered post-transcriptional and / or post-
translational modification of Ki-67 occurring in cancer cells. In addition, it is 
demonstrated, for the  first time, that the  protein is  translocated  outside the 
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Golgi apparatus later, where it can undergo further regulation steps.
As first general evidence, the obtained data clearly confirm that non-cancerous 
cells are able to control the down-regulation of Ki-67 during the G0/G1 phase of 
the  cell  cycle, while  cancer cells  over-express  the  protein during quiescence 
induced  by nutrients  starvation  (Figure  5.1). In particular,  as  confirmed  by 
fluorescence cytometry  (FC) analysis, a different regulation pathway of Ki-67 
between human dermal fibroblasts (HDF) (in which starvation leads cells to a 
quiescent stage, and to Ki-67 down-regulation) and breast cancer cells (MDA-
MB-231)  (where  fetal  bovine  serum (FBS)  deprivation  does  not  affect  the 
transfer through the cell cycle, neither the related down-expression of Ki-67) is 
likely to occur (Figure 5.2-A-B).
An important role seems to be played by  the two different splice variants of the 
protein, namely the α and the β, for controlling the cellular proliferation (Figure 
5.4 and 5.8). There is, in fact, a significant difference in the expression levels of 
the  two  isoforms  between HDF  and  MDA-MB-231 cells. In particular, the α 
variant is much more expressed in breast cancer cells, compared with human 
dermal  fibroblasts.  This  may  be  an  indication  that  the  two  isoforms  may 
undergo  very different degradation pathways  in non-cancer and  cancer cells. 
Another possibility is that each specific cell may  express different levels of the 
two variants. Hence, the possibility to control the transfer between the active 
and  quiescent  stage  (a  crucial  aspect  in  cancer  research)  seems  to  be 
significantly related  to  the  specific splice variant expressed by cells. Another 
consideration should be inferred. Although the transcript for Ki-67 undergoes a 
shRNA-related degradation process (Figure 5.4), the protein is anyway steadily 
present in MDA-MB-231 cells  (Figure  5.3), probably because  Ki-67 is  more 
stable herein or, alternatively, its post-translational degradation fails to occur in 
cancer cells. Hence, these  findings  strongly support the  hypothesis  that the 
design of  next generation of  anticancer drugs, based  on targeting the  Ki-67 
expression and / or regulation, should  consider the possibility to  selectively 
target the α variant.
However, the most interesting outcome regarding the Ki-67 study is  the first 
demonstration about its  translocation outside  the nucleus. This  represents  a 
new and surprising topic. It was confirmed that cells entering to the G0 phase of 
the cell cycle (i.e., during cell quiescence) promote a Ki-67 translocation outside 
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protein in the ER in order to then enter the quiescent phase). This will result in 
the activation of the ER-associated protein degradation (ERAD) signal pathway, 
which leads the molecular chaperone binding immunoglobulin protein (BiP) to 
bind  the newly ER  transferred  Ki-67 (Figure 5.10), eventually activating the 
unfolded  protein response  (UPR). In addition, it is  demonstrated that Ki-67 
interact  with  the  proteasome  system  (resulting  in  the  degradation  of  the 
protein)  (Figure  5.9),  and  this  complex  buds  from  the  ER  into  specific 
cytoplasmic coat protein complex II (COPII) coated vesicles (Figure 5.11), which 
are responsible to  transport their cargo  to  the Golgi apparatus (Figure 5.12). 
Herein, Ki-67 may be  further recycled and  / or degraded. While these  data 
suggested that the extranuclear molecular pathways of Ki-67 are well controlled 
in fibroblasts (control non-cancerous cell model), breast cancer cells may lose 
the  ability to  regulate  the  different  checkpoints  of  Ki-67 translocation  and 
regulation.  Hence,  the  fine  balance  between  expressed  and  degraded  Ki-67 
results hindered, and cancer cells are not able to control the transfer between 
the quiescent (i.e., the G0  phase of the  cell cycle) and  the proliferating state 
(namely, the S/G2/M steps) of the cell cycle.
At  the  end,  it  is  shown  the  possibility to  target  the  Ki-67  factor  via  the 
polymersomes-mediated  intracellular  delivery  of  anti  Ki-67  N-Terminus 
antibodies (Figure 5.15). These antibodies target the Ki-67 forkhead associated 
(FHA) domain present on the N-terminus amino acid sequence of the protein. 
The FHA domain is strongly correlated with others factors such as kinesin-like 
protein Hklp2 and nucleolar protein interacting factor NIFK. The interaction 
between Ki-67 FHA, Hklp2 and NIFK  is further described during the cellular 
division  and  thus  postulated  as  promoting  elements  for  the  cell  cycle 
progression (Sueishi et al., 2000; Takagi et al., 2001). The MTT assay and the 
quantification  of  the  cellular  proliferation,  carried  out using  non-cancerous 
(HDF)  and  cancerous  cells  (MDA-MB-231)  models,  showed  the  biological 
effectiveness of the applied approach. The cancerous cells resulted affected on 
their metabolic and  proliferative activity when treated with a polymersomes 
formulation containing the antibody cargo. On the other hand, similar results 
were not achieved with non-cancerous cells, thus indicating a selective action of 
the  treatment  (Figure 5 . 1 6 ) .  D e s p i t e  t h e s e  p r o m i s i n g  r e s u l t s ,  f u r t h e r  
investigations are needed to have a better picture concerning the Ki-67 role in 
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could  have  the  real  potential  to  open  new  avenues  in  targeted  anticancer 
therapies.
6.2. Future directions 
In this project, it is shown the possibility to use polymersomes as a nanocarrier 
for  the  intracellular  delivery  of  functional  antibodies  targeting  epitopes 
associated with cancer cell development. 
An  important  limitation  affecting  polymersomes  as  delivery  system  is 
represented  by the  effective  and  reproducible  encapsulation  of  hydrophilic 
biomolecules, such as IgG, within their lumen.
To achieve this scope, the electroporation technique was employed. Despite the 
promising results obtained in terms of loading efficiency (L) and encapsulation 
efficiency percentage (E), the use of electroporation as encapsulation method 
can still  be  improved. For instance, parameters  such as  total polymersomes 
volume  (ϕp), polymersomes  size, as  well as  the  ions  strength of  the sample 
solution  are  all  variables  that  have  the  potential  to  affect  the  final  cargo 
encapsulation. 
Besides  that,  the  comparison  between electroporation technique  with  other 
encapsulations  methods  has  demonstrated  film  rehydration  as  reliable 
approach  for  the  IgG  encapsulation  within  polymersomes.  The  promising 
encapsulation data obtained via film rehydration need however more insights, 
in order to better understand the mechanism driving in such a way the protein 
loading within polymersomes.  
Concerning the intracellular delivery of IgG, it is important to remark that more 
studies  are  necessary to  explain  the  observed  plateau  over  time.  Different 
hypotheses can be considered to explain this result, including the saturation of 
the  scavenger  receptor  SR-B1,  and  the  implication  of  the  tripartite  motif-
containing 21 (TRIM21). Therefore, future experimental efforts should focus on   
the clarification of the intracellular fate of the delivered IgG. 
In conclusion, I demonstrated that Ki-67 can be a potential target to block the 
proliferation of cancerous cells. However, because the complete pathway of this 
protein is still not well characterised, more experimental data are necessary to 
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characterisations  are  also  needed  to  better  understand  the  structural 
conformation of Ki-67, which is still mostly unknown. 
The  study  of  both  the  intracellular  pathway  of  Ki-67   and  its  structural 
conformation  could  finally  provide  new  important  details  on  the  possible 
strategies  to  target  this  protein.  This  is  very  much  important  to  stop 
uncontrolled proliferation of cancerous cells.
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Materials and Methods
7.1.  SURFACE  INTERACTIONS  BETWEEN  POLYMERIC 
ASSEMBLIES AND PROTEINS 
7.1.1 Block copolymers synthesis 
The  poly(2-(methacryloyloxy)ethyl  phosphorylcholine)-poly(2-
(diisopropylamino)ethyl  methacrylate)  (PMPC25-PDPA70  /  PMPC30-PDPA30) 
and  poly(ethylene  glycol)-poly(2-(diisopropylamino)ethyl  methacrylate) 
(PEG113-PDPA56 / PEG45-PDPA80) were  synthesised by Prof. S. Armes’ group, 
Chemistry Department, University of Sheffield as previously reported (Du et al., 
2005). 
The molecular structure of both block copolymers is shown in Figure 7.1.    
 
Figure 7.1. Molecular structure of the block copolymers used in this project. 
1827.1.2. Polymersome and micelle preparation 
Polymersome and micelle  were  prepared using two  different techniques: (A) 
film hydration and (B) pH switch. In both methods, initially 10 mg of diblock 
copolymer  were  solubilised  in  a  glass  vial  containing  9  ml  of  chloroform 
(CHCl3) : methanol (CH3OH) in 2:1 ratio (Sigma-Aldrich, UK). The dissolved 
copolymer was placed in a vacuum desiccator until the complete evaporation of 
the  solvent and  deposition of  a thin layer of  polymer  to  the  vial  wall. The   
polymer film was  subjected either to  film hydration or pH  switch protocol. 
Thus,  polymersomes  were  obtained  applying  the  film hydration  method  on 
copolymers  such as  PMPC25-PDPA70 a n d  P E G 45-PDPA80. The  film hydration 
method was also used for the assembly of micelles derived from the PMPC30-
PDPA30.  Instead,  the  pH  switch  method  was  applied  for  the  formation  of 
PEG113-PDPA56 micelles as reported from Pearson and colleagues (Pearson et 
al., 2013).
A. Film hydration
For the  film hydration protocol, the vial containing the  copolymer film was 
rehydrated by adding 2 ml of 1X phosphate buffered saline (PBS 0.1 M) at pH 
7.4. The  buffered  solution was  stirred (magnetic stirring at 200 rpm) for 8 
weeks to allow polymersomes self-assembling. 
Micelles  were  obtained  by film hydration reducing the stirring time from 8 
weeks to 12 h. 
B. pH switch
For the pH switch assembling protocol, the copolymer film was dissolved in pH 
2 1X PBS at the final concentration of 10 mg/ml. The pH of the solution was 
increased to pH 7.4 with 1 M NaOH, added a flow rate of 15 µl/min using an 
automated syringe pump. The process was performed under constant stirring at 
70 °C, as previously reported (Pearson et al., 2013).
Samples  were  purified using Size Exclusion Chromatography (SEC). For this 
propose, a 1 x 15 cm column was packed with Sepharose 4B (resin-bead sizes 
ranging from 45 to  165 µm; GE Healthcare, UK) and 500 µl of sample were 
loaded to the head of the column and the eluted through it using 1X PBS.
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Polymersome and micelle physical characterisation was performed by Dynamic 
Light Scattering (DLS) and Transmission Electron Microscopy (TEM).
The DLS analysis was achieved using the Malvern Zetasizer Nano set at 20 0C. 
Samples were diluted to 0.15 mg/ml in 1X PBS pH 7.4. 800 µl of diluted sample 
was then placed into a polystyrene cuvette (Malvern, DTS0012) and analysed. 
TEM  analyses  were  performed  using a  FEI  Tecnica  Spirit  microscope  with 
maximal working voltage of  120 KV and  equipped with Gatan1K  MS600CW 
CCD  camera.  The  copper  grids  used  for the  samples  analysis  were  initially 
coated  with  a  carbon  layer  (thickness:  ~20  nm)  using  a  carbon  coater. 
Subsequently, the prepared grids were submerged in the copolymer assemblies 
sample  (micelles  or  polymersomes)  and  afterwords  stained  using  a 
phosphotungstic  acid  (PTA)  solution (0.75%  w/w)  as  described  in  previous 
works (Pearson et al., 2013; Wang et al., 2012). The PTA staining was herein 
applied since it enables the detections of the ester bonds presents in the PMPC-
PDPA molecular structure. 
7.1.4. Protein labelling  
To  study the  surface-surface  interactions  between polymeric  structures  and 
proteins, Bovine Serum Albumin (BSA) (Sigma-Aldrich, UK), lysozyme (Sigma-
Aldrich, UK) and immunoglobulin G (IgG) (I5006;  Sigma-Aldrich, UK) were 
opportunely labelled with a fluorescent dye. 
The labelling protocol consisted of four steps:
1. In the first step the proteins were solubilised in pH ~8.3 sodium bicarbonate 
buffered solution at a final concentration of 5 mg/ml. 
2. In the second step, 0.25 mg of Cy5 (Cyanine5) NHS ester dye (λex= 649 nm, 
and  λem= 669 nm; Lumiprobe) previously dissolved  in 20 µl of  dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, UK), were added to the protein solutions 
and incubated at room temperature for 2 h in stirring conditions. This step 
was  necessary  to  allow  the  protein-dye  conjugations  between  the 
succinimidyl ester group present on the dye chemical structure and primary 
amines presents on the proteins. 
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via SEC using a Sephadex G-25 (Sigma-Aldrich, UK). 
4. Finally, the absorbance at 280 nm of the purified product was  measured. 
The absorbance of free dye was subtracted from the total absorbance and 
protein concentration was determined against a standard curve.
7.1.5. Protein zeta potential calculation
The  protein  zeta  potential  was  measured  using  a  Malvern  Zetasizer  Nano. 
Samples  were  diluted  in 1 ml  of  distilled  water  and  the  measurement  was 
performed at 20 °C.
7.1.6. Size exclusion chromatography for the evaluation of surface-
surface interaction
The SEC analysis was used to  evaluate the surface-surface interplay between 
polymeric structures and proteins. 
The protocol involved the use of a 1.5 x 30 cm column packed with Sepharose 
4B  (Sigma-Aldrich,  UK),  directly  connected  to  a  high  pressure  liquid 
chromatography (HPLC) instrument (Dionex, Ultimate 3000). 
100 µl of  mixed  samples containing proteins plus  polymersomes or proteins 
plus micelles were injected into the column and eluted through it using 1X PBS 
with constant flow of 260 µl/min.
Two  different chromatograms  were registered. One, detecting the copolymer 
UV-Vis absorbance at 220 nm and the other one exciting the sample at 649 nm 
and detecting the labelled protein fluorescent emission at 669 nm.
The  areas  corresponding  to  the  detected  packs  were  calculated  with  a 
MATLAB® based script.
7.1.7.  TEM  visualisation  of  the  subsisting  interaction  between 
micelle / polymersome and protein
TEM  was  used  to  visualise  the  interaction  between  polymeric  micelle  / 
polymersome  and  proteins  after  SEC  purification.  Both  polymeric  samples: 
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film hydration as described in Section 7.1.2. 
Two separated samples containing respectively  300 µl of 10 mg/ml of PMPC-
PDPA micelles or polymersomes and ~1.5 µg/ml 5 nm AuNP-IgG (gold labelled 
immunoglobulin G)  (Sigma-Aldrich,  UK) were  placed  in a 2 ml  plastic vial 
(Eppendorf,  UK)  and  kept  in  moderate  agitation  for  about  10  min. 
Subsequently, the  samples  were  passed  through the SEC applying the  same 
protocol as  explained  in Section 7.1.6 and the  eluted fraction corresponding 
either  to  the  polymersomes  or  to  the  micelles  (depending  on  the  injected 
sample) was collected and analysed by TEM. 
The  TEM  AuNP-IgG  visualisation was  performed using a FEI  Tecnica Spirit 
microscope  with  maximal  working  voltage  of  120  KV  and  equipped  with 
Gatan1K MS600CW CCD camera using the same protocol described in Section 
7.1.3.
7.1.8. Isothermal titration calorimetry (ITC)
A MicroCal VP-ITC instrument was used for the isothermal titration calorimetry 
analysis.  10  µl  of  1X  PBS  solution,  containing  47.6  µM  of  micelles  or 
polymersomes, was injected at regular interval of 10 min into the reference cell 
containing 15.2 µM of protein solution. The reference cell power was set at 10 
µcal/s. 
7.1.9. Statistical analysis
The  statistical comparison between two  group  of data resulting from the Ka 
calculation  was  performed  using  a t-test  setting  the  significance  level  with 
p<0.05. The experimental error is expressed as standard deviation (N=3). 
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POLYMERSOMES
7.2.1. Polymersome preparation and characterisation
The  PMPC-PDPA  polymersomes  preparation  for  the  subsequent  protein 
encapsulation via electroporation was achieved by film hydration as described 
in Section 7.1.2. Samples were purified by SEC and characterised by DLS and 
TEM as previously described (Section 7.1.2-B and 7.1.3). 
7.2.2. Antibody stability after electroporation process
Antibody stability after electroporation was assessed by (A) Enzymatic Linked 
Immunosorbent Assay (ELISA) and (B) immunohistochemistry. 
A. ELISA assay
This  assay  was  performed  following  the  product  protocol,  using  the  anti 
Interleukin 8 (IL-8) IgG as  a model. Briefly, 50 µl of provided anti IL-8 IgG 
enzyme conjugated antibodies, were diluted in 500 µl of 1X PBS and placed into 
a  2 mm width gap  electroporation  cuvette  (Eppendorf,  UK).  This  antibody 
solution  was  subjected  to  electroporation  using  an  Electroporator  2510 
(Eppendorf, UK) instrument and applying 5, 10 or 20 pulses depending on the 
experiment, and applying 2500 V each pulse. Every pulse was spaced with a 
time gap of 30 sec. Untreated antibodies were used as negative control, while 
the positive control antibodies (degraded proteins) were obtained placing them 
at 90 °C for 15 min. 
After the samples preparation, the ELISA assay (R&D Systems Inc., USA) was 
performed and the first step of it included the addition and the incubation for 2 
h at room temperature of 100 µl of standard  antigen into  an anti IL-8 pre-
coated 96 well plated. 
At this point, three consecutive washing steps with 1X PBS were thus necessary 
to  remove  all  the  unbounded  antigen.  Afterward,  the  prepared  antibodies 
samples (electroporation treated IgG, positive and negative control IgG) were 
added  into  separated  wells  of  the  plate  and  incubated  for  2  h  at  room 
temperature. After this step, the reacting wells were opportunely washed again 
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incubation protecting the samples from the light, the reaction was stopped and 
the absorbance was measured at 450 nm using a micro-plate reader (ELx800 
BioTek,  USA).  The  protein  stability  was  thus  evaluated  normalising  the 
measured absorbance resulting for the treated samples with the value obtained 
for the untreated antibodies control (100% absorbance value).   
B. Immunohistochemistry
The  second  validation  method  used  was  based  on  confocal  laser  scanning 
microscopy analysis  performed  in  fixed  Human  Dermal  Fibroblast  (HDF  - 
American Type Culture Collection (ATCC®, USA)). In this case, anti α-tubulin 
antibody (Abcam,  UK)  conjugated  with  AlexaFluor®647  dye  (λex=649  nm, 
λem=669 nm -  Life  Technologies™),  was  used  as  a model  and  subjected  to 
electroporation using the same protocol as before. Furthermore, also  for this 
validation, positive and negative control samples were prepared  as  described 
before for the ELISA assay (Section 7.2.2-A).
HDF cells were seeded in glass bottom dishes (35 mm diameter-IBIDI®) at a 
density  of  8 x 103  cells  per well and  grown for 24 h in complete Dulbecco's 
Modified Eagle Medium (DMEM) added with 10% (v/v) fetal calf serum, 2 mM 
L-glutamine,  100 mg/ml  streptomycin  and  100 IU/ml  penicillin. Cells  were 
incubated at 37 °C/5% CO2. Cells were periodically sub-cultured using Trypsin-
Ethylenediaminetetraacetic  acid  (EDTA)  solution  0.25%  for the  detachment 
process and centrifuged at 2000 rpm for 5 min for the pellet collection.
The antibodies structural stability was investigated under confocal microscope 
(Leica  TCS  SP8),  and  the  cellular  samples  were  prepared  applying 
immunofluorescence  protocol:  fixation  with  formaldehyde  3.7%  for 10  min, 
permeation with 0.1% Triton X-100 in 1X PBS for 10 min, blocking of unspecific 
sites with BSA 2% for 2 h and overnight incubation at 4 °C with the antibody 
sample. The microscope laser intensities and detector gains were kept constant 
between all images.
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concentration 
Reversed-phase high pressure liquid chromatography (RP-HPLC) is a technique 
that  allows  the  separation of  different molecules  that  are  initially adsorbed 
within a solid material (Aguilar, 2004; Jacob Bongers, 1997). The components 
of the analyte mixture pass over a stationary-phase of particles bearing pores 
large enough for them to enter. The analyte interactions within the adsorbent 
surface  remove  them  from the  flowing  mobile-phase  stream.  As  the  ratio 
between different solvents  (organic and  non) in the mobile phase change, it 
reaches a critical value for each analyte, which desorbs it from the stationary-
phase  surface and  allows  it to  elute  from the  column in the  flowing mobile 
phase. Since this  elution depends on the physical and chemical properties  in 
each species, each analyte elutes from the column at a characteristic time, and 
the resulting peak detected can be used to confirm its identity and quantify the 
latter (Aguilar, 2004; Jacob Bongers, 1997). 
The RP-HPLC technique was herein applied for the quantification of both IgG 
and PMPC-PDPA and thus to subsequently calculate the resulting encapsulation 
efficiency. 
An anti-tubulin IgG conjugated with AlexaFluor® 647 dye (λex= 650 nm, and 
λem= 669 nm) (ab6161;  Abcam®, UK) was  used as  a model. The  calibration 
curves were obtained using an RP-HPLC (Dionex, Ultimate 3000) with a C18 
analytic column (Phenomenex® Jupiter C18, 300A, 150 x 4.60 mm, 5 micron) 
and using a constant flow ratio of 1 ml/min. The eluents used were milliQ H2O 
added of 0.05 % V/V trifluoroacetic acid (TFA) (eluent A) and CH3OH with 0.05 
% TFA (eluent B). The gradient profile used is shown in Figure 7.2.
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189Figure 7.2. Gradient used for  the RP-HPLC characterisation  of PMPC-PDPA 
and IgG. 
The samples containing the specific amounts of antibody  and copolymer were 
prepared by dilution in 1X PBS at pH 5.5. The polymer UV-Vis absorbance was 
detected at 220 nm, while the antibodies fluorescence intensity was acquired at 
669 nm. Standard curves for PMPC-PDPA and IgG are shown in Figure 7.3. 
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characterisation. The detections of  the ﬂuorescently labelled AlexaFluor® 6 4 7  
anti-tubulin IgG was performed measuring its ﬂuorescent emission at 669 nm, 
while the block  copolymer  PMPC-PDPA UV-Vis  absorbance was detected at 
220 nm.
Chapter 7
191As  presented in Figure 7.3, the  IgG signal is  detectable in both fluorescence 
(because of the bounded dye) and UV-Vis  channel. The UV-Vis  detections is 
attributable to the i.e. tryptophan residues, that have absorbance between 280 
and  200 nm (Stoscheck, 1990).  As  a control experiment, it was  also  tested 
whether the fluorescent  signal  attributed  to  the  IgG  can be  affected  by the 
contamination of free dyes. The data showed in Figure 7.4 demonstrated that 
the dye has a different elution time when it’s not bound to the protein and it’s 
not detectable in the UV-vis channel at 220 nm. 
Figure 7.4. RP-HPLC analysis aimed to exclude the presence of free dye on 
the AlexaFluor® 647 (λex= 650 nm, and λem= 669 nm) labelled IgG sample. The 
free dye or labelled protein detections was performed evaluating its ﬂuorescent 
emission at 669 nm, while the protein UV-Vis absorbance was detected at 220 
nm.    
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antibodies were detected at a retention time of approximately 27 min in UV-Vis 
(220 nm) and fluorescence emission channel (669 nm), whilst the free-dye was 
revealed at ~29 min and only on the fluorescent emission channel (669 nm). 
Since the peak at ~29 min was not revealed on the previous protein standard 
curve  RP-HPLC  analysis  (see  Section  7.2.3),  the  data  shown  in  Figure  7.4 
exclude any possible over-estimations on the detected amount of protein given 
by the presence of free-dye thus validating the quantification method.
7.2.4. Protein encapsulation within polymersome 
Encapsulation efficiency of antibodies was compared across a range of different 
techniques  such  as  electroporation,  inclusion  during  pH  switch  and  film 
rehydration. For this  comparison, anti α-tubulin IgG (ab7291; Abcam®, UK) 
labeled  with AlexaFluor®647 dye  (Life  Technologies™,  USA)  was  used  as  a 
model.
A. Electroporation 
Empty polymersomes were prepared by film hydration as previously described 
(Section 7.2.1). The antibody encapsulation by electroporation was tested using 
different conditions such as different final protein concentrations (5, 10, 20 and 
40 µg/ml), different PBS molarity  (0.1, 0.2 and 0.5 M) and different number of 
electroporation  pulses  (5,  10,  15  and  20).  After  mixing  proteins  and 
polymersomes at the desired conditions depending on the experiment, 400 µl of 
the  mixture  was  loaded  into  a  2  mm  width  gap  electroporation  cuvette 
(Eppendorf, UK) and electroporated using an Electroporator 2510 (Eppendorf, 
UK) instrument, applying a voltage of 2500 V each pulse. 400 µl of sample was 
purified from the free protein by SEC using a 1 x 15 cm column packed with 
Sepharose 4B in 1X PBS. Purified samples were characterised by DLS and TEM 
(Section 7.1.3)  and  the  collected  total  amount of  polymer  and  protein  was 
calculated via RP-HPLC as described in Section 7.2.3.  
Chapter 7
193B. pH switch
The protein encapsulation exploiting the pH switch method was done following   
a modified version of the protocol described in Section 7.1.2-B. The acidified 1X 
PBS solution of copolymer was added of NaOH 1 M at room temperature. The 
antibody solution (final IgG concentration on the sample = 5 µg/ml) was added 
at  pH=6.  This  step  was  necessary to  avoid  any protein  structural  damage 
possibly occurring exposing the latter at acidic conditions or high temperature. 
Samples were purified by SEC and the protein and polymer concentrations were 
calculated  via  RP-HPLC  analysis  (Section  7.2.3).  Purified  samples  were 
characterised by DLS and TEM as previously showed (Section 7.1.3). 
C. Film hydration
The general film hydration protocol is described in Section 7.1.2. In this case, to 
achieve  the  protein  encapsulation  within  polymersomes,  the  antibody was 
diluted in 2 ml of 1X PBS (final IgG concentration on the sample = 5 µg/ml) and 
this solution was added to the thin film of copolymer. Samples were purified by 
SEC and characterised by DLS and TEM as previously  described (Section 7.1.2-
B and 7.1.3).
7.2.5. Statistical analysis
The statistical comparison between two group of data resulting from the ELISA 
assay and from the encapsulation experiments was performed using a t-test, 
setting the significance level with p<0.05. The experimental error is expressed 
as standard deviation (N=3).
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SYSTEM IN LIVE CELLS
7.3.1. Cell culture 
Primary human dermal fibroblasts (HDF), breast cancer cells (MDA-MB-231), 
ovarian carcinoma cells  (SKOV3), human skin melanoma cells (MEWO) and 
urinary bladder transitional carcinoma cells (RT112) were purchased from the 
ATCC®. HDF  cells  were cultured and  maintained  in DMEM  (Sigma-Aldrich, 
UK). MDA-MB-231 and RT112 cells were cultured and maintained in Roswell 
Park Memorial Institute  (RPMI) 1640 medium (Sigma-Aldrich, UK). SKOV3 
cells were cultured and maintained in McCoy's 5a Medium Modified (Sigma-
Aldrich,  UK)  and  MEWO  cells  instead  were  cultured  in  Eagle's  Minimum 
Essential Medium (MEM) (Sigma-Aldrich, UK). All the cell culture mediums 
were supplemented with 10 (v/v) fetal calf serum, 2 mM L-glutamine, 100 mg/
ml  streptomycin  and  100  IU/ml  penicillin (Sigma-Aldrich,  UK).  Cells  were 
incubated at 37 °C/5% CO2.
Cells  were  routinely sub-cultured  using  Trypsin-EDTA (Sigma-Aldrich,  UK) 
solution 0.25% for the detachment process and centrifuged at 2000 rpm for 5 
min for the pellet collection. 
7.3.2. MTT-assay
Cell viability after exposure  to  polymersomes  was  quantified  by MTT  assay. 
HDF, MDA-MB-231, SKOV3, MEWO and RT112 cells were seeded in a 24-well 
plate  at a density of  3 x 104  cells  per well and grown for 48 h in complete 
medium.  Cells  were  divide  in  four groups  and  treated  for  24 h  with fresh 
medium containing 10% volume of 1X PBS as a negative control and the three 
different polymersomes  concentrations:  0.5 mg/ml, 1 mg/ml and  1.5 mg/ml. 
Cells were washed three times with 1X PBS and then incubated in MTT solution 
(Sigma-Aldrich, UK) (0.5 mg ml-1 MTT in 1X PBS, 1 ml per well) for 1 h at 37 
°C/5%  CO2. Intracellular  metabolic  activity reduces  MTT  to  a  purple  water 
insoluble  formazan  salt.  Subsequently,  the  solution  was  aspirated  and  the 
insoluble  formazan product was  solubilised  by adding acidified  isopropanol 
(0.001 N of  HCl in isopropanol -  0.5 ml per well) (Sigma-Aldrich, UK) and 
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was measured using a plate reader spectrophotometer with optical density at 
570 nm (ELx800 BioTek, USA). 
7.3.3. Polymersome cargo delivery: microscopy quantification
For the confocal laser scanning microscopy (CLSM) quantitative analysis a glass 
bottom 96 well plate (BD Bioscience, USA) was seeded with HDFs at a density 
of 1.5 x 103 cells per well and grown for 24 h in standard medium DMEM. Cells 
were treated with fresh medium containing polymersomes encapsulated rabbit 
IgG (I5006; Sigma-Aldrich, UK) labelled with AlexaFluor®546 λex=550 nm, and 
λem=573 nm (Life Technologies™, USA) (1 mg/ml PMPC-PDPA and 0.1 µg/ml 
IgG as a final concentration in medium). 
The polymersomes preparation was performed as described in Section 7.1.2-A 
by film hydration, and the antibody  cargo was encapsulated by  electroporation
(Section 7.2.4-A).
Briefly, 5 µg/ml of IgG were added to 400 µl of a solution containing 10 mg/ml 
of  PMPC-PDPA  polymersomes  and  the  obtained  sample  was  subjected  at 
electroporation (5 pulses, 2500 V each pulse).
After the encapsulation step, both samples were purified by SEC and the relative 
copolymer and IgG concentrations were characterised by means of RP-HPLC as 
described  in  Section  7.2.3.  All  the  materials  applied  were  kept  in  sterile 
conditions.
Furthermore, a control group of cells was set up treating it with 5 µg/ml of free 
antibody diluted in sterile medium. Cells were thus incubated for different time 
points (0, 1, 5, 18 and 24 h) at 37 °C/5% CO2 and afterwards they  were washed 
three  times  with  1X  PBS  and  incubated  for  8  min  with  a  H2O  solution 
containing the nucleic acid staining SYTO®9 (λex= 485 nm, and λem=498 nm - 
Molecular probes®). Cells were then washed again three times with 1X PBS and 
added of DMEM imaging medium (Life Technologies™, USA).
The  CLSM  analysis  was  performed  using  a  Leica  TCS  SP8  confocal  laser 
microscope and the average IgG emission intensities calculation was achieved 
with ImageJ (U.S. National Institutes of Health, Bethesda, MD, USA). 
The microscope laser intensities and detector gains were kept constant between 
all images.
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HDFs  were seeded  in 6 well plates  (5 x 104  cells  per well) and incubated  in 
DMEM medium for 24 h as previously described (Section 7.3.3). After this first 
step, cells were treated with encapsulated antibody as described in Section 7.3.3. 
At the desired time point (0, 1, 5, 18 and 24 h) cells were washed three times 
with 1X PBS and placed at -20 °C overnight to induce the cellular lysis. 25o µl of 
1X PBS at pH 5.5 were used to recover the cell aggregates, the antibody  and to 
solubilise  the  copolymer.  The  solution  was  collected  in  a 2  ml  plastic  vial 
(Eppendorf, UK) and centrifuged  at 20000 rpm for 10 min to  eliminate cell 
aggregates. 100 µl of the resulting supernatant were analysed in RP-HPLC using 
the same protocol explained in Section 7.2.3, adjusting the fluorescence channel 
detection  considering  the  IgG  bonded  dye.  The  mathematical  equation  to 
calculate the amount of protein per cell is reported below:  
 
7.3.5. Polymersome cargo release: CLSM analysis
Polymersomes  endolysosomal  escape  and  cargo  release  in  HDF  cells  was 
analysed by CLSM. HDFs were seeded in glass bottom dishes (35 mm diameter-
IBIDI®, UK) at a density of 8 x 103 cells per well and grown for 24 h in complete 
DMEM  medium.  Cells  were  treated  with  fresh  medium  containing 
polymersomes  encapsulated  rabbit IgG  (I5006;  Sigma-Aldrich,  UK)  labelled 
with AlexaFluor®546 λex=550 nm, and λem=573 nm (Life Technologies™, USA) 
(1 mg/ml PMPC-PDPA and 0.1 µg/ml IgG as a final concentration in medium). 
The polymersomes preparation was performed as described in Section 7.1.2-A 
by film hydration, and the antibody  cargo was encapsulated by  electroporation 
(Section 7.3.3), keeping all the materials applied in sterile conditions. 
Cells were thus incubated overnight at 37 °C/5% CO2 and afterwards they were 
washed three times with 1X PBS and incubated for 15 min at 37°C / 5% CO2 this 
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197time  with  fresh DMEM  medium containing  50  nM  of  LysoTracker®  probe 
(λex=490 nm, and λem=511 nm). Cells were then washed again three times with 
1X PBS and added of DMEM imaging medium (Life Technologies™, USA).
CLSM analyses were performed with a Leica TCS SP8 confocal laser microscope 
and the images were analysed with ImageJ.
7.3.6. Polymersome cargo release: TEM analysis
HDFs were used as a cellular model also in this analysis and they were cultured 
and  maintained  as  previously described  (Section  7.3.1).  The  polymersomes 
sterile  sample  containing  15  nm  AuNP-IgG  (ab27236;  Abcam,  UK)  was 
encapsulated  in polymersomes  as  previously described  in Section 7.3.3. The 
cells  were  treated  with  fresh  medium  containing  1 mg/ml  of  PMPC-PDPA 
polymersomes loaded with 0.1 µg/ml of AuNP-IgG and incubated overnight in 
medium  at  37  °C/5%  CO2.  Control  cells  were  treated  with  fresh  medium 
containing 0.1 µg/ml of free AuNP-IgG and incubated overnight using the same 
conditions applied for cells treated with the polymersomes antibodies  loaded 
sample. Subsequently, the cells were washed three times with 1X PBS and fixed 
in epoxy resin to be sectioned with a microtome (Tian, 2014). The slides were 
analysed by TEM  (FEI  Tecnai 120 kV, FEI  Co., USA). Images were analysed 
with ImageJ. This experiment was  performed thanks to  the  help of  Dr Tian 
Xhiaohe.
7.3.7. Polymersome cargo release: CLSM analysis optimisation 
To  study  the  possibility  to  reduce  the  signal  originating  from  the  endo-
lysosomal organelles thus improving the confocal microscopy analysis regarding 
the  specific  antibodies-antigen  intracellular  recognition  (mediated  by   the 
delivered of fluorescently labelled IgG), two groups of HDFs were treated with 
two  different  polymersome  formulations  and  the  respective  results  were 
compared. 
Polymersome  were  loaded  with  Brilliant  Violet  421™  anti-γ-Tubulin  IgG 
(λex=407 nm, and λem=421 nm - 529201; BioLegend®, USA) and the quencher 
molecule Trypan blue  (Sigma-Aldrich, UK). Instead, the  other polymersomes 
formulation contained only the fluorescent antibodies without the quencher.
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7.1.2-A, and the encapsulation of both quencher and antibodies was performed 
as explained in Section 7.2.4-A. 
Briefly, to  produce the  first formulation (polymersome  loaded  with IgG and 
quencher molecule), 10 µl of Trypan blue 0.4% were added into  400 µl of a 
solution containing 10 mg/ml of PMPC-PDPA polymersomes  and 5 µg/ml of 
Brilliant Violet 421™ IgG and subjected at electroporation (5 pulses, 2500 V 
each pulse). Instead, to  obtain the second formulation (polymersome  loaded 
with only IgG), 5 µg/ml of Brilliant Violet 421™ IgG were added to 400 µl of a 
solution containing 10 mg/ml of PMPC-PDPA polymersomes and the obtained 
sample was subjected also in this case at electroporation as a before (5 pulses, 
2500 V each pulse).
After the encapsulation step, both samples were purified by SEC and the relative 
copolymer and IgG concentrations were characterised by means of RP-HPLC as 
described  in  Section  7.2.3.  All  the  materials  applied  were  kept  in  sterile 
conditions. 
HDF cells were seeded in glass bottom dishes (35 mm diameter-IBIDI®, UK) at 
a density of  8 x 103  cells  per well and  grown for 24 h in complete  DMEM 
medium. Afterwards, the two groups of cells were treated separately with fresh 
medium  with  one  of  the  two  polymersomes  formulations  (in  both  cases 
containing 1 mg/ml PMPC-PDPA, ~0.1 µg/ml of Brilliant Violet 421™ IgG) and 
incubated with it overnight at 37 °C/5% CO2. Cells  were washed three times 
with 1X  PBS  and  incubated  for 15  min  with a H2O  solution containing the 
nucleic acid staining SYTO®9 (λex= 485 nm, and λem=498 - Molecular probes®). 
At this  stage, cells  were  added  of  DMEM  imaging medium and  analysed  by 
confocal microscopy (Leica TCS SP8). 
7.3.8. Delivery of functional antibody for sub-cellular targeting
The γ-Tubulin sub-cellular targeting was performed at the same conditions as 
described  in Section 7.3.7. Two  groups  of  cells  were seeded  in glass  bottom 
dishes (35 mm diameter-IBIDI®, UK) at a density of 8 x 103 cells per well and 
grown  for  24 h  in  complete  DMEM  medium.  Subsequently,  the  cells  were 
treated with a polymersome formulation (1 mg/ml PMPC-PDPA) loaded with   
fluorescently  labelled anti-γ-Tubulin IgG (0.1 µg/ml of  Brilliant Violet 421™ 
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at 37 °C/5% CO2. Subsequently, each group of cells was washed three times with 
1X  PBS and  incubated  for 5 or 30  min with a H2O  solution containing the 
nucleic acid staining SYTO®9 (λex= 485 nm, and λem=498). Afterward, they  were 
placed in DMEM  imaging medium and analysed under confocal microscopy 
(Leica TCS SP8).
7.3.9.  Intracellular delivery of  anti  γ-Tubulin IgG  in  different cell 
models 
The experiment described in Section 7.3.8 was repeated at identical conditions 
with other cell models. The only   difference was that in this case all the cells were 
all exposed at 5 min with a H2O solution containing the nucleic acid staining 
SYTO®9 (λex= 485 nm, and λem=498). Indeed, human adenocarcinoma cells 
(HeLa),  murine  fibroblasts  (NIH-3T3)  and  murine  brain  endothelial  cells 
(bEnd3)  were  purchased  from the  ATCC®  and  cultured  in  DMEM  (Sigma-
Aldrich, UK). Human embryonal carcinoma stem cells (NTera2) were provided 
from Prof. Peter Andrews  (University  of  Sheffield, UK) and  they were  also 
cultured DMEM (Sigma-Aldrich, UK). Human melanoma cell (A375) instead 
were  provided  by  Prof.  Sheila  MacNeil  (University  of  Sheffield,  UK)  and 
cultured in MEM (Sigma-Aldrich, UK). All the used cell culture mediums were 
supplemented with: 10 (v/v) fetal calf serum, 2 mM L-glutamine, 100 mg/ml 
streptomycin and 100 IU/ml penicillin (Sigma-Aldrich, UK) and the cells were 
grown at 37 °C/95% air/5% CO2. All the cell models were routinely sub-cultured 
using Trypsin-EDTA (Sigma-Aldrich, UK) solution 0.25% for the detachment 
process and centrifuged at 2000 rpm for 5 min for the pellet collection.
7.3.10. Statistical analysis
The statistical comparison between two group of data resulting from the MTT 
assay and  from the  TEM  analysis  was  performed  using  a t-test, setting the 
significance level with p<0.05. The experimental error is expressed as standard 
deviation (N=3).
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THERAPY
7.4.1. Cell culture 
HDF, MDA-MB-231, HeLa, and oral carcinoma (FaDu) cells were purchased 
from ATCC®. HDF, HeLa, and FaDu cells were cultured and maintained using 
DMEM  (Sigma-Aldrich, UK) containing: 10 (v/v) fetal calf  serum, 2 mM  L-
glutamine, 100 mg/ml streptomycin and 100 IU/ml penicillin (Sigma-Aldrich, 
UK).  Cells  were  cultured  at 37 °C/95%  air/5%  CO2. Human  umbilical  vein 
endothelial  cells  (HUVECs)  were  purchased  from  Life  Technologies™  and 
cultured using Medium 200 with Low Serum Growth Supplement (LSGS) (Life 
Technologies™, USA) and maintained as described for the previous cells. MDA-
MB-231 cells were cultured in RPMI 1640 medium (Lonza, UK), containing: 10 
(v/v) fetal calf serum, 2 mM L-glutamine, 100 mg/ml streptomycin and 100 IU/
ml penicillin (Sigma-Aldrich, UK). Cells were periodically sub-cultured using 
Trypsin-EDTA solution 0.25% (Sigma-Aldrich, UK) for the detachment process 
and centrifuged at 2000 rpm for 5 min for the pellet collection. 
The cellular synchronisation was obtained by  incubating the cells with serum-
deprived medium, at different time points (18, 24, 36 and 48 h), depending on 
the experimental conditions.
7.4.2. Quantification of Ki-67 expression in different cell models
For the quantification of Ki-67 expression HDF, HUVEC, MDA-MB-231, HeLa 
and FaDu cells were initially seeded in glass bottom dishes (35 mm diameter-
IBIDI®)  at a density  of  8 x 103  cells  per  well, grown  for 24 h in  complete 
medium. Afterward the cells were subjected to three washing steps with 1X PBS 
and finally analysed by  confocal microscopy (Leica TCS SP8). A CLSM analysis 
was  applied  to  visualise  the  protein  expression.  The  cellular  samples  were 
prepared with immunofluorescence protocol: fixation with formaldehyde 3.7% 
for 10  min, permeation with 0.1% Triton X-100 in 1X PBS  for 10 min and 
blocking of unspecific sites with BSA 2% for 2 h and overnight incubation at 4 
°C with the antibody sample.
Ki-67  protein  was  directly  investigated  through  a  mouse  IgG  anti-Ki-67 
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(BioLegend® -  λex=405 nm, and λem=421 nm). Cell nucleus were stained with 
SYTO®9 (Life Technologies™ - λex=490 nm and a λem=525 nm). The microscope 
laser intensities and detector gains were kept constant between all images. The 
average  Ki-67 overlap  value  intensity with  SYTO®9  was  calculated  with  a 
specifically developed MATLAB® script. 
7.4.3. Ki-67 expression as a function of the cell cycle
Fluorescence cytometry (FC) analysis was used to quantify the Ki-67 expression 
in relation to the cell cycle stage using a BD FACSArray instrument. HDF and 
MDA-MB-231 cells were cultured and maintained as previously described and 
growth  in  T75  flasks.  The  cell  cycle  analysis  was  performed  as  previously 
reported  (Pozarowski  and  Darzynkiewicz,  2004).  Briefly,  the  cells  were 
detached  from the  T75  flasks  using  Trypsin-EDTA solution  0.25%  (Sigma-
Aldrich, UK) and centrifuged at 2000 rpm for 5 min for the pellet collection. 
Subsequently, the cells were fixed and permeabilised in 70% ethanol for 2 h at 4 
°C.  The  cellular  DNA  staining  was  obtained  exposing  the  fixed  cells  to  a 
propidium  iodide  (PI)  solution  (0.1%  (v/v)  Triton  X-100,  10  µg/mL  PI 
(Molecular Probes, Inc.), and 100 µg/mL DNase-free RNase A in 1X PBS). The 
Ki-67 detection was instead achieved treating the cells for 2 h with a blocking 
solution  containing  2%  BSA in  1X  PBS  and  subsequently incubating  them 
overnight at 4 °C with the anti-Ki67  antibody sample (ab15580; Abcam®, UK), 
conjugated with Alexa Fluor® 647 dye (BioLegend, USA - λex=635 nm, and a 
λem=670 nm). 
The  PI  staining used  in this  study, allows  the  deconvolution analysis  of the 
cellular DNA content histogram (see Figure 7.5). This in turn lead to reveal the 
cellular distributions across the three major phases of the cell cycle (G1, S and 
G2/M). Furthermore, these phases were correlated with the Ki-67 expression.  
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with  PI.  This  analysis  reveals  the cellular  distributions  across  the  cell  cycle 
phases: G1, S and G2/M.    
7.4.4. Ki-67 gene knock-down experiment
The  genes  knockdown analysis  was  performed  using the Thermo  Scientific™ 
GIPZ lentiviral™ system, following the company protocol. 
Briefly, HDF and MDA-MB-231 cells were treated with shRNA loaded viruses, 
and cultured in serum-free medium respectively with 12 x 106 Transducing units 
per ml (TU/ml) and 3.6 x 106  TU/ml for 6 h. Subsequently, the medium was 
substituted with fresh one and the cells were incubated for 0 h, 24 h and 48 h at 
37 °C/95% air/5% CO2. The effectiveness of the shRNA gene translation was 
evaluated under confocal microscopy (Leica TCS SP8) detecting the expression 
of the TurboGFP reporter gene (λex=490 nm, and a λem=525 nm) which is also 
present on the pGIPZ lentiviral vector. 
Afterward, the  mRNA gene  target expression  was  quantify with  (A)  CLSM 
analysis and in (B) RT-qPCR. 
As negative control, a non-silencing virus, expressing the scrambled sequence 
TCTCGCTTGGGCGAGAGTAAG  was  used; Ki-67 gene  was  targeted  with the 
following  shRNA  antisense  sequence:  TCCTTAGGAGTCTGTAGCT  (cloneId: 
V3LHS_387958). 
Finally,  the  antisense  sequence  CCTCATTTCCTGGTATGACAA  was  used  to 
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A. CLMS analysis 
The  CLMS  analysis  was  performed  in  a  glass  bottom  96  well  plate  (BD 
Bioscience, USA) and  both HDF and  MDA-MB-231 cells  were  seeded with a 
density  of 1.5 x 103 cells per well and grown for 24 h. After the treatment with 
Thermo Scientific™ GIPZ lentiviral™, the Ki-67 was quantified as described in 
Section 7.4.2 while the TurboGFP reporter gene was detected at λex=490 nm, 
and a λem=525 nm. The microscope laser intensities  and detector gains  were 
kept constant between all images.  
B. Real time-quantitative polymerase chain reaction (RT-qPCR)
HDF and MDA-MB-231 cells were cultured in a 6 well plates with a density  of 5 
x 104 cells per well and incubated in appropriate medium for 24 h as previously 
described (see Section 7.4.1). Subsequent to that, the cells were incubate with 
the  Thermo  Scientific™ GIPZ  lentiviral™ treatment  following  the  company 
protocol. 
Following lentivirus treatment, cells were washed three times in 1X PBS and 
lysed with radio-immunoprecipitation assay (RIPA) buffer (20 mmol/L Tris, pH 
7.5, 150 mmol/L NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mmol/L 
EDTA,  0.1%  SDS)  (Sigma-Aldrich,  UK),  containing  complete  mini  protease 
inhibitors (Roche, UK) used according company protocol.  
Total  RNA  was  collected  using  RNeasy  Mini  Kit  (Qiagen,  UK).  RNA 
concentration  was  measured  with  NanoDrop8000  spectrophotometer. 
Complementary DNA (cDNA) was synthesized from every 1 µg of total mRNA in 
20 µl volume per tube with QuantiTect Rev. Transcription Kit (Qiagen, UK). 
GAPDH was used as a reference gene, and the two Ki67 isoforms (α and β) were 
analysed using the following list of primers:
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Quantitative analysis was performed with QuantiTect SYBR Green RT-qPCR Kit 
(Qiagen, UK). The amplification process  was  done in 20 µL/tube, using the 
following steps: 95°C for 5 min to make active the DNA Polymerase, followed by 
40 cycles of 95°C (10 sec) for denaturation, and 60°C (30 sec) for combined 
annealing and extension for all primers. Melting curve was  also  acquired, to 
analyse the sample quality, from 55°C to 99°C, by  increasing of 1°C/min. Data 
were analysed via ΔΔCt value. 2-ΔΔCt was calculated as  follows: ΔCt=  Ct Ki67 -  Ct 
GAPDH; ΔΔCt=ΔCt (treated) - ΔCt (control).
7.4.5. Ki-67 expression in cancerous and non-cancerous cells before 
and after nutrients deprivation: western blot analysis
For the western blot analysis the cells were cultured in T75 flasks and they were 
lysed and prepared as describe for the RT-qPCR samples preparation. The total 
protein initial concentration was calculated using the bicinchoninic acid assay 
(BCA) (Smith et al., 1985) (Thermo Fisher Scientific, USA) and thus normalised 
for all the cellular samples. All the samples were denatured for 5 min at 950C 
prior the western size-based assay or the standard western blot assay.  
A. Western size-based assay
The western blot analysis for the KI-67 protein quantifications was performed 
with an automated  western size-based  assay (ProteinSimple-Simon™,  USA), 
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The  specific  antibody  applied  against  Ki-67  was  purchased  from  Abcam® 
(ab15580), while the ERK  1/2 positive  control antibody was  provided by the 
Simon™ analysis kit (Boge et al., 2012; Rustandi et al., 2012). 
B. Standard western blot assay
NuPAGE4-12% TrisGels (Life Technologies™) was used to achieve the protein 
fractions separation. Each sample (20 µg of protein in a volume of 40 µl) was 
loaded  into  the gel  well and  their alignment on the  gel front was  achieved 
applying a voltage  of  100 V for 15 min. Subsequently, the  protein fractions 
separation was obtained with a voltage of 180 V per 150 min.
After this step, the gel trapped  proteins  were transferred thanks  to  the iBlot 
instrument (Life Technologies™) to  a nitrocellulose membrane. The transfer 
was performed applying a voltage of 100 V per 60 min. 
Subsequently,  the  membrane  was  blocked  with  1  h  incubation  at  room 
temperature with 5% (w/v) milk powder in Tris-buffer with 0.5% (v/v) Tween 
20  (blocking  solution).  The  membrane  was  stained  for Ki-67 by overnight 
incubation at 40C with anti-Ki-67 antibodies  diluted in blocking solution (ab 
15580; 1:500; Abcam®, UK). The membrane was then washed three times with 
1X  PBS  and  incubated  with  horse-radish  peroxidase  (HRP)  secondary 
antibodies,  also  diluted  in  blocking  solution  (1:10000;  Cell  Signaling 
Technologies,  UK).  Finally,  the  membrane  was  treated  for  5  min  with the 
enhanced  chemiluminescence  kit  (Thermo  Fisher  Scientific,  USA).  The 
photographic  development  of  the  obtained  results  was  performed in a dark 
room exposing  a  photographic  film  to  the  obtained  membrane  for  1 min. 
Afterwards, the  photographic film was  immersed  for 5  sec  in a developing 
solution and fixed by placing it for 30 sec in a fixing solution.  
7.4.6.  Ki-67 α a n d  β splice  variant expression as  a function of the 
nutrients deprivation
HDF and MDA-MB-231 cells were cultured in a 6 well plates with a density  of 5 
x 104 cells per well and incubated in appropriate medium for 24 h as previously 
described  (see  Section  7.4.1).  Afterwards,  the  cells  were  subjected  at  serum 
deprived  medium  at  different  time  point  and  the  cDNA  was  subsequently 
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A. Reverse transcription polymerase chain reaction (RT-PCR),  and 
PCR assays
For the RT-PCR, the samples were run in a standard agarose gel (1%). 
GAPDH was used as a reference gene, and the two Ki67 isoforms (α and β) were 
analysed using the list of primers shown in Table 7.2.
Table 7.2. List of primers used RT-PCR characterisation.
B. Real time-quantitative polymerase chain reaction (RT-qPCR) 
This analysis was performed with identical protocol and materials as described 
in paragraph 7.4.4-B.
7.4.7.  Nuclear-independent  molecular  mechanisms  of  Ki-67 
regulation
Intracellular proteins  distribution and  interactions  were  analysed  by CLSM. 
Cells were seeded at a density of 8 x 103 cells per well and allowed to grown for 
24 h in complete medium before analysis.
The protein-protein interactions were investigated under confocal microscope 
(Leica  TCS  SP8),  and  the  cellular  samples  were  obtained  with 
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permeation with 0.1% Triton X-100 in 1X PBS for 10 min, block with BSA 2% 
for 2 h.
Ki67  protein  was  directly  investigated  through  a  mouse  IgG  anti-Ki-67, 
conjugated with Brilliant Violet 421™ dye (350505; BioLegend® - λex=405 nm, 
and λem=421 nm). The Golgi compartment staining was  achieved  by treating 
cells  with  a  modified  baculovirus  expressing  a  fusion  construct  of  a  Golgi 
marker and  a red  fluorescent  protein (CellLight®  Golgi-RFP  -  C10593;  Life 
Technologies™  -  λex=540  nm,  and  a  λem=625  nm).  All  the  other  confocal 
characterisations were carried out using specific unlabelled primary  rabbit IgG 
incubating  the  cellular  sample  for 2  h  with  the  latter.  Proteins  were  then 
enlighten  by  secondary   DyLight™  649  donkey   anti-rabbit  IgG  (406406; 
BioLegend® - λex=655, nm and a λem=670 nm) which was incubated within the 
sample overnight. The proteasome detections was achieved with a specific IgG 
recognising  the  20s  proteins  subunit  (ab3325;  Abcam®,  UK).  The  COPII-
vesicles detections was performed using an IgG recognising the Sec31A subunit 
(HPA005457; Sigma-Aldrich®). The BiP investigation was obtained through an 
antibody recognising the specific N-term aa sequence of the protein (G9043; 
Sigma-Aldrich®).  Finally,  the  nucleic  acid  staining  was  obtained  with  the 
molecular probe SYTO®9 (Life  Technologies™  -  λex=490 nm and  a λem=525 
nm).
7.4.8. Ki-67 as intracellular target for anticancer applications  
A. CLSM analysis
This analysis was performed using MDA-MB-231 cells as model. The cells were 
treated with a polymersome formulation loaded with a mouse anti-Ki-67  IgG 
conjugated with Brilliant Violet 421™ dye (350505; BioLegend® - λex=405 nm, 
and  λem=421  nm)  (1  mg/ml  PMPC-PDPA  and  0.1  µg/ml  IgG  as  a  final 
concentration in medium). The protocol applied for this experiment is the same 
protocol as described in Section 7.3.8. The image analysis was performed with 
ImageJ software. 
Chapter 7
208B. MTT assay
The MTT assay  was herein performed as explained in Section 7.3.2. After 18 h of 
serum starvation, the HDF and MDA-MB-231 cells were treated with different 
concentrations of empty polymersomes or polymersomes loaded with anti Ki-67 
IgG (39799; ActiveMotif®, UK) (0.5, 1 and 1.5 mg/ml PMPC-PDPA, 0.05 - 0.1 - 
0.15 µg/ml IgG). Furthermore, a control group of cells treated with 10% 1X PBS 
in media was tested. The MTT analysis was performed 24 h after the treatment. 
C. Cells counting assay
For  this  analysis,  HDF  and  MDA-MB-231 cells  were  cultured  and  treated 
following the same protocol and materials as described for the MTT assay  in 
Section 7.4.8-B. The cell counting was performed using the BIO-RAD TC20™ 
Automated Counter. 
7.4.9. Statistical analysis
The statistical comparison between two group of data obtained in experiments 
such  as  FC  characterisation,  Simple  Western™  quantification,  RT-qPCRs, 
confocal colocalisation experiments and MTT assay was performed using a t-
test. The statistical comparison between more than two groups of data obtained 
in experiments such as the confocal quantitative analysis and the gene knock-
down  experiment  was  performed  using  a  two-way ANOVA  test.  For  both 
statistical comparisons (t-test and two-way ANOVA), the significance level was 
set-up with p<0.05. The experimental error is expressed as standard deviation 
(N=3).
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